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Abstract
Topoisomerase II p-binding protein 1 (TopBPl) is an essential BRCT domain containing 
protein involved in DNA damage signalling, replication and repair. BRCT domains have 
the ability to bind single and double stranded DNA as well as phosphopeptides and are 
found within a large group of proteins involved in the DNA damage response. These 
domains give the proteins the ability to bind damaged DNA and change their interacting 
partners following DNA damage, maldng their role in the DNA damage response 
essential for efficient signal transduction and the activation o f DNA damage checkpoint 
and repair. TopBPl binds single and double stranded DNA and co-localises to sites of 
DNA damage with other sensory proteins including BRCAl, NBSl and Rad9 and is an 
essential protein in the activation o f the downstream checkpoints and the initiation of cell 
cycle arrest. No other protein contains as many as eight BRCT domains indicating that 
TopBPl plays an essential role in these responses. TopBPl has been implicated as a 
possible transcription factor activating transcription of the HPV16 
ti'anscription/replication protein E2 and repressing the activation of E2F1 and M izl. The 
modification of clu'omatin is essential for all functions of TopBPl; this thesis has 
describes the identification of three chromatin modification domains within thr ee distinct 
BRCT domains o f TopBPl. The function of one o f these domains is mediated by a direct 
interaction with the chromatin remodeling enzyme Brgl and the transcriptional 
regulation by this protein-protein interaction is regulated by DNA damage. The
XXI
identification of these domains and then* regulation by DNA damage provides further 
insight into the mechanism of DNA damage signalling, repair, transcription and 
replication by TopBPl via the modification o f chromatin.
In addition to the identification of chiomatin modification domains, gene targets of 
TopBPl were also identified. This was carried out using MCF7 cells with endogenous 
TopBPl down-regulated by siRNA tieatiuent. These studies identified several pathways 
regulated by TopBPl expression, all o f which play a role in breast carcinogenesis. These 
results provide more evidence supporting a role for TopBPl in the development o f breast 
cancer; previous studies have shown aberrant expression of TopBPl in breast cancers as 
well as polymorphisms pre-disposing towards this disease.
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Chaplei '  1 - IrUroduction
Chapter 1 - Introduction
1.1. The DNA Damage Response
Cells are continually bombarded with endogenous and exogenous DNA damaging 
agents which produce as many as 1,000,000 lesions in DNA per cell per day (Lodish 
et al. 2004). The type o f damage to DNA which results depends upon the source of 
the damage, but irrespective o f the type of damage the DNA damage signal 
transduction pathway is the same, consisting of sensors, transducers and effectors 
(Figure 1). The responses activated during this pathway include 1) DNA repair, 2) 
the activation o f cell cycle checkpoints 3) Transcription and 4) Apoptosis. The roles 
of these distinct set of proteins within the cascade are as follows 1) Sensors; identify 
the damage and initiate the DNA damage cascade, 2) Transducers; phosphorylate 
downstream targets and 3) Effectors induce cell cycle anest, repair and apoptosis.
Figure 1
C h a p le r  1 - IiUroduclioi)
DNA
Damage
S ensors
9-1-1, BRCAl, TopBPl,RPA
Transducers
ATM, ATR, ATRIP, Chkl, Chk2
Effectors
p53, Cdc25, Cdk1
Cell Cycle 
Arrest DNA Repair TranscriptionApoptosis
Figure 1: Diagrammatic Representation of the DNA Damage Signalling 
Cascade. This diagram represents the DNA damage response signalling cascade, 
showing the position o f  the sensors, transducers and effectors within the cascade. 
The end results being the activation o f  DNA repair, cell cycle arrest apoptosis and 
transcription.
C h a p le r  1 - h i troduc lion
Table 1
Soecies
Function Mammals S.pom bo S.eereW s/ae 0.rtig/an.oga?fer
Ç ensor
RFCI-like Rad17 Rad17 Rad24 Rad24
PCMA-iike Rad9 Rad9 Dcd1
Rad1 Rad1 Radi 7
Husi Hus1 Mec3
ssONA binding RPA RFA
DSB recognilion/nuciease Mre11 Fî0d32 Mrel 1 Mfa1
RAD50 RadGO RadSO RadSO
NBSl Xrs2 Nbsl
Giaspin Mrc1 Mrcl
BRCT containing TopBPl Cuts Dpb11 MuslOI
BRCA1 Crb2 Rad9
tvlDCI
T ransducers
Pi3 Kinases ATM Tei1 Ten ATM
ATR Rad3 M ed Mei-41
Pi3 kinase binding partners ATRIP Rad26 Dcd2 Mus304
Ser/Thr Kinase Chkl Chk1 Chk1 Grapes
Chk2 Cds1 Rad53 Chk2
Effector;
Transcription Factor p53 Dp53
Phospliataso Cdc25A String
Cdc25B
Cdc25C
Kinase Cdkl Cdc2 Cdc28 Cdk1
Table 1: Sensor, Transducer and Effector proteins involved in the DNA  
Dam age Response. This table list the sensors, transducers and effectors in the DNA 
damage response, in mammals, Saccharomyces cerevisiae, Schizosaccaromyces 
pombe and Drosophila melanogaster. The grey box indicates proteins which are 
sensors but are also involved in the activation of the cell cycle checkpoints (1.2).
C h a p le r  1 - h i t rodüc lion
1.1.1. Sensors
Sensors are proteins which either directly bind DNA or indirectly bind DNA via a 
DNA-protein-protein interaction. The interactions of these proteins recognise the 
lesion and initiate the cascade of events which lead to the activation o f the cell cycle 
checkpoints, repah transcription or apoptosis. These proteins and the homologs in S. 
cervisiae, D. melanogaster and S>. pombe  as listed in Table 1. However although the 
proteins described here play a sensory role following DNA damage several also 
function during the initiation of both the cell cycle checkpoints and repair 
(Discussed later 1.2.).
RFC and PCNA like sensors are recruited to the sites of DNA damage and include 
the Rad9-Radl-ITusl (9-1-1) complex, Rad 17 and the replication factor complex 
proteins (2-5). Under “norm af’ conditions the RFC subunits 1-5 form a complex and 
act as a “clamp loader” loading the PCNA “sliding clamp” onto the site of 
replication. However following DNA damage the RFCl subunit is replaced with 
R ad i7, and again this complex acts as a clamp loader this time loading the 9-1-1 
complex (Venclovas et al. 2000). The loading o f the 9-1-1 complex then facilitates 
the recruitment o f repair proteins onto the scaffold.
ssDNA binding occurs during the repair o f double strand breaks when intermediate 
single strand breaks occur. These sections o f DNA are recognised and coated by the
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replication protein A (RPA), this loading o f RPA is dependent on the Radl7-RFC2- 
5 and the 9-1-1 complex and in turn this coating o f RPA recmits the DNA damage 
transducer complex ATR-ATRIP (1.1.2.) continuing the damage signal (Manke et 
a l  2003).
DSB recognition occurs via protein-DNA, protein-protein interactions described 
here but DSB are also recognised by the modification of the surrounding chromatin 
(Discussed later 1.5.) One such DSB recognition complex is the M rell-RA D 50- 
NBS-1 (MRN) complex which binds DNA (Mirzoeva et a l  2006) and localises to 
the site of double strand breaks, with other sensoiy and repair proteins; BRCAl, 
RAD51, PCNA, and proteins involved in mismatch repair. Although MRN is 
involved in the sensing o f DNA damage, this complex also functions in the 
activation of the cell cycle checkpoints (1.2.) experiments in ATM null AT cell lines 
show a failure to phosphorylate N SBl in response to gamma irradiation and ultra 
violet light. In addition Mre-11 NBSl deficient cells continue to replicate following 
IR showing a defective checkpoint response (Shiloh et a l  1997) demonshating the 
role of MRN in both sensing DNA damage and activating the cell cycle checkpoints 
(Gatei et a l 2000, Wu et a l  2000). Claspin is a mediator of signalling o f DNA 
damage and binds the sites of DNA damage via Rad9 of the 9-1-1 complex (Lee et 
a l  2003) and is essential for Chkl phosphorylation by ATR (1.1.2.).
BRCT containing sensory proteins include BRCAl, TopBPl, 53BP1 (53 binding 
protein 1) and M DCl (Mediator of DNA damage checkpoint 1). The BRCT
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domains contained within this group of proteins have the ability to bind ssDNA, 
dsDNA, and phosphopeptides providing a mechanism for these proteins to bind at 
the sites o f DNA damage and recruit repair proteins by phospho-protein interactions 
(Yu et al. 2003). Breast Cancer Susceptibility Gene 1 (BRCAl) directly binds DNA 
(Pauli et al. 2001) and co-localises with other sensor proteins, TopBPl (Yamane et 
al. 2002, Yamane et al. 1999), the MRN complex and PCNA (Wang et al. 2002) to 
the sites of DNA damage. In doing so BRCAl recruits substrates for the downstream 
kinase transducers (Figure 2) and acts as a link between the two phases of the 
response. TopBPl interacts directly with NBSl of the MRN complex (Morishima et 
al. 2007), and the localisation of TopBPl to damage foci is dependent on this 
interaction, as NBS BRCT domain point mutations abolish TopBPl localisation. In 
addition TopBPl localisation to the sites o f DNA damage is also dependent on a 
direct interaction with the 9-1-1 subunit Rad9 (Greer et al. 2003).
TopBPl is involved in the activation of the transducers, Chkl and the protein 
kinases ATR and ATM as following DNA damage TopBPl interacts directly with 
the phosphorylated S345 o f Rad9 via BRCT 1 and 2 (Delacroix et al. 2007). As 
described following replication stalling the exposed ssDNA is coated with RPA 
(Zou et al. 2003), which facilitates the loading o f the 9-1-1 complex. TopBPl has 
recently been shown to provide a link between the recognition of the damage and the 
activation of Chkl. The binding o f Rad9 to TopBPl is essential for Rad9 to interact 
with ATR-ATRIP and consequently activate the cell cycle checkpoints (see below).
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1.1.2. Transducers
Transducers are proteins which amplify the signal from the sensor proteins and 
phosphorylate effector proteins to continue the DNA damage cascade.
The Phosphoinositide-3 kinase related kinases (PIKKs) are two DNA damage 
transducers, ataxia telangiectasia mutated (ATM) and ataxia telangiectasia mutated 
and Rad3 related (ATR). ATM and ATR are both large proteins 350kDa and 
303kDa respectively which contain a catalytic kinase domain which phosphoiylate 
downstream effector proteins serine and threonine residues to amplify the DNA 
damage signal. ATM exists as an inactive homodimer which is autophosphorylated 
at S I981 following DNA damage releasing the active monomers (Bakkenist et al.
2003). Active ATM then phosphorylates BRCAl (Cortez et al. 1999), TopBPl 
(Yamane et al. 2002), NBSl (Lim et al. 2000) and the downstream transducer Chk2 
mediating repair and cell cycle arrest. ATM activity is linked to chromatin 
modifications (1.5.) and the sensor complex MRN, as binding o f ATM to Mre-11 
increases the ability o f ATM to phosphorylate its targets (Lee et al. 2004).
Unlike ATM, ATR does not exist as a homo dimer but forms a heterodimer with 
ATRIP (ATP Interacting Protein) both budding yeast and fission yeast homologues 
o f ATR, M ecl and Dcd2 have also shown similar binding with the ATRIP homologs 
Dcd2 and Rad26 (Edwards et al. 1999). The ATR-ATRIP complex is recruited by
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the sensoiy protein RPA and can only bind ssDNA coated with RPA (Zou et al.
2003). ATR then phosphoiylates Chkl (see below) to continue the DNA damage 
signal pathway.
Whether ATR or ATM is activated depends on the type of DNA damage which 
occurs (Discussed later). Mutations within both ATM and ATR are associated with 
human disease; Ataxia Telangiectasia (Shiloh et a l  1997) and Seckel syndrome 
respectively (O’Driscoll et a l  2007) resulting in an increase in cancer predisposition 
for disease sufferers.
Serine/Threonine K inases, Chkl and Chk2 (Checkpoint kinase) are also 
transducers (Figure 2) which are activated via phosphorylation by ATM or ATR 
(Walworth et al. 1996). As discussed following DNA damage ATR phosphorylates 
S317 and S345 of Chkl (Zhao et a l  2001). This phosphorylation o f Chkl then 
activates the effectors Cdc25A, B and C mediating cell cycle arrest. Following ATM 
phosphorylation at T68 Chk2 phosphorylates p53, Cdc25A and C mediating cell 
cycle arrest, and BRCAl facilitating DNA repair (Bartek et a l  2003).
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1.1.3. Effectors
The effector proteins are discussed in the context of the effect they produce; 
activation of the DNA damage checkpoints (1.2.), DNA repair (1.3.) or apoptosis 
(1.4.).
1.2. DNA Damage Checkpoints
Cell cycle arrest by the induction o f cell cycle checkpoints is essential to allow time 
for the DNA damage to be repaired and prevent damaged DNA from being 
replicated. These checkpoints occur via different mechanisms depending upon what 
point in the cell cycle the damage occurs; G l, S or G2. A diagram of these 
checkpoints is shown in Figure 2 and each checkpoint is described below.
1.2.1. G l Checkpoint
The G l cell cycle checkpoint allows time for repair and prevents damaged DNA 
from being replicated. Cell cycle control is controlled by p53 levels which are 
“normally” kept low as it is continually targeted for degradation by the proteosome 
by MDM2 (Vargas et a l 2003). However to activate the checkpoint following DNA 
damage, p53 is stabilised and the levels increased. In response to DSB, ATM
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phosphorylates Chk2 at T68 (Matsuoka et a l  2000). Phosphorylated Chk2 then 
phosphorylates S20 of p53, which prevents the interaction between MDM2 and p53, 
resulting in an increase in p53 levels. The phosphorylation o f S20 o f p53 is essential 
for its stabilisation, but during the activation of the Gl arrest S15 of p53 is also 
phosphorylated, by both ATR following UV and ATM following IR. The 
phosphorylation of S15 activates p53 and increases transcription of target genes; 
MDM2, GADD45a and p21 (Banin et a l  1998, Canman et a l  1998). The increase in 
the cyclin dependent kinases inhibitor p21 levels decreased Cyclin E/Cdk2 kinase 
activity and promotes a G l arrest (Bartek et al. 2001). p21 also binds Cdk4-Cyclin D 
and prevents p53 phosphorylation o f Rb; it is the phosphorylation of Rb which 
results in the transcription o f S-phase genes (Bartek et a l  2001).
1.2.2. S phase
The S-phase checlcpoint decreases the amount of DNA synthesis following DNA 
damage. Following IR ATM phosphorylates Chk2 at T62 (Falck et al. 2001). Chlc2 
targets Cdc25A for degradation by phosphorylating S I23, meaning that it camiot 
remove inhibitory phosphorylation on Cdk2 (T14 and Y 15). Therefore 
Cdk2/CyclinE and Cdk2/Cyclin A remain inactive and prevent completion of DNA 
synthesis. ATM also phosphorylates NBS (S343), BRCAl (S I387), SMCl 
(Structural maintenance of chromosome 1, at S957 and 966), and TopBPl (S345). 
These complexes form a multi-protein complex BASC (BRCAl-associated genome 
surveillance complex). The loading of CDC45 is dependent on the MRN complex;
10
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blockage of this complex renders cells radioresistant following gamma irradiation 
(Falck et a l  2002). ATR also phosphorylates Chkl at S317 and S345 which 
phosphorylated Cdc25A and targets it for degradation (Zhou et a l  2002).
1.2.3. G2 Checkpoint
The G2 checkpoint stops the cell cycle prior to chromosome segregation. This 
checkpoint is primarily activated following the formation of a DSB, however high 
dose of UV do activate this checkpoint. This is perhaps due to the formation of 
lesions close to each other on the separate DNA strands. Chkl and Chk2 are 
activated by ATM and ATR and phosphorylate W EEl and the phosphatase Cdc25C 
on S216 (Peng et a l  1997) which creates a binding site for the 14-3-3 proteins. 14-3- 
3 then interacts with Cdc25C and sequesters it to the cytoplasm where it can no 
longer activate Cdc2 by removing the inhibitory phosphorylations (T14 and Y15) 
meaning that Cdc2/Cylin B1 complex remains in its inactive state and the entry to 
mitosis is blocked.
1 1
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Figure 2: Activation of the G l, S and G2 phase. This diagram shows the 
activation o f  the cell cycle points see text for details.
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1.3 Repair
Damage to DNA can be caused by a wide variety of endogenous and environmental 
sources. Radiation (gamma rays and x-rays), ultraviolet light, reactive oxygen 
species (ROS) by-products o f cellular metabolism, and alkylating agents. The type 
of damage caused and the repair mechanism initiated depends on the damage agent 
(Figure 3). Base loss occurs spontaneously, indeed several thousand purines and 
hundreds of pyrimidines are lost a day. The primary amino group is unstable and can 
be converted to keto groups, changing cytosine to uracil. Chemical changes can 
occm's from reactive oxidative species (H2O2, ’OFI, -O) which are produced as by­
products of normal cellular metabolism. X-Rays, and ionising radiation (IR), can 
cause double strand breaks and thymine oxidation producing thymine glycol. Photo 
damage occurs when UV light is absorbed by the bases and results in the formation 
of bonds between pyrimidines, causing cyclobutane pyrimidine dimers (SPD) TT 
being the most common, but T-C and CC dimers do occur. Errors during replication 
can result in mismatch, insertions or deletions. Bis-alkylating agents such as 
psoralens produce crosslinked strands. In addition to double strand breaks, IR can 
also cause normally transient topoisomerase-DNA interactions to be stabilised 
leading to protein-DNA crosslinks. The faithful repair of these DNA lesion is 
essential to prevent the loss/alteration o f genetic material which might result in 
tumorigenesis. The different methods o f DNA damage repair proceed as follows.
13
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Figure 3: Summary of the Types of DNA damage and the Repair Mechanisms.
This diagram shows the types o f  DNA damaging agents which cells are subjected to, 
the damage to DNA these damaging agents cause and the repair mechanisms which 
take place to repair the lesion.
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1.3.1. Nucleotide Excision Repair
Nucleotide excision Repair (NER) removes bulky DNA lesions following ultra 
violet radiation or aromatic hydrocarbon exposure. This method of repair is 
activated by two mechanisms, either by smweying the whole genome for bulky 
lesions, or by responding to stalled RNA polymerases in transcription-coupled repair 
(TCR). In response to damage not on an actively transcribed DNA, the heterodimer 
DDBl-XPE bind to lesions induced by UV. XPE recruits XPC to the damage site, 
which then results in the dis-association of XPE from the DNA allowing XPC access 
to the site of the damage. The transcription factor TFIIH unwinds the DNA duplex 
in an ATP dependent manner. This unwinding of DNA then recruits other repair 
proteins; RPA which binds to the DNA ends; XPG which makes the 3 ’ incision and 
ERCCl which makes the 5’ incision. The gap between the incisions is then filled by 
DNA polymerase 5 and s, via PCNA and RFC and ligated by DNA ligase I. TCR 
follows the same repair process although it does not require XPE but does require 
RNA polymerase.
1.3.2. Mismatch Repair
Mismatch repair coiTects mistakes made during replication and accounts for 99% of 
all repair. MMR proteins follow behind the replication fork and remove mismatched 
nucleotides, insertions and deletions caused by template slippage or DNA
15
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polymerase misincorporation. The RFC-PCNA complex identifies gaps in DNA that 
occur near to mismatched nucleotides and binds DNA at the 3 ’ ends. MSH2 
(MutSûf/p/îfl) and M LIil QA\xX\.alphd) then cause another nick in the DNA, resulting 
in two cuts either side o f the mismatched nucleotides. The DNA including the 
mismatch is degraded in a 5 ’ to 3 ’ direction by exonuclease I and the gap is then 
filled as in BER and NER by DNA polymerase 5 and the ends are ligated by DNA 
ligase I.
1.3.3. Base Excision Repair
Damage which is caused by endogenous sources such as reactive oxygen species 
(ROS), the by-products of normal metabolism are repaired by BER. The type of 
DNA damage that occurs include; depurination (cleavage of the link between 
deoxyi'ibose and the purine bases), deamination (removal of the amino group) of 
cytosine, the formation o f covalent adducts and damage to the DNA backbone 
(Review see Wilson et a l  1998). BER can repair these lesions either by a short (1-2 
nucleotides) patches or long (2-10 nucleotide) patches. The initiation of both is 
carried out by DNA glycosylase which removes the base resulting in an apurinic or 
aryprimidinic (AP) site. Endonucleases then cleave the phosphodiester bond. For 
short patches the gap is filled by DNA Pol(3, and ligated by DNA ligase III via 
XRCCl. Long patches are replicated by Pol 5 and Pol e, via PCNA and then ligated 
by DNA ligase III.
16
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1.3.4. DSB repair, Homologous Repair (HR) and Non-Homologous 
End Joining (NHEJ)
Double strand breaks are a direct result o f ionising radiation or reactive oxygen 
species (ROS). ROS may cause DSB by several mechanisms; by creating long 
“nick” in DNA or by a free radical reaction on one strand which then starts a chain 
reaction resulting in a crosslink and eventually a DSB, in addition these “nicks” in 
DNA can form DSB during replication. DSB are repaired by one of two 
mechanisms; either by homologous recombination (HR) or by non-homologous end 
joining (NHEJ). Which repair takes place depends on what point during the cell 
cycle the break occurs; HR occurs primarily during S-G2 phase when the sister 
chromatid is available (Takata et a l  1998) and NHEJ occurs outside S-phase.
HR is error free using a homologous sister chromatid as a template for the damaged 
DNA. M rel 1/Rad50/NBS1 (MRN) complex facilitates the loading o f RAD52 to the 
ends of the breaks (Sonaoda et a l  2001). The importance o f the MRN complex is 
shown by the failure o f cells from NBS patients where NBS is mutated, to repair 
DSB resulting in an increase in cancer predisposition for sufferers. RAD52 senses 
the broken DNA ends and recruits RAD51, which binds the single stranded 
overhangs. With the aid o f RPA, RAD53, Rad54, BRCAl and BRCA2 RAD51 
searches for the homologous template on the sister chromatid. RAD51 binds RAD53 
and via BRCAl and BRCA2 facilitates the strand invasion. MMS4 cleaves the 3 ’
17
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non-homology and following branch migration results in the formation o f a Holliday 
junction, which is then resolved by resolvase (Figm'e 4a).
The second method of DSB repair; NHEJ is more error prone as no homologous 
template is used and occurs when the sister chromatid is not available outside S- 
phase. Genetic alterations can result from the ligation o f unr elated DNA sequences 
creating fusion proteins. One such frision protein is the oncogenic BCR-Abl protein 
which is found in chromic myeloid leukaemia (CML) and acute lymphocyte 
leukaemia (Laurent et al. 2001), which results from a frision of the serine/thr eonine 
kinase BCR (Breakpoint cluster region) and the oncogene ABL, BCR activates ABL 
giving rise to tumourigenesis. To repair DSBs by NHEJ, the heterodimeric protein 
complex Ku70-Ku80 binds the DNA ends and recmits DNA-PK, XRCC4 and DNA 
ligase IV (Jackson et a l  2000). DNA-PK phosphorylates XRCC4 and the Ku 
heterodimer aligning the broken DNA ends and then following alignment the ends 
are then ligated by DNA ligase IV via XRCC4 (Figure 4b).
18
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Figure 4: Repair of DSB by Homologous Repair (HR) and Non-homologous 
End Joining (NHEJ). This diagram shows the mechanism and proteins involved in 
HR (a) and NHEJ (b).
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1.4. Apoptosis
If the damage a cell receives is too extensive to be repaired the cell undergoes 
apoptosis, and a failure to induce apoptosis in damaged cells plays a critical role in 
tumorigenesis. The apoptotic pathway is a signal cascade involving sensors, 
transducers and effector proteins. The key effectors of which are the cysteine 
aspartyl proteases (caspases), and the BCL2 proteins. Two methods by which cells 
may undergo programmed cell death particularly o f relevance to the data presented 
in this thesis are via p53 and E2F1. As discussed, following DNA damage and the 
activation of ATM the transcription factor p53 is stabilised leading to the induction 
o f several cell cycle regulators including GADD45 and p21, and target genes 
required for the apoptotic pathway including Bax, CD95, and Death receptor 5 (Wu 
et al. 1999, Oda et al. 2000) triggering apoptosis. Stabilisation of p53 by CHK2 
following DNA damage promotes its translocation to the mitochondrial membrane, 
and this disruption of the mitochondrial membranes leads to activation of the 
caspases and the induction of apoptosis. Similarly to p53, E2F1 is also 
phosphorylated by ATM following DNA damage, leading to the stabilisation and 
activation of E2F1. This stabilisation is dependent several proteins including Mdm2 
(Blatmer et al. 1999) and TopBPl (Discussed later 1.6). Liu and colleagues showed 
that E2F1 is regulated by TopBPl via the recruitment of the chromatin remodelling 
complex; SWISNF (Discussed 1.5.2.) to inhibit E2F1 transcriptional activity and
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that this regulation o f E2F1 by TopBPl is essential for E2F1-dependent apoptosis 
following DNA damage (Liu et aL 2004).
1,5. Role of Chromatin in DNA Damage Response
The activation of the DNA damage response depends upon the modification of 
chromatin (Review Costelloe et a l  2006). The nucleosome is the basic unit of 
chromatin and consists of a histone octamer core (Figure 5a) around which is 
wrapped 147bp of DNA (Kornberg et a l 1999). This tight packing of DNA can 
inhibit the accessibility of repah* proteins to the lesion (Hara et a l  2000); therefore 
the chromatin suiTounding DNA damage must be modified during the DNA damage 
response to ensure efficient repair. Chromatin is modified in two ways during the 
DNA damage response; by histone modification and by ATP-dependent remodelling 
enzymes.
1.5.1. The Modification of Histones
Histones contain serine, threonine, lysine and arginine polar residues, which are 
displayed on the surface of the nucleosome and are modified during the DNA 
damage response. In response to DNA damage a variant of histone H2, H2AX is 
phosphoiylated at S139 (yH2AX) by the protein kinases (ATR, ATM and DNA- 
PK). ATM is the most important o f the three kinases, as ATM-/- fibroblasts fail to
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form yH2AX foci (Celeste et a i  2003) and the ATM inhibitor wortmannin inhibits 
H2AX phosphorylation (Pauli et al. 2000). This phosphorylation o f H2AX occurs in 
the region surrounding double strand breaks (a Mb on either side (Lowndes et al.
2005)) but it is not phosphoiylated specifically at the break (Berkovich et al. 2007). 
This phosphorylation o f H2AX aids the recmitment of the repair proteins including 
BRCAl, NBSl and M D Cl, and acts as a docking site; MDCl via its BRCT domain 
binds phosphorylated H2AX directly (Stucki et al. 2005). The importance of H2AX 
phosphoiylation in the recmitment o f repair proteins is shown in mice lacking 
H2AX which show an increase in cancer incidence (Celeste et al. 2003) and fail to 
produce damage foci (Bassing et al. 2004). In addition the phosphorylation of H4 
(SI) by casein Idnase II is localised to the sites of DSB and promotes NHEJ in S. 
cerevisiae (Cheung et al. 2005).
The addition of methyl groups (CH3) to lysine residues o f the histones removes the 
positive charge and dismpts the DNA-histone interaction, and is essential for the 
recmitment o f the BRCAl homologues in yeast; méthylation o f H3 (79) is essential 
for the recruitment of the Rad9 in budding yeast (Huyen et al. 2004), and Crb2 is 
recruited via H4 K20 méthylation in fission yeast (Sanders et al. 2004).
Similarly to méthylation the addition o f an acetyl group to the lysine residues within 
the histones disrupts the DNA-histone bonds (Narlikar et al. 2002), and increases 
access of the repair proteins (Downey et al. 2006). This acétylation is earned out by 
two groups of enzymes; histone acetyltransferases (HAT) which acetylates the lysine
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residues and histone deacetyltransferase (HDAC) enzymes which remove the acetyl 
group. One HAT enzyme in humans Tip60 has two roles in the DNA damage 
response; firstly it acetylates ATM activating the kinase (Jiang et al. 2006) and 
secondly it acetylates H4 and H2AX facilitating the loading o f the repair proteins 
BRCAl and RAD51 to the sites of DNA damage (Loizou et a l  2006),
The ubiquitination of histones is important in the regulation of the DNA damage 
response, as the ubiquitin associated proteins localise to y-H2AX foci and of H2AX, 
H3 and H4 acétylation is induced following both IR and UV damage (Wang et al.
2006). As discussed previously following DNA damage H2AX is acetylated by the 
HAT enzyme Tip60, this acétylation of H2AX has now been shown to be an 
essential event in the subsequent ubiquitination of H2AX by the ubiquitin 
conjugating enzyme (UBC13), and the modification of chromatin stracture (Ikura et 
a l  2007).
1.5.2. Modification of Chromatin by ATP-dependent Chromatin 
Remodellers
The modification o f the core nucleosomes by ATP-dependent chromatin remodellers 
use ATP to dismpt the bonds between DNA and the nucleosomes, sliding the 
nucleosome resulting in a looping out of the surrounding DNA. This results in a 
more “open” chromatin state increasing accessibility for the repair proteins. These 
enzymes belong to a large family o f enzymes which contain a central ATPase
23
C h a p te r  1 - l in roduc lion
catalytic subunit. Studies in yeast have shown that these chromatin remodellers are 
recruited to the sites o f DNA damage (Shim et al. 2005) and are essential for both 
the recruitment of RAD51 to the site of DNA damage and the loading of RAD51 
onto ssDNA (Tsukuda et al. 2005). In addition these complexes are also required for 
strand invasion dming HR (Chai et al. 2005). The mechanism of chromatin 
remodelling by these enzymes is linked to other histone modifications as the actions 
o f Brgl (Brahma related gene 1) the ATPase subunit of the chromatin remodeller 
SWISNF (Switch Mating Type, Sucrose Non-Fermenting) binds the acetylated 
lysine following DNA damage (Shen et al. 2007).
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Figure 5: Summarisation of chromatin modifications during the DNA damage 
Response, a) Each nucleosome contains a histone octamer core containing histones 
H2A, H2B, H3 and H4, with 147bp o f  DNA wrapped around, b) Phosphorylations 
o f histones H2AX (8129) and H4 (SI), b) Méthylation o f H4 (K20), and H3 (K79, 
K4). c) Acétylation o f  histones H4 (K5, K8, K12, K16, and K91), and H4 (K9, K14, 
K18, K27 and K56). e) Chromatin remodelling by the chromatin remodelling 
enzymes results in a looping out o f the DNA surrounding the nucleosome. f) 
Ubiquitination o f H2B (K123).
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1.6. TopBPl
TopBPl is an essential nuclear protein, as downregulation of TopBPl results in 
decreased cell viability (Yamane et al. 2002), this protein, and its role in 
transcription, replication and repair provides the main focus of this thesis. TopBPl 
was first identified as an interacting protein for Topoisomerase II (3 using a yeast two 
hybrid assay (Yamane et al. 1997). Following DNA damage TopBPl is 
phosphoiylated by ATM (Yamane et al. 2002) and localises to the sites o f DNA 
damage (Yamane et al. 2002), co localising with other sensoiy proteins including 
NBSl o f the MRN complex (Morishima et al. 2007), BRCAl, PML (Xu et al. 2003) 
and the 9-1-1 subunit Rad9 (Greer et al. 2003). TopBPl is also involved in the 
activation of the transducers following DNA damage; TopBPl interacts directly with 
the phosphoiylated S345 of Rad9 via BRCT 1 and 2 (Delacroix et al. 2007), 
facilitating the loading o f the 9-1-1 complex and the activation of Chkl via ATR- 
ATRIP and ultimately the activation o f the cell cycle checkpoints. Further to this 
XTopBPl has been shown to interact directly with XATR-XATRIP via amino acids 
978-1192 and activate ATR kinase activity, this interaction is dependent on all tlnee 
proteins and point mutant o f TopBPl W1138R still binds XATR-ATRIP but fails to 
activate XATR kinase activity (Kumagai et al. 2006). TopBPl may also monitor 
recombination at DSB, as it co-localises with ATR, during meiosis (Perera et al. 
2004).
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1.6.1. Structure of TopBPl
TopBPl contains eight BRCT (Breast Cancer Susceptibility Gene 1 [BRCAl] 
Carboxyl Terminus) domains (Yamane et a l  1999) which were originally identified 
within the carboxyl terminus of BRCAl and as discussed (1.1.1.) BRCT domains 
are found in a variety o f proteins involved in cell cycle control, DNA repair and 
transcriptional regulation [BRCAl (Glover et a l  2006), NBS (Kobayashi et a l
2004) and RAD9 (Hammet et a l  2007)]. BRCT domains consist o f hydrophobic 
tandem repeats, which are involved in interacting with other proteins, 
phosphoiylated peptides (Glover et a l  2004), as well as single and double stranded 
DNA (Yu et a l  2003). Therefore following DNA damage, BRCT domains can alter 
their interacting partners and potentially interacting directly with damaged DNA, 
making their role in the DNA damage response essential for the correct regulation of 
the response. In addition no other protein has as many as eight BRCT domains 
indicating that TopBPl plays an essential role in the processes described.
1.6.2. Homologues of TopBPl
DNA repair pathways are integral to all cellular organisms and are highly conserved 
in eukaryotes, the fission yeast Schizosaccaromyces Pombe (Rad4), budding yeast 
Saccharomyces Cerevisiae (D bpll), Drosophila melanogaster (Mus 101), Xenopus 
laevi (XTopBPl) and Caernorhabditis elegans (F37D6.1) all have TopBPl
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homologues. Therefore further insight into roles of TopBPl in the DNA damage 
response comes from the study o f these proteins. Figure 6 shows the amino acid 
sequence similarity and BRCT domains which are conserved by the TopBPl 
homologues discussed within this chapter.
1.6.2.1. Fission Yeast Schizosaccaromyces Pombe Homologue Rad4/ 
Cuts
The Schizosaccaromyces Pombe TopBPl homolog was first identified as a radiation 
sensitive mutant (Rad4^°^^^^l and later as a “cell ultimately torn” mutant, Cut5 in a 
separate yeast screen (Saka et a l  1993). This fission yeast homologue o f TopBPl 
contains four BRCT domains and has roles in the S phase checkpoint and the DNA 
damage response. Saka et a l  showed that Rad4^°*’®^  ^ was essential for S~M 
checkpoint, and the initiation o f replication in mutants of Rad4^°'’^ ^^  show a cell 
cycle defect resulting in an increased the percentage of cells in S-phase (Spiga et al.
2004). Rad9 phosphoiylation at Thi‘412 and Ser423 in response to DNA damage 
activates Rad4^°*’®^  ^ binding via BRCT three and four (Fiuaiya et al. 2004). 
Rad4^°^®^  ^associates with Rad26"^^^^^ and Rad3'^^‘^  (Taricani et al. 2006) which then 
activates Clikl. The Rad3 ^^^-Rad26 phosphoiylation o f Chkl requires Crb2 
(Saka et al. 1997). Crb2 contains one BRCT domain and forms foci in response to 
DNA damage (Du et al. 2003). Rad4^°^®^  ^ binds Crb2 via BRCT I and II, and using 
a yeast two hybrid assay Du et al. 2006 showed Crb2 binds Rad4^°^’®^* via its BRCT 
domain and that Rad4^°^°*"' is essential to recruit Crb2 to the sites of DNA damage.
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1.6.2.2. Budding Yeast Saccharomyces Cerevisiae Homologue D p b ll
The budding yeast Saccharomyces cerevisiae TopBPl homologue D p b ll (DNA 
polymerase B possible subunit 11) contains four BRCT domains and was identified 
as an interacting partner o f DNA polymerase II (Araki et al. 1995). D pb ll like 
Rad4^“’’®^  ^ has roles in both DNA replication and DNA damage. D p b ll co- 
immunoprecipitates with Pol e in S-phase extracts but not G1 extracts (Masumoto et 
al. 2000) and forms a complex with DNA polymerase II (Araki et al. 1995) 
recmiting it to the origins o f replication (Masumoto et al. 2000). Chromatin 
immunoprécipitation showed that D p b ll associates with DNA pol s, at the origins 
o f replication; and this association with these origins is dependent on MCM and 
RPA. D pb ll interacts with Dcdl (Rad9 homologue) of the Dcd 1 -Rad 17-Mec3 
(similar to human 9-1-1) complex via BRCT III and IV (Wang et al. 2002) mutant 
D pbll-1  cells carry a tmncated D p b ll (lacking C-terminal) which has a defective 
DNA damage response as it cannot interact with Dcdl.
1.6.2.3 Drosophila Melanogaster Homologue MuslOl
The mutagen sensitive 101 (M uslOl) gene was identified through a sensitivity to 
DNA-damaging agents screen in Drosophila melanogaster (Yamamoto et al. 2000). 
This sensitivity is specific to double strand breaks and not to UV radiation, and 
results in defective replication repair and a failure to recondense heterochromatin.
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M uslOl encodes seven BRCT domains when aligned with TopBPl, and sequence 
aligmnent o f these two proteins revealed that BRCT6 was the region absent in 
M uslOl (Yamamoto etal. 2000).
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Figure 6
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Figure 6: Diagrammatic Representation TopBPl homologues. This diagram 
shows the conservation between the TopBPl homologues. The number o f  BRCT 
domains in each protein is indicated (Blue box). The number o f amino acids in each 
TopBPl homologue and the percentage o f  both similar and identical residues 
(Compared against the human TopBPl) are indicated on the right o f  the diagram 
(Garcia et al. 2005). The sequence comparison o f D p b l l*  and Rad4* were 
performed using ClustalW^'^ .
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16.2.4. Xenopus Laevi Homologue
Xenopus Laevi homologue of TopBPl (XTopBPl) provides more evidence of a 
role of TopBPl in the DNA damage response and replication. XTopBPl binds 
chromatin after the initiation o f replication (Hashimoto et al. 2003). The N-terminal 
of XTopBPl encompassing BRCT 1-4 is required for the initiation of replication; 
depletion o f endogenous Xenopus XTopBPl abolished replication (as shown by the 
incorporation of radio-labelled dCTP in xenopus speim DNA), however replication 
was restored with the addition of XTopBPl containing BRCT 1-4 but not with the 
addition o f a C-terminal (BRCT5-8) XTopBPl. The C-terminal region (BRCT 5-8) 
was however shown to be the region essential for checkpoint activation via 
phosphorylation o f XTopBPl S1131 (Hashimoto et al. 2006), as phosphorylation of 
Chkl was abolished in XTopBPl depleted extracts imtil the addition of the C- 
terminal XTopBPl (Hashimoto et al. 2006). XTopBPl interacts directly with XRad9 
via BRCT I and II and not only is this region essential for the binding o f XRad9 this 
region is also essential for the checkpoint signalling as no phosphorylation of XChkl 
is found in nuclear fractions lacking XTopBPl (Lee et al. 2007). Immunodepletion 
of XTopBPl from Xenopus egg extracts results in a loss of Radi phosphoiylation by 
ATR (Lupardus et al. 2006) and a failure to phosphorylate Chkl and induce cell 
cycle arrest, however Chk2 is not similarly effected.
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1.6.2.5. Caernorhabditis elegans Homologue F37D6.1
The Caernorhabditis elegans (C.elegans) TopBPl homologue F37D6.1 contains 8 
BRCT domains. C.elegans provide a tool for studying genes involved in the DNA 
damage response as these genes can be specifically loiocked down in these animals 
by feeding E.coli clones expressing double stranded RNA. Van Haaften and 
colleagues used this model system to investigate genes essential for the DNA 
damage response (Van Haaften et a l  2004), They used a strain o f C.elegans 
(NL1832) which show an increase in DSB, and knocked out 74 genes involved in 
the DNA damage response to determine if  the knock down of any o f these genes 
resulted in a lethal phenotype. They identified three genes which resulted in 
lethality; one of which was the TopBPl homolog F37D6.1. They also showed that 
knockdown o f F37D6.1 resulted in an increase in chromosome aberrations following 
gamma irradiation, demonstrating that TopBPl is essential for the repair of DSB 
following DNA damage.
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1.6.3. TopBPl-A Possible Transcription Factor?
Research indicates that TopBPl is possible a transcriptional regulator. TopBPl 
interacts with and represses the transcription and apoptotic effects o f E2F1 in a 
Brgl/Brm  dependent manner as repression of E2F1 was not seen in the Brgl/Brm 
compromised C33a cell line (Liu et ah 2003). Lui et al. 2003 showed that TopBPl 
directly interacts with E2F1 via BRCT6, and is recruited to E2F1 responsive 
promoter. TopBPl interacts with the HPV16 viral transcription/replication protein 
E2 and co-activates transcription and replication (Boner et al. 2002), In addition 
TopBPl directly interacts with M izl via BRCT 7 and 8, and the interactions o f these 
two proteins is essential for the repression of Myc targeted genes (Herold et al. 
2002, Myc review see Eisenman et al. 2001). The transcription factor c-myc belongs 
to a family of genes that are found in human cancers resulting from an increase in 
the expression of the proteins (He et al. 1998).
As discussed earlier (1.1.1) BRCAl plays an essential role in the regulation of the 
DNA damage response (Zhang et al. 1998). BRCAl contains two BRCT domains 
within the carboxyl teiminal and a domain spanning this region o f BRCAl (amino 
acids 1560-1863 including the BRCT domains) can act as a transcriptional activation 
domain when fused to GAL4 DNA binding domains (Monteiro et al. 1996). In 1997 
Monteiro and colleagues found that a common disease predisposing mutation 
(SeiT613Cys) within the transactivation domain could not activate transcription in
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yeast compared to a common non-disease variant of the same residue (Monteiro et 
al. 1997). This work demonstrated that BRCAl tumour suppressor activity was 
directly linked to its transcriptional activity. Further analysis o f these BRCT 
domains has shown that they are frequently the region mutated in early onset breast 
cancer (Futreal et al. 1994) resulting in a loss of BRCT structure (Glover et al. 
2006). This is supported by the studies in mice in which truncation o f the BRCT 
domains resulting in a loss o f BRCT stmcture causes tumours in mice (Ludwig et al. 
2001). This precedence for the role of BRCT domains in transcriptional regulation 
and ftmction set by BRCAl suggested that the ability o f TopBPl to modulate 
transcription was perhaps via one o f the eight BRCT domains.
1.6.4. TopBPl and Breast Cancer
The importance o f a faithM  functioning DNA damage response is demonstrated by 
the disease states which are a direct result of defects within DNA damage response 
proteins. Table 2 summarises some of these diseases which arise from a failure to 
respond correctly to DNA damage and indicates the phase of the DNA damage 
response where these proteins function. In addition to similarities between the BRCT 
containing proteins TopBPl and BRCAl in sensing DNA damage and repair, there 
is increasing evidence that like BRCAl, TopBPl plays a critical role in breast cancer 
implicating it as a possible breast cancer susceptibility gene.
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10% of all breast cancer cases are familial cases; o f which 50% are a result of either 
BRCAl or BRCA2 mutations and 5% are a result of other gene alterations (p53 
(Malkin et a l 1990), ATM (Swift et a l 1991)) however the susceptibility genes in 
the remaining 35% are still unaccounted for. Karppinen et a l  provided the first 
evidence for TopBPl as a breast cancer susceptibility gene (Karppinen et a l  2006), 
To investigate the possible involvement of TopBPl in hereditary breast cancer they 
screened for germline polymoiphisms within the TopBPl gene in 125 familial breast 
cancers and compared the results to 187 non-hereditary breast cancers and 697 
control samples. They identified a novel variant Arg309Cys, the incidence o f which 
was increased compared to both healthy and non-familial breast cancer controls. In 
addition none of the familial samples carrying this polymorphism contained either a 
BRCAl or BRCA2 mutation, thus implicating TopBPl as a breast cancer 
susceptibility gene.
Karihtala et a l  investigated the relationship between the levels of ROS and the 
expression of repair enzymes in benign, hyperplasia, in situ tumours and stage I 
breast tumours to identify if expression of these repairs enzymes correlated with the 
amount of damage within these cells (Karihtala et a l  2006). The measurement o f 8- 
hydroxydeoxyguanosine (8-OHdG) was used as a marker o f DNA damage by ROS 
because 8-OHdG is produced following an imbalance in H2O2 redox reactions when 
the enzymes involved are overwhelmed by the accumulated DNA damage. 8-OHdG 
expression increased from benign to invasive tumours, consistent with previous 
results which showed 80HdG levels increased 15 fold in breast carcinomas
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(Musarmt et al. 1996). TopBPl associated with 80HdG but not with other markers 
o f damage and the expression o f TopBPl also increased during cancer progression 
from hypeiplasia to invasive tumours (10% hyperplasia, 8% in situ (low grade), 45% 
in situ (high grade) and 35% of stage I tumours). This correlation between an 
increase in TopBPl staining and cancer progression was also obseiwed by Morris et 
al. 2007. They stained 123 feline mammary lesions for TopBPl and found that the 
percentage of cells with TopBPl staining increased as the histology of the lesion 
increased from benign to high grade carcinomas (10 samples in the high grade 
lesions showed strong TopBPl staining in 80-100% of cells compared to only 1 
sample in non-neoplastic samples). Furthermore, an increase in TopBPl cytoplasmic 
staining was observed as the malignancy increased (P< 0.001). Aberrant cytoplasmic 
staining of TopBPl in breast cancer was also obseiwed in another study in which 
9/59 human breast cancer samples (ranging from grade I to grade III invasive 
carcinomas) showed either nuclear and cytoplasmic or solely cytoplasmic staining 
(Going et al. 2007).
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Table 2
D isease P ro te in F unction R efe ren ce
S e n s o r
Testicular tumors Rad 17 RFCITike von Delmling e ta f .  1999
Nonsmall cell lung carcinoma Rad9 PCNA-like Manlwa ef al. 2005
A-T-iike disorder (A-TLD) Mre11 DSB recognition/nuclease Stewart et s/. 1999
Nijmegen b reakage syndrom e NBSl DSB recognltlon/nuclease Varon e ta l .  1998
Breast C ancer TopB Pl BRCT containing Going et al. 2007
Breast and Ovarian Cancer BRCA1 BRCT containing Hartlkalnen ef a/. 2007
T ra n sd u c e rs
Ataxia-teiengiestcfasia (AT) ATM PI3 Kinases B ro ek sefa /. 1998
Familial B reast Cancer Broeks ef al. 2000
Seckei Syndrome ATR PI3 Kinases Alderton ef al. 2004
Breast Cancer Durocher ef al. 2006
Colorectal Cancer Chkl Ser/Thr Kinase M adoz-Giirplde et al 2007
Li-Fraumeni Syndrome Chk2 Ser/Thr Kinase Allinen ef al. 2001
Familial B reast C ancer
Prostate Cancer Dong e ta l .  2003
E ffector
LI-FraumenI Syndrom e p53 Transcription Factor Capponcelli ef a l . 2005
B reast/Pancreatic Cancer Malkin etal .  1990
Ttiyroid iymptioma Cdc25A P hosphatase ito e f af, 2005
B reast C ancer ito e fa /. 2004
Thyroid Iymptioma Cdc25B P hosphatase ito ef al. 2005
Prostate  C ancer Cdc25C P hosphatase Ozen ef al. 2005
Breast C ancer BRCA2 Repair Fackenthal ef al. 2002
Ovarian Cancer Hartlkalnen ef al. 2007
Colorectal C ancer MSH2 Repair Froggatt ef a/. 1999
Colorectal C ancer MLH1 Repair LIpkin e f al. 2004
Turcot's syndrom e Hamilton ef a/. 1995
FalconI Anaem ia FANCD2 Repair Futaki e t al. 2001
Hodgkin lymphoma Cdkl Kinase Bal etal .  2005
Table 2; Diseases associated with defects within the DNA dam age response. This 
table lists the DNA damage response proteins which are altered/lost in the disease 
indicated. The reference for each protein-disease link is also given.
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Although TopBPl is a possible transcription factor and a suspected breast cancer 
susceptibility gene the domains and protein partners involved ai e not clearly defined, 
therefore this thesis has three main aims:
I. To identify any transcriptional regulatory domains within TopBPl, such 
domains modify chromatin and therefore could be involved in all aspects of 
TopBPl function; transcription, replication and repair.
II. To identify fimctional TopBPl interacting partners.
III. To identify the genes regulated by TopBPl under “normal” conditions and in 
response to double strand breaks.
39
Chapter 2 - Materials and Metliods
2 - Materials and Methods
2.1. Materials
2.1.1. Antibodies
Abeam Pic (Cam bridge, United Kingdom)
Anti-Sheep IgG horseradish peroxidase linked whole molecule (raised in Donkey) 
Catalogue Number: Ab6900
Am ersham  International pic (Buckingham shire, United Kingdom)
Anti-Mouse IgG horseradish peroxidase linked whole molecule (raised in sheep) 
Catalogue Number: N X A 931
Applied Biosystems (California, USA)
Anti-mouse IgG (whole molecule) FITC conjugate, developed in goat 
Catalogue Number: T5393
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BD Transduction Laboratories (Oxford, United Kingdom)
Anti-TopBPl (amino acids 204-216) murine monoclonal antibody 
Catalogue Number: 611875
Santa Cruz Biotechnology Inc (Heidelberg, Germany)
Anti-Brgl (amino acids 209-296) polyclonal rabbit antibody 
Catalogue Number: sc-10768
Anti-Brgl N-terminus polyclonal goat antibody 
Catalogue Number: sc-8749
Sigm a-Aldrich Com pany Ltd. (Dorset, United Kingdom)
Anti-Rabbit IgG (whole molecule) peroxidase developed in goat 
Catalogue Number: A6154
Upstate (Dundee, United Kingdom)
Anti-phospho-H2A.X (Serl39) developed in rabbit 
Catalogue Number: 07-164
Dr. Stefan Roberts (University o f  M anchester, United Kingdom)
The Anti-GAL4 DNA binding domain polyclonal sheep antibody was a kind gift 
from Dr. Stefan Roberts (University of Manchester).
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TopBPl polyclonal antibody R1180 against amino acids 861-1287 was raised in a 
rabbit, method of preparation of the antibody and the preimmune have been 
described previously (Boner et al. 2002).
2.1.2. Bacteriology
Becton Dickinson Labware (Oxford, United Kingdom )
15ml polyproplylene tubes - Catalogue Number; 348206 
50ml polypropylene tubes - Catalogue Number; 358206 
20ml sterile syringe - Catalogue Number: 301031 
BD BactO™ Agar - Catalogue Number: 214010
Bibby Sterliii Ltd (Staffordshire, United Kingdom)
90mm bacteriology petri dishes - Catalogue Number: 502014
Institute o f Com parative M edicine Central Seiwices (University o f Glasgow, 
United Kingdom)
Luria Broth (L-Broth), 1 litre: lOg Tryptone, lOg NaCl, 5g yeast extract completed 
ddH20)
Luria Bertai agar, 1 litre: lOg Tryptone, lOg NaCl, 5g yeast extract, 15g 
bacteriological agar completed with ddH?0).
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Invitrogen Ltd (Paisley, United Kingdom)
Max efficiency® chemically competent cells - Catalogue Number: 18258
Subcloning e f f ic ie n c y D H 5 a ™  chemically competent cells - Catalogue Number: 
18265
Sigma Chemical Co. Ltd (Dorset United Kingdom)
Ampicillin - Catalogue Number: 10047
Isopropyl-(3-D-l-thiogalactosidase (IPTG) - Catalogue Number: 15502 
Kanamycin - Catalogue Number: K1876
5“Brom o-4-chloro-3-indolyl-|3-D"galaGtopyranoside (X -G A L ) - Catalogue Number: 16664 
Typtone microbiology tested - Catalogue Number:T7293
2.1.3 Cell lines
C33a cells are derived from a HPV negative cervical carcinoma and are defective 
for both p53 and pRb function. C33a cells were obtained from Cancer Research UK 
(Cancer Research United Kingdom (CRUK), London).
Human Embi-yoiiic K idney 293T (HEK293T) are derived from the 293 cell line in 
which the SV40 T-antigen was inserted. HEK293T cells were a kind gift from Dr. 
Brian Willet, University o f Glasgow.
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M CF7 cells derived from a Human Caucasian breast adenocarcinoma were 
purchased from Cancer Research UK (CRUK, London United Kingdom).
M RC5 cells are a primaiy human foetal derived cell line was purchased from 
CRUK (CRUK, London United Kingdom).
U 2 0 S  are an oesteosarcoma cell line, expressing wild type p53 and were purchased 
from CRUK (CRUK, London United Kingdom).
2.1.4 Chemicals and Reagents
Am ersham  International PLC (Buckingham shire, United Kingdom )
Enhanced Chemiluminescence (ECLplus) detection substrate - Catalogue Number: PN2132 
Hyperfilm X-ray film - Catalogue Number: 93184
Applied Biosystems (W arrington, United Kingdom)
Hi-Di™ Formamide - Catalogue Number: 4336697
Invitrogen Ltd (Paisley, United Kingdom)
Agarose (ultrapure electrophoresis grade) - Catalogue Number: 41025
Roche Biosystem s (Basel, Switzerland)
Complete Protease Inhibitor Cocktail Tablets - Catalogue Number: 12481800
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Sigm a Chemicals Co. Ltd (Dorset, United Kingdom)
l- (4 , 5 -D im ethylth iazol-2-yl)-3 , 5 -diphenyl formazan (MTT) - Catalogue Number:M2003
3',5',5''~TetrabromophenoIsulfophethalein (Brom phenol B lue) - Catalogue Number: BO 126
4-(2-H ydroxyethyl) p ip erazine-l-etlianesu lfon ic acid (H EPES) - Catalogue Number: H4034
3-Hydroxy-4-(2-sulfo-4-[4-sulfopheiiylazo] phenylazo)-2, 7-naphthaIenedisulfonic
acid sodium salt (Ponceau S) -Catalogue Number: P7170
Acetic acid sodium salt (Sodium acetate) - Catalogue Number: S2889
Bicinchonoinic Acid (BCA) solution - Catalogue Number: B9643
Boric Acid ~99% - Catalogue Number:B6768
(3-Mercaptoethanol - Catalogue Number: M6250
Caffeine 99% tissue culture grade - Catalogue Number: C8960
Copper (II) sulphate (pentahydrate 4% (w/v) solution) - Catalogue Number: C2284
Ethidium Bromide - Catalogue Number: E1510
Magnesium Chloride (MgCl2) anhydrous beads - Catalogue Number: 449172  
N-lauroylsarcosine solution - Catalogue Number: L7414 
Nonident P-40 (NP40) - Catalogue Number: 18896
Phenol: Chloroform: Isoamyl Alcohol (25:24:1) - Catalogue Number: P3803 
Sodium Acetate - Catalogue Number: S2889  
Sodium Chloride - Catalogue Number: S7653
Tween 20 (Polyoxethylene sorbitan nonolaurate) - Catalogue Number: P I379 
Tris B ase  (2 -A m in o-2-(h yd roxym eth y l)-l, 3 -propanediol) - Catalogue Number: T6066 
Thiazolyl Blue Tétrazolium Bromide (MTT) - Catalogue Number: M5655
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University o f  Glasgow Stores (G lasgow, United Kingdom)
Crude ethanol
VW R  International (Leicestershire, United Kingdom)
Absolute 99.7-100% AnalaR® ethanol - Catalogue Number: I0107EP
AnalaR® Sodium Hydroxide pellets - Catalogue Number: 102524X
AnalaR® Glycine molecular biology grade - Catalogue Number: 101194M
AnalaR® D-(+)-Glucose - Catalogue Number: 101176K
AnalaR® Glycerol - Catalogue Number: 10118EU
Crystal Violet - Catalogue Number: 340245L
Dimethyl sulfoxide (DMSO) - Catalogue Number: 8029122500
Ethylene diamine tetra acetate (EDTA) disodium salt - Catalogue Number: 30031.294  
Hydrochloric acid - Catalogue Number: 101252F 
Methanol AnalaR® - Catalogue Number: 10158FK
Propan-2-ol (Isopropanol) Molecular Biology Grade - Catalogue Number: 437423R 
Sodium dodecyl sulphate (SDS) AnalaR® - Catalogue Number: 108073J
2.1.5 Enzymes
Cambrex Bioscience (W okingham , United Kingdom)
Takara DNA ligation Kit (version V) - Catalogue Number 6022
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Invitrogen Ltd (Paisley, United Kingdom)
BamHl and reaction buffer (REact® 3) - Catalogue Number: 15201 
EcoRl and reaction buffer (REact ® 3) - Catalogue Number: 15202 
Kpnl and reaction buffer (REact ® 4) - Catalogue Number: 15232 
Platinum ® Taq DNA polymerase - Catalogue Number; 10966
New England Biolabs (Hitchin, United K ingdom )
Antarctic phosphatase and reaction buffer - Catalogue Number: MD289L
Prom ega Ltd (Southam pton, United Kingdom )
Pfu DNA Polymerase lOX Reaction Buffer with MgS04 - Catalogue Number: M7741
dATP lOOmM (40pmol) - Catalogue Number: U1205
dCTPlOOmM (40pmol) - Catalogue Number; U1225
dGTPlOOmM (40pmol) - Catalogue Number: U1202
dTTP lOOmM (40pmol) - Catalogue Number: U1235
2,1.6 Kits
Applied Biosystem s (W arrington, United Kingdom)
BigDye® Terminator v3.1 Cycle Sequencing Kit - Catalogue Number: 4337455
Invitrogen Ltd (Paisley, United Kingdom)
ChargeSwitch® Plasmid ER Mini Kit - Catalogue Number: CSlOlOO
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ChargeSwitch® PGR Clean-Up Kit - Catalogue Number: CS12000
Pureiink® plasmid maxiprep kit - Catalogue Number: K 210006
NuPAGE® 4-12% Bis-Tris 12 well 1.0 mm gels - Catalogue Number: NP0302BOX
NuPAGE® 4-12% Bis-Tris 10 well 1.0 mm gels - Catalogue Number: NP0301BOX
NuPAGE® Sample Reducing Agent (lOX) - Catalogue Number: NP0009
NuPAGE® Antioxidant - Catalogue Number: NP0005
NuPAGE® MES SDS Running Buffer (20X) - Catalogue Number: NP0002
NuPAGE® Transfer Buffer (20X) - Catalogue Number: NP0006
Prom ega Ltd (Southam pton, United Kingdom)
Luciferase Assay System - Catalogue Number: E l500 
Reporter Lysis Buffer (5x solution) - Catalogue Number: E3971
Qiagen Ltd (Crawley, United Kingdom)
QIAquick Gel Extraction Kit - Catalogue Number: 28704 
QIAquick PCR Purification Kit - Catalogue Number: 28104 
QIAGEN Plasmid Midi Kit - Catalogue Number: 12162 
RNAeasy RNA extraction Kit - Catalogue Number: 74104 
QIAprep Spin Miniprep Kit - Catalogue Number: 27106
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2.1.7 Miscellaneous
Corning® Life Sciences (Leicestershire, United Kingdom)
96 Well Clear Flat Bottom Microplate - Catalogue Number: 3635
Decon Laboratories Ltd (Hove, United Kingdom)
Decon 75® Liquid
Elkay International (Basingstoke, United Kingdom)
1.5ml microcentrifuge tubes with attached cap - Catalogue Number: MICR050 
0.5ml microcentrifuge tubes with attached cap - Catalogue Number: MICROS 1 
Plastic Pasteur pipettes - Catalogue Number: P 511
EquiBio (Kent, United Kingdom)
2mm electroporation cuvettes - Catalogue Number: ECU-102
Kim berley Clark (Brighton, United Kingdom)
Safeskin Disposable Purple Nitrile Exam Gloves - Catalogue Number: 014602
M orrisons Superm arket (Anniesland, United Kingdom)
Marvel dried skimmed milk
Sigma Chemicals Co. Ltd (Dorset, United Kingdom)
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Protein G Sepharose® Fast Flow in 20% ethanol - Catalogue Number: P3296
Thermo Labsytem s Corporation (W arwickshire, United Kingdom )
Lmninoskan Acsent Luminometer and Ascent software (version 2.4.2)
Ultra Violet Productions (UVP) (Cam bridge, United Kingdom )
UVP Multi-doc gel documentation system
Fligh performance ultra-violet transilluminator (UVP VB-26)
Vector Laboratories, Ltd., (Peterborough, United Kingdom)
VECT A SHIELD Mounting Medium with DAPI - Catalogue Number: H-1200
2.1.8. Molecular Weight Markers
Invitrogeii Ltd (Paisley, U.K.)
100 bp DNA Ladder - Catalogue Number: 15628 
1Kb DNA Ladder - Catalogue Number: 15615
See Blue® Pre-stained protein standard - Catalogue Number: LC5925
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2.1.9. Plasmids
pA C T vector expresses the herpes simplex virus VP 16 activation domain amino 
acids 411-456 under control of the cytomegalovirus (CMV) immediate early 
promoter (Promega Ltd Southampton, United Kingdom).
pBIND vector contains the yeast GAL4-DNA binding domain upstream of a 
multiple cloning region. (Promega Ltd Southampton, United Kingdom). 
pC G B rgl (4638) vector expresses wild type Brgl under the control of the 
cytomegalovirus (CMV) promoter, and was a kind gift from Dr. Christian Muchardt, 
referred to as Brg (wt) in the text.
pC G B rgl ATP mutant (4639) vector expresses ATP mutant Brgl under the control 
of the cytomegalovirus (CMV) promoter, and was a kind gift from Dr. Christian 
Muchardt, referred to as Brg (-/-) in the text.
pCGBrm  (4102) vector expresses wild type Brm under the control of the 
cytomegalovirus (CMV) promoter, and was a kind gift from Dr. Christian Muchardt, 
referred to as Brm (wt) in the text.
pCGBrm ATP mutant (4137) vector expresses ATP mutant Brm under the control 
of the cytomegalovirus (CMV) promoter, and was a kind gift from Dr. Christian 
Muchardt (Pasteur Institute, Paris) and is referred to as Brm (-/-) in the text.
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pCM V mammalian expression vector was a kind gift from Peter Howley (Harvard 
University, Boston, USA).
pE 2F l vector expresses the full length E2F1 under the control of the 
cytomegalovirus (CMV) promoter, and was a kind gift from Dr. Kevin Ryan 
(Beatson Institute for Cancer Research, Glasgow).
pGBKT7 expresses proteins fused to amino acids 1-147 o f the Gal4 DNA binding 
domain, in yeast proteins are expressed from the ADHl promoter.
pGSIuc contains five GAL4 binding sites upstream o f a minimal TATA box, 
upstream of the firefly luciferase gene (Promega Ltd Southampton, United 
Kingdom).
pGL3 control contains SV40 promoter and enhancer sequences driving the 
expression of firefly luciferase (Promega Ltd Southampton, United Kingdom).
pGL3 basic lacks promoter and enhancer sequences (Promega Ltd Southampton, 
United Kingdom).
ptk6E2Iuc contains the thymidine kinase promoter from HSV-1 cloned into the 
pGLB luciferase vector upstream of 6 HPV-16 E2 binding sites (Vance et a l  1999).
pT opB Pl expresses the full length TopBPl under control of the cytomegalovirus 
promoter and was a kind gift from Dr. Kazuhiko Yamane.
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p73Iiic luciferase vector contains E2F1 binding sites has been described previously 
(Irwin et al. 2000), and was a kind gift from Dr. Kevin Ryan (Beatson Institute for 
Cancer Research, Glasgow).
2.1.10. Tissue Culture
Amaxa Biosystems (Cologne, Germany)
Nucleofectoi'T''^ II device
Cell line Nucleofector K it V- Catalogue Number VGA - 1003
Corning incorporated (Leicestershire, United Kingdom)
100mm X 20mm non-pyrogenic cell culture dishes - Catalogue Number: 3296 
60mm X 15mm non-pyrogenic cell culture dishes - Catalogue Number: 4301 
25ml disposable serological polystyrene pipettes - Catalogue Number: 4251 
10ml disposable serological polystyrene pipettes - Catalogue Number: 4101 
5ml disposable serological polystyrene pipettes - Catalogue Number: 4135 
6 well flat bottom non-pyrogenic cell culture cluster - Catalogue Number: 3506 
12 well flat bottom non-pyrogenic cell culture cluster - Catalogue Number: 3512 
24 well flat bottom non-pyrogenic cell culture cluster - Catalogue Number; 3524 
96 well flat bottom non-pyrogenic cell culture cluster - Catalogue Number: 3596 
External thread cryogenic vials - Catalogue Number: 430287 
Cell scraper - Catalogue Number: 3010
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Greiner Bio-one Ltd (Stonehouse, United Kingdom )
50ml polypropylene centrifuge tubes - Catalogue Number: 210201 
15ml polypropylene centrifuge tubes - Catalogue Number; 188261
Invitrogen Ltd (Paisley, U nited Kingdom)
DMEM 1 X w/GlutaMAX^WGlucose Na Pyr - Catalogue Number: 11995 
Distilled water - Catalogue Number; 15230 
Foetal bovine serum - Catalogue Number: 16141
Penicillin-Streptomycin Solution (5000:5000) liquid - Catalogue Number: 15070 
Tiypsin-EDTA ( I x )  0.05% trypsin 0.53mM EDTA'Na - Catalogue Number: 25300
Nunc™  Part o f Thermo Fisher Scientific (Hereford, UK)
25cm tissue culture flasks with filtered caps - Catalogue Number: 136196 
80cm tissue culture flasks with filtered caps - Catalogue Number: 178905 
175cm tissue culture flasks with filtered caps - Catalogue Number: 178883
Prom ega Ltd Southam pton, United Kingdom
Phosphate buffered saline (PBS) tablets - Catalogue Number: P4417
2.1.11. Yeast Materials
Clontech Ltd (W okingham , United Kingdom )
AH 109 Yeast strain - Catalogue Number: 630444
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Invitrogen Ltd (Paisley, United Kingdom)
BL21 E. coli competent cells - Catalogue Number: C6070
Sigm a Aldrich Ltd (Dorset, United K ingdom )
Sodium carbonate (Na2C03 ) - Catalogue Number: S7795
Magnesium sulfate (MgS04) - Catalogue Number: M2643
Poly (ethylene glycol) (PEG) - Catalogue Number: 81150
Sodium trichloroacetate (TCA) - Catalogue Number: 45670
6-Aminopurine hemisulfate salt Adenine sulfate salt - Catalogue Number: A9I26
L-histidine monohydrate - Catalogue Number: H8000
L-Leucine - Catalogue Number: L8912
L-Tryptophan - Catalogue Number: T0254
Potassium Chloride (KCl) - Catalogue Number: P9333
Ammonium sulfate molecular biology grade >99.0% - Catalogue Number: A4418 
Lithium Acetate - Catalogue Number: 517992 
Yeast Nitrogen Base - Catalogue Number; 51483
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2 . 2  M e t h o d s
The protocols used in this thesis are described in the following section. The 
manufacturers and distributors details for the materials used are given in the 
previous section.
2.2.1 Molecular Biology
2.2.1.1. Agarose Gel Electrophoresis
Agarose gel electrophoresis was typically carried out using 1% agarose gels. The 
appropriate amount of electrophoresis grade agarose (Invitrogen) was weighed and 
dissolved in 0.5 x TBE Buffer (10 x TBE; 900mM Tris base, 900mM boric acid, 
25mM EDTA, pH8.0) by heating. For a 200ml solution 5pi (lOmg/ml) ethidium 
bromide was added, and the solution cooled to room temperature, before pouring 
into the assembled gel cast containing an appropriate sized comb. Once cooled and 
set the gel was placed into the electrophoresis tank, and submerged in 0.5 x TBE 
Buffer (as above). Sample volumes typically ranged between 10-30pl and contained 
1 X loading buffer (10 x loading buffer; 65% (w/v) sucrose, lOmM Tris-HCl pH 7.5, 
lOmM EDTA, 0.3%(w/v) broniophenol blue). Samples were loaded into individual 
wells, along side a 1Kb or lOObp ladder (depending upon predicted sample size) as a 
molecular weight marker. The sample DNA was separated by electrophoresis using 
50V until the separate bands and sizes were easily distinguishable. The DNA was
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visualised by UV light and photographed using a UVP Gel Documentation System 
(UV Productions).
2.2.1.2. DNA /RNA concentration determination
The concentration of plasmid DNA was measured using an absorbance measurement 
at 260nm (Biotech spectrophotometer -model U V llO l). An optical density reading 
(OD) o f 1 being equivalent to 50pg/ml of double stranded DNA. RNA concentration 
was determined similarly and OD o f 1 is equivalent to 40pg/ml RNA. A 
260nm/280nm absorbance ratio was measured for all plasmid preparations a reading 
of between 1.8 and 2.1 indicative o f a pure sample.
2.2.1.3. Restriction enzyme digests
Restriction digests were performed using the required restriction enzyme and the 
appropriate buffer following the manufacturer’s instructions. In general, the 
restriction digests were completed in a total volume of 30pl. This typically contained 
5-lOpl sample DNA, Ipl restriction enzyme, 3pi restriction enzyme buffer, 
completed to 30pl with distilled water. Digests were incubated at 37°C for 2-3 hours.
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2.2.I.4. DNA purification using phenol chloroform
Restriction digests, sequencing and ligation reactions were purified using phenol: 
chloroform to remove all residual contaminants. Sample volumes were typically 
completed to 100/200pl prior to extraction. An equal volume of phenol: chloroform: 
isoamyl alcohol (24:25:1 v/v/v) was added to the sample, vortexed well and 
centrifuged for 10 minutes at 15000g 4°C. This resulted in the separation of the 
aqueous and organic phases; the top aqueous phase was removed and pipetted into 
clean microcentrifuge tubes and the bottom organic phase was discarded.
2.2.15. Ethanol Precipitation of DNA
Following purification using phenol: chloroform DNA was precipitated using 
ethanol precipitation. 1/10th the sample volume of 3M sodium acetate, pFI 5.2 and 
2,5x the sample volume 100% ethanol, was added to the sample. The samples were 
vortexed and left to incubate at -20°C for 30-60 minutes. Following this 
precipitation the samples were centrifuged at 15000g, at 4°C for 20 minutes, and the 
ethanol discarded. The resulting pellet was then washed by adding Ix sample 
volume 70% ethanol and centrifuging for a further 20 minutes under the same 
conditions. The ethanol was again discarded and the pellet dried either by the use of 
a vacuum, or naturally until no ethanol remained. The precipitated DNA was then 
resuspended in 20pl distilled H2O.
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2.21.6. Phosphatase Treatment
Following restriction digests cut vectors were de-phosphorylated using antarctic 
phosphatase™ (New England Biolabs) to prevent vector re-ligation, lp.1 phosphatase 
was added to the restriction digest and incubated at 37°C for 15 minutes. The 
phosphatase and restriction enzymes were inactivated by heating to 70“C.
2.2.1.7. DNA ligation
Following restriction enzyme digests and dephosphorylation of the vector, the vector 
and insert were ligated in a typical volume of lOpl. Typically this contained; 4pi 
insert, Ipl de-phosphorylated vector, and 5pi ligase (Takara). Ligations were 
incubated at 16°C for 1 hour or overnight.
2.2.1.8. Transformation of Chemically competent Bacterial Cells
DH5a chemically competent E. coli were transformed during cloning or and prior to 
plasmid maxiprep extraction. Ipl of a ligation reaction or lOng plasmid DNA was 
added to 20pl DH5a cells and incubated on ice for 30 minutes. Following the 
incubation the cells were heat shocked at 42“C for 1 minute and placed back on ice 
for 5 minutes. lOOpl SOC medium (25ml bactotiyptone, 0.5% yeast extract, lOmM 
NaCl, 2.5mM KCl, lOmM MgCfi, lOmM MgS04  and 20mM glucose) was added to 
each tube and they were incubated at 37“C whilst shaking (225rpm) for 1 hour.
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Following the incubation the samples were plated out on antibiotic resistant agar 
plates, inverted, and incubated overnight at 37°C. Colonies were picked the 
following day and grown in 5ml L-broth (2.1.2.), 50mg/ml antibiotic, overnight at 
37°C with shaking (225rpm) prior to both small and large scale preparations of 
plasmid DNA.
2.2.1.9. Electroporation of E. coli
40pl electrocompetent BL21 cells (Invitrogen) were incubated with Ipg plasmid 
DNA and transformed by electroporation using 2.5pF, 200D 1.8kV. This was then 
transferred to 500pl SOC medium and incubated at 37°C for 1 hour with agitation 
(225rpm) before plating out on to kanamycin resistant plates.
2.2.1.10. Large Scale preparation of Plasmid DNA (Maxiprep)
Large scale preparation of plasmid DNA was carried out according to the 
manufacturer’s instmctions. Briefly, 1ml of a 5ml overnight bacterial culture in L~ 
broth ampicillin/kanamycin was used to inoculate 100ml of L-broth with selective 
antibiotic in a 2-litre glass conical flask. This bacterial culture was incubated at 37°C 
225rpm overnight. Following incubation the bacterial cells were pelleted by 
centrifugation at 5000g for 30 minutes at 4°C. The resulting supernatant was 
discarded, and the bottles inverted for 5 minutes at room temperature to remove any 
excess. The bacterial pellet was resuspended in 10ml resuspension buffer (50mM
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Tris-Cl pH 8.0, lOmM EDTA, lOOpg/ml RNase A) by vortexing and pipetting, 
before adding 10ml lysis buffer (200mM NaOH, 1% SDS) and mixing gently by 
inversion 6 times. The lysis reaction was allowed to continue for 5 minutes at room 
temperature. 10ml chilled precipitation buffer (3.0M potassium acetate pH 5.0) was 
then added and mixed gently be inversion before incubation on ice for 30 minutes. 
The resulting solution containing the genomic DNA, proteins and cell debris in the 
form o f a white fluffy precipitate was centrifuged at 5000g for 30 minutes. 
Following centrifugation the supernatant was filtered to remove the precipitate and 
the cleared lysate was added to the extraction column. The column had been 
equilibrated by adding 15ml equilibration buffer (750mM NaCl, 50mM MOPS, pH 
7.0, 15% isopropanol (v/v) and 0,15% Triton r X-100 (v/v)) before the addition of 
the lysate. The lysate was left to drain by gravity flow and a total o f 60ml wash 
buffer (l.OM NaCl, 50mM MOPS pH 7.0, 15% isopropanol) per column was added 
and left to drain by giavity flow. The wash buffer is essential to remove 
contaminants from bacterial strains which have a high amount of carbohydrate. The 
DNA now captured on the resin was eluted by adding 15ml elution buffer (1.25M 
NaCl, 50mM Tris-Cl (pH 8.5) and 15% isopropanol), and collected in 50ml 
centrifuge tubes. 12ml isopropanol was then added and to the eluted DNA and the 
sample centrifuged at 5000g 4°C for 1 hour. The resulting supernatant was decanted 
and the cell pellet washed in 10ml 70% ethanol before centrifugation at 5000g 4^C 
for 30 minutes. The pellets were allowed to air dry before being resuspended in 
300pl distilled water, and stored at-20°C  until required.
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2.2.1.11. Small scale Plasmid Purification (Miniprep)
Bacterial colonies were picked and grown overnight in 5ml L-broth at 37°C with 
shaking (225rpm). 1ml of culture was then transferred to a microcentrifuge tube. The 
samples were pelleted at 15000g at 4°C for 1 minute, and the supernatant discarded. 
The bacterial pellets were resuspended in 300p.l resuspension buffer (50mM Tris-Cl 
(pH 8.0), lOmM EDTA and lOOpg/ml RNase A) by pipetting. 300 |l i 1 lysis buffer 
(200niM NaOH, 1% SDS) was then added and mixed gently by inversion to allow 
the lysis reaction to proceed for 5 minutes at room temperature. Following lysis 
300p.l chilled precipitation buffer (3.0M potassium acetate pH 5.0) was then added 
and mixed by inversion resulting in a cloudy precipitate. This solution was then 
centrifuged for 10 minutes at 15000g, 4°C with the formation of a compact white 
pellet. The supernatant was then pipetted into an eppendorf containing 40pl 
magnetic beads, and incubated for 1 minute at room temperature. This was placed 
into a magnetic rack for 1 minute with the formation of a tight pellet. The 
supernatant was removed and 1ml wash buffer added to resuspend the magnetic 
beads. This was then placed on the magnetic rack for 1 minute to form a tight pellet 
and the supernatant discarded. This wash process was repeated once before the 
addition of 50pl elution buffer. Samples were then placed on the magnetic rack for 2 
minutes and the purified DNA was removed and transferred to an eppendorf.
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2.2.1.12, Polymerase chain reaction (PCR)
PCR reactions were routinely carried out in a volume of 50pl. Using 1-1 Ong of 
template DNA, lOpmol o f each primer (forward and reverse), 200pM each dNTP 
(dATP, dTTP, dCTP, and dGTP), Ipl polymerase and 5pi lOx Pfu polymerase 
reaction buffer, completed to 50pl with distilled water. Amplification was carried 
out using a MJ Research PTC200 gradient cycler. The cycle conditions were 
routinely as follows: 95“C for 10 minutes (dénaturation step), 94°C for 1 minute, 
55“C for 1 minute (annealing step), and 72°C for 3 minutes (elongation step). This 
cycle was repeated 25 times after which samples underwent 94“C for 1 minute 50°C 
for 1 minute, 72°C for 10 minutes and held till required at 4°C. The elongation step 
was changed depending on the desired size of PCR product.
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Table 3: 5’ Primers for cloning TopBPl into pBIND
Primer Sequence 5’-3 ’
Restriction
Site
T o p B P l2 CGCGGATCCGTCACCACCAGCGATGTGTC BamHl
TopBPl 113 CGCGGATCCGTATTTTTCTTGGTTGCATA BamHl
TopBPl 181 CGCGGATCCGTGACAGTATTGAGAAAGGT BamHl
TopBPl 253 CGCGGATCCGTACACTTGAAAATCTAGAA BamH 1
T o p B P l341 CGCGGATCCGTG AGTGTTTCAGTAAAGGT BamHl
TopBPl 460 CGCGGATCCGTACAATAACTGAAGAAGCG BamHl
TopBPl 470 CGCGGATCCCGCGTCTGAAGCCAGTACGG BamHl
TopBPl 500 CGCGGATCCGTCTGAGCAGAACTGTTGCG BamHl
TopBPl 586 CGCGGATCCAGTGCAAGTGTTCAAGAATAC BamHl
TopBPl 635 CGCGGATCCGTGAGACTGCTAGAACGGGA BamHl
TopBPl 710 CGCGGATCCGTCAACATGCCAGACAGGTC BamHl
TopBPl 798 CGCGGATCCGTCTTTCTGCCAGCCCTCAA BamHl
TopBPl 1169 CGCGGATCCGTACGAATAGAGGAGACTCAT BamH 1
TopBPl 540 GCGGGATCCGTTTTGATCCAAAGTCGAAT BamHl
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Table 4: 3 ’Primers for cloning TopBPl into pBIND
Primer Sequence 5’-3 ’ Restriction Site
TopBPl 258 CGGGGTACCTTCTAGATTTTCAAGTGT Kpnl
T o p B P l591 CGGGGTACCGTATTCTTGAACACTTGC Kpnl
TopBPl 803 CGGGGTACCTTGACCCATGGCAGAAAG Kpnl
TopBPl 914 CGGGGTACCGATATCCAAGCTCATTTT Kpnl
TopBPl 1435 CGGGGTACCGTGTACTCTAGGTCGTTT Kpnl
Top 675 CGGGGTACCAGTATCTGAATTTAGATTGAT Kpnl
Table 5: Primers for cloning TopBPl into pGBKTT
Primer Sequence 5 ’-3 ’
Restriction
Site
3’ Top 258(pGBkT7) GCCGGA rCCGTTAGATTTTCAAGTGTAGG EcoRl
3’ Top 591 (pGBkT7) GCCGGATCCGTGTATTCTTGAACACTTGC EcoRl
5’ Top 253 (pGBkT7) CGGGAATTCACACTTGAAAATCTAGAA BamHl
5’Top 2 (pGBkT7) CGCGGATCCGTCACCACCAGCGATGTGTC BamHl
3’ Top 258 (pGBkT7) CGCGG ATCCGTTAGATTTTCAAGGTAGG EcoRl
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Table 6: Primers for cloning VP 16-G AL4/VP16-T op BP 1 -G AL4
Primer Sequence 5’-3 ’
Restriction
Site
5’ Top 258/VP 16 GTTCGGGGGGGCCGTCGATAGATTTTCAAGTGTAGG
5’ VP16/Top 258 CCTACACTTGAAAATCTATCGACGGCCCCCCGACC
5’ VP16 CGCGGATTCGTTCGACGGCCCCCCCGAGC BamHl
3’ V pl6 Act CGGGGTACCTCCCGGACCCGGGGAATC Kpnl
2.2.1.13. PCR Purification
PCR products were purified either using QIAquick PCR clean up (Qiagen) or 
ChargeSwitch® PCR Clean-Up Kit (Invitrogen). Both protocols are briefly 
described below.
2.2.1.13.1. QIAquick PCR clean up Protocol
Briefly, 500pl Buffer PB added to lOOpl PCR sample and vortexed. This mixture 
was pipetted into a column and centrifuged for 1 minute at 15000g, 4°C and the flow 
through discarded. 750pl Buffer PE was then added to the centre o f  the gel column 
and centrifuged at 15000g, 4°C for 1 minute. The flow through was discarded, and 
the column placed into a clean microcentrifuge tube. Depending on the
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concentration of the PCR product required for further protocols the DNA was eluted 
by adding 30/50pl EB Buffer, before centrifuging for I minute under the previous 
conditions. The purified DNA then stored at -20°C until required.
2.2.1.13.2. ChargeSwitch® PCR Clean-Up
Briefly 50jil PCR purification buffer was added to the 50p,l PCR product and 
incubated with lOpl o f magnetic beads for 1 minute. The solution was placed on the 
magnetic rack forming a tight pellet. The supernatant was then removed and the 
pellet was washed twice with 150pl wash buffer. The excess wash buffer was then 
removed and the pellet resuspended with 20p.l elution buffer and incubated at room 
temperature for 1 minute. The solution was then placed onto the magnetic rack until 
a tight pellet formed. The supernatant containing the purified DNA was then 
removed and stored at -20°C until required.
2.2.1.14. Gel Extraction
Restriction digest products were occasionally following agarose gel electrophoresis 
using PurelinkT»^ Gel Extraction protocol (Invitrogen). The area o f the gel containing 
the DNA to be purified was cut out and weighed. To this slice 30pl gel solubilisation 
buffer per lOmg of gel was added. The gel was then heated to 50°C for 15 minutes 
with occasional agitation to ensure it was completely dissolved. The solution was 
then placed into a gel extraction column and centrifuged for 1 minute at 12000g. The
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flow through was discarded and the column was washed twice with 700pl wash 
buffer at 12000g for 1 minute. 50|il warm (70°C) elution buffer was then added to 
the centre of the column before a final spin (12000g). The purified DNA stored at - 
20°C until required.
2.2.1.15. DNA sequencing
To check plasmids for mutation and that inserts were cloned in frame, plasmids 
were routinely sequenced using an applied Biosystems 3100 automated sequencer. 
The region of interest was sequenced using a primer complementary to the 
appropriate region. Reactions were carried out in 0.5ml PCR tubes and contained 
0.5fxg plasmid DNA, 3.2pmol primer, 2pi Big Dye Terminator Reaction mix and 4pl 
5 X Big Dye Buffer (Applied Bio systems) completed to 14pl with distilled water. 
Samples were heated to 96°C for 10 seconds, 50°C for 5 seconds, and 60°C for 4 
minutes. This cycle was repeated 25 times and the sequencing reaction held at 4°C 
till required. PCR reactions were purified using phenol: chloroform ethanol 
precipitation (as described 2.2.1.4.). Following purification the reactions were 
resuspended in 25pi formamide and analysed using an ABI 300 automatic 
sequencer.
2.2.1.16. BCA / CuS04 Assay
Bovine serum albumin (BSA) protein standard solutions were made up at the
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following concentrations from a stock (2mg/ml) solution; 80, 100, 200, 400, 1000 
and 2000pg/ml. lOpl of each standard and protein lysate to be measured were loaded 
into a 96 well plate. 200pl developing solution was then added (5ml BCA 
(Bicinchoninic Acid Sigma) lOOpl Copper II Sulphate pentahydrate 4% w/v solution 
(Sigma)). The plate was then incubated at 37°C for 30-60 minutes, before the 
absorbance was measured at 462mn. The absorbance readings for the BSA standards 
were used to derive a standard curve, from which the sample concentrations were 
deduced.
2.2.1.17. Western Blotting
Protein concentrations were determined using a BCA/CUSO4 assay as described 
(2.2.1.16.). Equal amounts of protein were added to 2pl NuPage™ sample reducing
TMagent (lOX) and 5pl NuPage sample buffer (4x) (Invitrogen) and heated to 70°C 
for 10 minutes. The pre-cast gels either 10/12 well were placed into the gel tank 
filled with Ix MES running buffer. 400pi lOX anti oxidant was added to the running 
buffer before loading the sample. lOpI See-Blue® kDa marker (Invitrogen) was also 
loaded as marker using fine pipette tips. SDS-Page gels were run for 1 hour at 200V. 
The buffer was discarded and the gel cast was carefully cracked open and the top 
plate peeled of to leave the gel in place. The wells were removed and the gel was 
transferred to a nitrocellulose membrane using one of three methods depending on 
the size o f the protein o f interest (Indicated in results). 1) Wet transfer; 7 blotting 
pads were soaked in 1 x transfer buffer (50ml transfer buffer (TB), 100ml methanol
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completed to 1 litre with distilled water). 3 pads were placed in the blotting module 
followed by a filter paper also soaked in transfer buffer. Following the filter paper 
the gel was placed on top before placing the nitrocellulose membrane and another 
filter paper on top. Any air bubbles from this stack were removed by rolling before 
the addition o f 4 more transfer buffer soaked blotting pads. The blot module was run 
at 30V for 1 hour. 2) Semi-dry transfer; the gel and two blotting pads were soaked in 
transfer buffer for 10 minutes. Two blotting pads were placed onto the senii-diy 
blotter and rolled to remove any air bubbles; a wet filter paper, the gel and then 
another filter paper were added to the blotting pads and again rolled before the 
addition of two blotting pads. This gel stack was then run at lOV for 2 hours. The 
semi-diy transfer was a better method of transfer for large proteins (>150kD). 3) Dry 
transfer; using Invitrogen i-blot transfer following the manufacturer’s instructions. 
Following transfer the nitrocellulose membrane was incubated with 5% milk PBS-T 
(1 X PBS 0.1% tween) to remove any non-specific bands. Following blocking the 
primary antibody appropriately diluted in 5% milk PBS-T was incubated for 1 hour 
with gentle agitation at room temperature. The antibody was then removed and the 
membrane washed in PBS-T for 15 minutes, and 3 x 5  minutes at room temperature 
with gentle agitation. The secondary antibody was then added diluted in 5% milk 
PBS-T and incubated at room temperature for 1 hour with gentle agitation. The 
antibody was then removed and the wash steps repeated. The proteins were detected 
using ECLplus (GE Healthcare) according to the manufacturer’s instructions. Briefly 
1ml detection reagent A and 25 pi detection reagent B was mixed and added to the 
membrane and incubated at room temperature for 5 minutes. The excess was
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removed and the membrane placed into a cassette and developed with X-ray 
hyperfilm (Amersham).
2.2.1.18. Stripping membranes
Membranes were stripped in order to remove any traces of a previous antibody 
before reprobing. The membrane was submerged in stripping buffer containing 
lOOmM 2-Mercaptoethanol, 2% SDS, and 62.5mM Tris-HCl pH 6.7, and incubated 
at 50°C for 30 minutes with occasional agitation. Following this incubation the 
membrane was washed twice for 10 minutes with PBS-T at room temperature, and 
blocked for Ihour in 5% milk PBS-T, before adding the desired antibody.
2.2.1.19. Coomasssie staining
Following separation by SDS-PAGE (2.2.1.17), the gel was removed from the case 
placed in 100ml ddHzO and heated at 900W for 1 minute in microwave. The gel was 
then incubated at with gentle agitation for 1 minute at room temperature. This wash 
step was repeated 3 times and the water discarded. 30ml simply Blue Safe Stain 
(Invitrogen) was added to the gel and heated at 900W for 1 minute. The gel was 
incubated in the stain for 10 minutes at room temperature, and then washed with 
100ml ddHzO for 10 minutes. The wash was discarded and 20ml 20% NaCl added to 
destain for 1 hour at room temperature with occasional agitation. The resulting 
stained gel was dried between papers and stored at room temperature.
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2.2.1.20. Immunoprécipitation
Cell lysates were harvested as described (2.2.2.7.). The antibody for the 
immunoprécipitation was added at a 1:250 dilution and incubated at 4°C overnight 
with rotation. Following the incubation 30pl Protein G-beads were added to the 
reaction and incubated for 1 hour with rotation at 4°C. The lysates were then 
centrifuged at 80g for 1 minute. 15 pi supernatant was removed into an eppendorf as 
a control for antibody binding, and the remaining supernatant discarded. The beads 
were washed 4 times in 500pl lysis buffer, centrifuged at 80g for 1 minute and the 
supernatant discarded following each wash. The beads were then resuspended in 
15pl PBS, 5pi sample buffer (Invitrogen NuPAGE'^'^) and 2pl sample reducing 
agent (Invitrogen NuPAGE™). Samples were then heated to 70°C for 10 minutes 
and separated on a SDS-PAGE gel 200V for 1 hour and the proteins detected by 
western blotting (2.2.1.17.).
2.2.1.21. Flow Cytometry
Cells were plated out and treated/transfected as required. Cells were washed with 
5ml PBS, 1ml trypsin was added and the plated incubated at 37^C for 15 minutes. 
The trypsin was inactivated with the addition if 4ml ice cold IF A buffer and the cells 
transferred to a 15ml falcon tube and centrifuged at 80g for 10 minutes. The 
supernatant was aspirated leaving 500pi to resuspend the pellet. On a vortex at low 
speed 4.5ml ice-cold 70% ethanol was added dropwise, keeping the samples on ice.
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The samples were then incubated on ice for 30 minutes, before centrifugation at 80g 
4°C, The cell pellet was then washed in 5ml PBS and spun again. The pellet was 
then resuspended in 500pl propidium iodide, stored at 4°C in the dark until required. 
To analyse the cell cycle profile samples were run using EXP032ADCXL4.color 
program. To induce an early S-phase arrest and synchronise cell populations, 5p,g/ml 
aphidicolin was added to the plates for 16 hours prior to release and harvest.
2.2.1.22. Chromatin Immuno-Precipitation (ChIP) Assay
Cells were plated out as described and transfected/treated as described. 36hrs post 
transfection cells were fixed using 190pl 37% formaldehyde added directly to the 
plates at a final concentration of 1%. The plates were incubated at 37°C for 10 
minutes and a final concentration of 0.125M glycine added to stop the crosslinking 
and the plates incubated on ice. Cells were harvested by scraping into a 15ml falcon 
the cells were pelleted at 80g for 5 minutes. The resultant pellet was washed twice 
with 5ml PBS/0.5%NP40 at lOOg, 4°C. The samples were then incubated on ice with 
40ml high salt buffer (HSB; 0.5%NP40, PBS IM NaCI) for 30 minutes. Following 
this incubation the cells were washed twice with PBS/0.5% NP40 with 
centrifugation at 200g 4°C. The pellet was then resuspended in 40ml low salt buffer 
(LSB; 0.1% NP40, lOmM Tris-HCl, pH 8.0, ImM EDTA, O.IM NaCl) and 
incubated on ice for 30 minutes before being washed twice with PBS/0.5% NP40 
with centrifugation at 200g 4°C. The pellet was resuspended in 1ml LSB and passes 
tluough a 26G needle. 300pl sarcosyl was added to the sample and the volume
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competed to 3ml using LSB. The sample was then pipetted into a 50ml falcon tube 
containing 40ml LSB, lOOmM sucrose and centrifuged at 700g 4°C for 10 minutes. 
The supernatant was discarded and the process repeated. The supernatant was 
discarded and the pellet resuspended in 2m 1 TE (lOmM Tris pH 8.0, ImM EDTA). 
Samples were then sonicated on ice using Biosonicator 12x on high 15 seconds on 
15 seconds off. Following sonication 200pl 1IX NET buffer (1.65M NaCl, 5.5mM 
EDTA, 5.5% NP40, 550mM Tris-HCl pH 7.4) was added to the sample and the 
sample split into two eppendorfs and centrifuged at 13000g for 5 minutes at 4°C. 
The resultant supernatants’ were transferred to eppendorfs and 10% sample volume 
removed and stored at 4“C for the input DNA sample. One eppendorf was incubated 
with the desired antibody and the second incubated with a non-specific antibody as a 
control over night at 4°C with rotation. Following the antibody incubation 50pl diy 
bead volume protein G beads were added and the samples incubated with rotation 
for 1 hour at 4°C. The samples were then transferred to a chromatography column 
and washed twice with 10ml RIPA buffer (50mM Tris-HCl pH 8.0, 150niM NaCl, 
0.1% SDS, 0.5% deoxycholate, ImM  EDTA pH 8.0), the washes drain by gravity 
flow. Following the RIPA wash the beads were washed twice with 10ml LiCl buffer, 
then twice with 10ml TE. The beads were removed from the column using 0.5ml TE 
and transferred to an eppendorf. The beads were centriftiged at 2000rpm for 
30seconds and resuspended in 200pl TE, 1%SDS to elute the DNA from the beads. 
The beads were incubated with TE,1%SDS at room temperature for 10 minutes and 
centrifuged at 5000g for 1 minute. The resultant supernatant was transferred to an 
eppendorf and the beads eluted again using a further 200pl TE, 1%SDS as
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described. This second elution was added to the first and the samples centrifuged at 
5000g for 1 minute and the supernatant transferred to an eppendorf. 5 pi lOmg/ml 
proteinase K was added to each sample and incubated at 42®C overnight or 60 °C for 
4 hours to reverse the crosslinks. Samples were then phenol; chloroform purified 
twice as described (2.2.1.4.) and ethanol precipitated (2.2.1.5). The pure pellet was 
resuspended in 40pl filtered TE, and stored at 4°C. Immunoprecipitated DNA was 
quantified by PCR performed on the input and bound fractions, using primers 5'- 
GAGGACAACGGGGACAGTAA-3' and 5'-TCCACCAGAAAAACTCCAGC-3' 
for p73 promoter and 5'-GACAGGTACGGCTGTCATCA-3' and 5'- 
AACGGCAGACTTCTCCTCAG-3' for the p-actin control,); cycling parameters 
were 95 °C for 3 min, 25 cycles o f 95 °C for 1 min, 52 °C for 1 min and 72 °C for 
1 min, and 72 °C for 5 min as described (2.2.1.12.).
2.2.1.23. RJVA Extraction
RNA was extracted using Qiagen RNAeasy protocol according to the manufactures 
instructions. Briefly, cells were plated out as described and treated/transfected. To 
harvest the RNA the culture medium was removed and 350pl lysis buffer (RET 
Qiagen) was added and the cells harvested by scraping. This sample was transferred 
to a QIAshredder column to homogenise the sample and centrifuged at 15000g for 2 
minutes. 350pl 70% ethanol was then added and the sample including any 
precipitate that might have formed were transferred to an RNAeasy column and 
centrifuged for 15 seconds at 12000g. The flow through was discarded and the
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column washed with 700pl wash buffer (RW l Qiagen) with centrifugation at 8000g 
for 30 seconds. The flow through was discarded and the column washed with 500pl 
RPE (Qiagen) at 10,000rpm for 30 seconds. The column was then transferred to a 
new collection tube and 50pl RNAase free water was added directed onto the 
column membrane, and centrifuged at 15000g for 1 minute. The concentration of 
RNA was determined (2.2.1.2.) and the quality checked on a 1% agarose gel 
(2 .2 . 1. 1.).
2.2.1.24. HAT Assay Protocol
2x10^ 293T were plated out and transfected using a calcium phosphate precipitation 
protocol as described (2.2.2,2.). 36 hours following transfection the medium was 
removed and the cells harvested by incubating the cells with 1ml trypsin, at 37 °C 
for 10 minutes. 5ml culture medium was then added to inactivate the trypsin and the 
cells collected into a 15 ml centrifuge tube and centrifuged at 80g for 5 minutes. The 
cell pellets were washed in 1ml cold PBS and centrifuged for an additional 5 
minutes at 80g. The pellets were then lysed in lOOpl NP40 lysis buffer (0.5% NP40, 
150mM NaCl, 50mM Tris pH 8.0 containing 1/10 volume protease inhibitor cocktail 
tablet) and incubated on ice for 30 minutes. Cell debris was pelleted by 
centrifugation at 15000g for 10 minutes. The supernatant was transferred to a new 
eppendorf and the concentration of protein determined using a BCA/CUSO4 assay (as 
described 2.2.1.16.). 50pg of each sample was completed to 400pl with NP40 lysis 
buffer (0.5% NP40, 150mM NaCl, 50mM Tris pH 8.0 containing 1/10 volume
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protease inhibitor cocktail tablet), and Ipl o f the appropriate antibody was added. 
The samples were then incubated at 4°C with rotation for 1 hour. Following the 
incubation lOpl pre-swollen (5ml PBS overnight) protein sepharose-G beads were 
added and incubated for 1 hour at 4°C with rotation. The samples were then 
centrifuged at 80g for 1 minute and the pellet washed 5X with 500pl NP40 lysis 
(0.5% NP40, ISOmM NaCl, 50mM Tris pH 8.0). After the final wash the pellet was 
resuspended in 40pl HAT buffer (Promega) and transferred to a 96 well plate. 50gl 
of HAT assay buffer was then added to each including a HAT assay buffer only 
sample as a negative control. 5pi substrate I and 5pi substrate II were added before 
the addition of 5pi enzyme mix to start the reaction. The plate was incubated at 37 
°C and the absorbance at 450nm taken every 15 minutes until the enzyme reaction is 
complete.
2.2.2. Tissue Culture
2.2.2.1. General Growth
All cell culture experiments were carried out in a room specifically for the purpose 
and under strict sterile conditions. Cell culture work was performed inside a flow 
hood (Class II Microbiology Safety Cabinets, Gelaire BSB4). 293T, C33a, MCF7, 
MRC5 and U 20S cell lines were grown in DMEM 10% FCS, 1% Penicillin 
Streptomycin in an atmosphere at 37°C containing 5% C 02 (v/v) (Napco model 
5410, Napco Scientific). Cell lines were split 1/10 twice a week in 35ml DMEM 
10% FCS, 1% Penicillin Streptomycin.
77
Chapter 2 - M aterials and Metliods
2.2.2.2 Calcium Phosphate Transient Transfection
Cells were transiently transfected using a calcium phosphate precipitation technique. 
Approximately 3 x 10  ^C33a/MCF7/MRC5 or 2 x 10  ^ 293T/U20S cells per 60mm 
culture dish were plated out in 5ml DMEM (containing 10% foetal calf serum and 
penicillin). The following day, the 2pg of the DNA of interest was completed to 
450pl with distilled water. 50pl o f 2.5M CaClz was then added forming an opaque 
precipitate in between 15 and 30 minutes. This 500pl solution was then added drop 
wise to 2 X HEPES Buffered saline (50mM HEPES, 280mM NaCl, and 1.5 mM 
Na2HP0 4 .2H20  to pH 7.02 with a few drops o f O.IM NaOH), The solution was left 
until the formation of the precipitate. As samples were carried in duplicate, 500pl of 
the precipitate was added to each duplicate monolayer, and left to incubate for 16-18 
hours. The cell monolayer was then washed twice with 3ml PBS, and 5ml fresh 
medium was added before an additional 24-hour incubation.
2.2.2.3. Lipofectamine 2000^^ Transfection
For siRNA knockdown experiments, siRNA oligos against TopBPl and luciferase 
were designed (Dharmacon). Two transfections solutions were prepared; firstly 
2.5pl of the desired oligo was added to 497.5pi optimem (Invitrogen), and secondly 
15pi lipofectamine 2000™ was added to 485pi optimem. These two separate 
cocktails were incubated at room temperature for 5 minutes before being mixed and
78
Chapter 2 - M aterials and Metliods
incubated for a further 20 minutes at room temperature. Following the incubation 0.5 
X 10  ^ MCF7 cells were added to the lipofeetamine/oligo solution and plated out 
onto a 60mm tissue culture plate incubated at 37°C 5% CO2 (v/v).
2.2.2.4. Luciferase assay
Cells were transfected using the calcium phosphate precipitation protocol as 
described (2.2.2.2.). The cells were removed from the incubation and the medium 
removed. The tissue culture dishes were washed twice with 3ml PBS removing all 
excess PBS from the second wash by pipetting. 300pl of 1 x Reporter Lysis Buffer 
(Promega) was added to each plate and left to incubate at room temperature for 10 
minutes. The resultant cell lysate was scraped using a sterile plate scraper into a 
clean microcentrifuge tube. These were centrifuged at 13000g for 10 minutes at 4°C. 
The supernatant was then pipetted into fresh microcentrifiige tube, and stored at -  
70°C until required. To assay luciferase activity 80pl of each sample was loaded into 
a 96 well plate and the luminescence measured using the Luciferase Assay System 
(Promega) and a Luminoskan Ascent plate reader (Thermo Labsystems).
2.2.2.5. Colony Survival Assay
3 X 10  ^ MCF7 cells per 100mm culture dish were plated out in 7ml DMEM 
(containing 10% foetal calf serum and penicillin), and siRNA treated as described 
(2.2.2.3). 48 hours later the cells were trypsinised, counted and 2000 cells per
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100mm culture dish were plated out in 7ml DMEM (containing 10% foetal calf 
serum and penicillin). 12 days later the medium was removed and the cells washed 
twice with 5ml PBS. The surviving colonies were visualised by staining with 2mls 
0.5% erystal violet solution (25% methanol, ddH^O) for 20 minutes at room 
temperature with gentle shaking. The plates were washed with tap water until the 
solution ran clear, dried overnight at room temperature before the colonies were 
counted.
2.2.2.6. MTT Cell Viability Assay
The MTT assay provides an additional method of measuring cell viability. Cell lines 
to be assayed were plated out and transfected using Lipofectamine 2000™ as 
described (2.2.2.3.). 36 hours post transfection, the cells were harvested by 
trypsinisation and 500 cells plated out into each well of a 96 well plate (DMEM 10% 
FCS, 1% Penicillin Streptomycin). At the time points indicated, the medium was 
removed and lOOpl 10% MTT solution (l-(4, 5-Dimethylthiazol-2-yl)-3, 5- 
diphenyIfbrmazan) was added to the cells and the plate incubated at 37“C for 2 hours 
until the formation of a precipitate. The media was then removed and the precipitate 
resuspended in lOOpl DMSO. The absorbance (560nm) of each well; samples and 
negative control (MTT only) were measured.
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2.2.2 J ,  Preparation of protein extracts
For the detection of proteins using western blotting 2 x 1 0 ^  293T/U20S or 3 x 10  ^
C33a/MCF7/MRC5 cells were plated out on 10cm tissue culture plates in 7ml 
DMEM 10% FCS, 1% Penicillin Streptomycin. Cells were transfected using the 
calcium phosphate precipitate as described (2.2.2.2.). 36 hours post transfection; 1ml 
trypsin was added to each plate and incubated at 37“C for 10 minutes. The cells were 
then transferred to a 15ml centrifuge tube and spun at 80g for 5 minutes. The 
resultant pellet was washed in 5ml PBS and the cell pellet was lysed in 300pl NP40 
lysis buffer (0.5% NP40, 150mM NaCl, 50mM Tris pFl 8.0 containing 1/10 volume 
protease inhibitor cocktail tablet), and incubated on ice for 30 minutes. The lysate 
was then centrifuged at 15000g and the resultant supernatant containing the cell 
proteins was transferred to a clean mierocentrifuge tube and stored at -80°C until 
required, the pellet was discarded.
2.2.2.8. Inhibitors and Damaging Agents
Cells were treated with varying doses (Gy = IGy corresponds to the absorption of 
one joule of energy by one kilogram o f matter) of gamma irradiation from a Co^ ® 
source at the Beatson Institute for Cancer Research (Switchback Road, Glasgow) 48 
hours after plating out. Cells were transported and damaged 4 hours prior to 
harvesting for luciferase transcription assays. Control plates which were not treated 
were also transported as a control. The PIKK inhibitors, caffeine (2mM)
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wortmannin (lOOnM) and LY294002 (lOOpM) were added to eell culture medium 
one hour prior to gamma/mock irradiation at the concentrations described.
2.2.3. Yeast Protocols
2.2.3.1. Synthetic Dropout media (SD) Preparation
0.85g Yeast Nitrogen Base, 2.5g Ammonium sulphate and lOg Agar were dissolved 
in 350ml ddHsO and autoclaved. Following sterilisation 25ml 40% glucose and 5ml 
o f each lOOx stock amino acid required for the media was added (Table 7). The 
volume was competed to 500ml with ddHiO and the plates were poured and stored 
at 4°C until required. For SC-trp plates adenine, histidine and leueine were added. 
For SC-trp-his/ade adenine and leucine, or adenine and histidine were added 
respectively. For SC-trp-his-ade media only leucine was added.
82
Chapter 2 - M aterials and Methods
Table 7: Amino acid stocks
Amino Acid 1 OOx stock Manufacturer
L-adenine hemisulphate salt 2g in 1000ml Sigma
L-histidine HCL monohydrate 2g in 1000ml Sigma
L-Ieucine lOg in 1000ml Calbiochem
L-tryptophan 2g in 1000ml Calbiochem
2.2.3.2. TCA preparation of cell lysates
Yeast cultures were grown until an ODeoonm was reached, and the cells were then 
pelleted and resuspended in 1ml 0.3M NaOH and incubated at room temperature for 
10 minutes with occasional agitation. The cell lysate was then ineubated on ice for 
10 minutes before the addition of 150pl TCA (w/w) and a further incubation of 10 
minutes on ice. The samples were then centrifuged at 15000g for 10 minutes at 4°C, 
the supernatant removed and the pellet centrifuged again for a further 10 minutes 
under the same conditions. 15pi sample reducing buffer (Invitrogen) was added to 
resuspend the pellet and the sample heated to 100°C before a brief spin to pellet any 
debris. The proteins were then separated by SDS-PAGE separation and transferred 
(as described 2.2.1,17.) and probed for the presence of GAL4 fusion proteins.
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2.2.3 3. Liquid p-GAL Assay
Overnight yeast cultures were centrifuged for 3 minutes at 15000g and the pellet 
washed in 1.5ml Z Buffer (60mM NaiHPO^, 40mM Na2H2PÜ4, lOmM KCl, ImM
MgS04  pH7.0) and centrifuged again under the same conditions. The resulting pellet
was resuspended in 300pl Z Buffer (as above) and freeze thawed in liquid nitrogen 
for 15 seconds. 700pl Z buffer containing 50mM p-mercaptoethanol, and 160pl O- 
Nitro-D-Galactoside (lOmg/ml) was added and the timing started. Absorbance 
readings at 420nm and 550nm were taken at 5 minute intervals and the reaction 
terminated by the addition of 400pl Na2CÜ3. The units used in the assay are as 
follows:
Units = 1000 X ifOD^inl-1.75 x fODssn)!
Time (Hours) x Volume Culture x (OD^oo)
2.2.3.4. Transformation of Yeast by Heat Shock
40pl AH 109 were mixed with Ipg plasmid DNA before the addition o f 300pi 
LiPEG (lOOmM Lithium acetate, lOmM Tris pH 8.0, ImM EDTA and 40% PEG 
3350). The cells were vortexed and incubated at room temperature for 20 minutes. 
Following the incubation 35pi DMSO was added and the sample incubated at 42°C 
for 15 minutes. The cells were then centrifuged for 3 minutes at 80g and the
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resulting supernatant discarded. The pellet was resuspended in 75pl H2O and the 
cells plated out onto kanamycin resistant agar plates and incubated at 37°C 
overnight. AH 109 contained the following;
AH109 MATa, trpl-190, leu2-3,112, ura3-52, his3-200, galA, galSOA, LYS2;
GAL 1UAS_GAL 1 TATA_HIS3, GAL2UAS_GAL2TATA_ADE2,
URA3 :MEL 1 UAS_MEL 1 TATA_LacZ
2.2.3.5. Making Electrocompetent Yeast
20ml L broth (2.1.2.) was inoculated with a single BL21 colony and grown 
overnight at 37°C 225rpm. From this culture 8mls was used to inoculate 400ml L 
broth (2.1.2.) which was grown until and ODgoo of 0.6 was reached. The bacteria 
were then pelleted with centrifugation at 2000g for ISminutes, washed twice with 
500ml ice cold water and centrifuged again under the same conditions. The pellet 
was then resuspended in 20ml filter sterilised ice cold glycerol and centrifuged at 
2000g for 10 minutes 4°C. The pellet was then resuspended in 2ml filter sterilised 
glycerol and stored at -80“C until required.
2.2.3.6. Testing for Transactivation by Replica plating
A single colony from each construct was picked and inoculated into 500pi ddH2 0 . 
This solution was used to spot the colony onto SC-trp plates with 100 grid squares,
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one colony per square, and incubated at 30X  for 3 days. This plate was used as a 
master plate to replica plate onto plates lacking tiyptophan and adenine (SC-trp-ade), 
tryptophan and histidine (SC-trp-his) and plates lacking tryptophan, adenine and 
histidine (SC-trp-his-ade). Colonies which grew on this triple dropout media 
indicated that the TopBPl constructs were capable of transactivating the 
transcription o f the reporter genes.
2.2.4 Microscopy
2.2.41. Plating cells and Fixation
For immunofluorescence MCF7 cells were plated out at 2 x 10  ^cells per 60mm plate 
onto glass 15mm diameter coverslips. 72 hours later the medium was removed and 
the cells fixed in 4% formaldehyde at 37°C for 10 minutes. The cells were then 
washed three times with 5ml PBS and the excess removed. The coverslips were then 
permeablised using 1ml ice cold methanol per 60mm plate and incubated for 10 
minutes on ice. The coverslips were then washed with 5ml of PBS three times and 
stored in 1ml PBS at 4“C until staining (2.2.4.2.).
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2.2.4.2. Staining coverslips
Coverslips were fixed (2.2.4.1.) and stained for the presence of yH2AX foci. The 
fixed coverslips were incubated with 20pl, 1/250 dilution o f monoclonal yH2AX 
antibody in PBS for 1 hour at room temperature. The coverslips were then washed 
five times with 1ml PBS before a further incubation with 20pi secondary anti-mouse 
FITC conjugate (1/400 dilution in PBS) for 1 hour at room temperature in the dark. 
Following this incubation the coverslips were washed five times with I ml PBS and 
the excess removed. The coverslips were placed eell surface down onto a glass 
microscope slide and immunofluorescence detected using Lieca confocal software.
2.2.5 Statistics
2.2.5.1 Mean and Standard Error
The mean ± the standard error o f the mean (SEM) are shown in several experiments 
as a control for experimental reproducibility. The standard error of the mean (SEM) 
gives a measure of the precision of the mean giving a representation o f the spread of 
the data, indicating how far the mean o f sample is from the true mean.
SEM = Standard Deviation (o f  
V [Sample number (n)]
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Calculated using Microsoft Excel using =STDEV (X-Y)/SQRT (COUNT(X,-Y))
2.2.5.1 Statistical Significance
Statistical significance for the data presented in this thesis was typically calculated 
using a Students-T-test to give a significance value (p). This was carried out using 
Microsoft Excel (T-TEST function). The cut off for all experiments was taken as 
0.05, therefore if two sets of data return a p value of <0.05 there is a less than 5% 
chance that the result observed is due to chance, and the two groups are therefore 
statistically significantly different.
Cimpter 3-Results
3- Results
3.1. TopBPl Contains Multiple Transcriptional 
Modification Domains
TopBPl plays an essential role in signalling the DNA damage response and repair 
and has been proposed as a transcriptional regulator, both activating and repressing 
transcription. TopBPl co-activates transcription with the HPV16 E2 protein when E2 
is bound to target promoters (Boner et al. 2002) and represses the transcriptional 
activity o f  E2F1 (Liu et a l  2003). Following UV damage cell cycle arrest is induced 
by the inhibition of Cdk via the up-regulation o f p21 by M izl, TopBPl has been 
shown to bind M izl and regulate p21 transactivation (Herold et a l 2002). These 
regions which modify chromatin in order to facilitate these functions of TopBPl have
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not been identified therefore this chapter investigated if TopBPl contains any 
transcriptional regulatory domains.
3.1.1. Identification of a Transcriptional Activation Domain
In order to investigate if TopBPl contains transcriptional regulatory domains, 
TopBPl sequences were eloned into the GAL4 DBD (DNA binding domain) 
expression vector pBIND (Figure 7a). The ability of these GAL4-TopBPl fusion 
proteins to regulate transcription from the luciferase reporter pG51uc, which contains 
five GAL4 binding sites, was determined (2.2.2.4.) and the results are shown in 
Figure 7b. This experiment was carried out in 293T cells, and the luciferase activity 
was normalised against total protein present in each sample using a BCA/CUSO4 
assay (2.2.1.16.). All luciferase assays described were carried out at least three times 
in duplicate, and the results show the mean ± S.E.M. (Standard Error of Mean,
2.2.5.1.). The plasmids encoding all the GAL4-TopBPl plasmids were sequenced and 
the correct protein expression was determined by transfecting the plasmids into 293T 
cells and preparing total protein extracts (2.2.2.7.). Figure 7a lists the predicted mass 
o f each protein in kDa (Right hand side). Equal amounts of each lysate were 
separated by SDS/PAGE (2.2.1.17.) and the proteins detected using an anit-GAL4 
DBD antibody (2.1.1.).
As shown in Figure 8 all TopBPl fusion proteins are expressed, although some more 
strongly than others. This was repeated at least twice for each construct and similar
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results were always obtained. The GAL4 fusion protein, TopBPl amino acids 586- 
1435 shows a significantly reduced level o f expression and a reduction in 
transcriptional activity compared to the other eonstructs although this will be 
discussed later (3.1.3.), It is clear from Figure 7b there are transcriptional repression 
domains encoded by TopBPl, when normalised against the empty vector pBIND 
(Equivalent to 1). TopBPl 2-591 shows significantly higher activity compared to 
TopBPl 2-258 suggesting there may be a domain between amino acids 258-591 
containing transcriptional activation properties.
To investigate whether TopBPl amino acids 258-591 contains activation domain 
additional GAL4-TopBPl fusion expression plasmids were constructed (Figure 9a). 
TopBPl 253-591 shows a 50 fold increase in transcription compared to the empty 
vector pBIND (Figure 9b), suggesting that a transcriptional activation domain is 
contained between amino acids 253-591. Similar to the results which identified the 
BRCAl transactivation domain (Monteiro et al. 1996), the full length fusion shows 
no increase in transcription, the activation domain is only revealed using protein 
truncations. This region of TopBPl contains both the third and fourth BRCT 
domains, therefore these domains were deleted from the activator construct to create, 
TopBPl 253-591 ABRCT3 and TopBPl 253-591ABRCT4. The removal of BRCT3 
has no significant effect on the transcriptional activation (p= 0.96), although the 
removal of BRCT4 from TopBPl 253-591 significantly alleviates 24% of the activity 
(P=0.03), indicating that the activation domain lies partially within BRCT4. The 
expression of these GAL4-TopBPl fusion proteins is shown in Figure 14b.
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Figure 7
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Figure 7: Transcriptional Analysis o f  G AL4-TopBPl fusion proteins, a)
Schematic representation of the GAL4-TopBPl fusion proteins, designed for the 
initial study of transeriptional activation and repression. Shaded boxes eorrespond to 
the location of BRCT domains. Numbers correspond to amino acid number of 
TopBPl. Amino acid numbers in fusion name indicates the first and last amino aeid 
of TopBPl contained in each construct. The predicted size of these proteins in kDa is 
shown on the right of each construct, b) Luciferase assay showing the fold effect 
against the empty vector pBIND (being equivalent to 1), in transcriptional activity of 
the constructs indicated in a). All luciferase assays were carried out in duplicate at 
least three times; this graph shows the mean of the triplicate experiments, ± S.E.M.
93
C h a p te r  3 -R esu lts
Figure 8
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Figure 8: Protein Expression o f G A L 4-T opB Pl Fusions. Western blot showing the 
expression o f the GALd-TopBPl fusion proteins indicated in Figure 5a) in 293T cells 
using anti-GAL4 DBD antibody. Cell lysates were harvested as described (2.2.2.7.). 
The location o f the molecular weight marker (kDa) is shown on the left o f the blot.
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Figure 9
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Figure 9: Identification o f a Transcriptional Activation Dom ain, a) Sehematic 
representation o f the GAL4-TopBPl fusion proteins. Numbers correspond to amino 
acid number of TopBPl. The predicted size of these proteins (kDa) is shown on the 
right of each construct, b) Luciferase assay showing the fold effect against the empty 
vector pBIND (being equivalent to 1), in transcriptional activity of the GAL4- 
TopBPl amino acid 253-591, ABRCT3 and ABRCT4 fusion proteins ±S.E.M.
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In order to further characterise the activation domain within TopBPl amino acids 
253-591, a further series of truncations were cloned into pBIND (Figure 10a). The 
BRCT domains present in each o f these constructs is indicated, and the predicted size 
of these proteins is listed on the right of the diagram. The ability of these fusion 
proteins to activate transcription from the luciferase reporter pG51uc was assayed as 
previously described and the mean + S.E.M. of these fusion proteins is shown in 
Figure 10b. TopBPl 253-591, 341-591 and 460-591 show a strong increase in 
transcription, compared to the empty vector pBIND. In contrast TopBPl 470-525, 
TopBPl 340-460, and TopBPl 500-591 show no increase in transcriptional activation 
compared to the empty vector indicating that an essential region o f the activation 
domain lies within TopBPl amino aeids 460-500. Figure 11 shows a multiple 
sequence alignment using the ClustalW™ program (European Bio informatics 
Institute (EBI) an outstation freely available from European Molecular Biology 
Laboratory (EMBL)) of the human TopBPl sequence from amino acids 460-500, 
comparing the sequences from a variety of species as indicated. * indicates identical 
residues conserved across species, : indicates residues in which the charge of the 
amino acid is conserved, the hydrophobic residues which are conseiwed are indicated 
by •. Similar to other transcriptional activation domains, this activation domain in 
TopBPl contains hydrophobic pockets interspersed with acidic residues, (Roberts et 
a l  1993).
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Figure 10: The Transcriptional Activation Domain resides partially within  
BRCT4. a) Schematic representation of the GAL4-TopBPl fusion proteins. 
Numbers correspond to amino acid number o f TopBPI; the shaded boxes indicate the 
regions containing BRCT domains. The predicted size of these proteins in kDa is 
shown on the right of each construct, b) Luciferase assay showing the mean fold 
effect against the empty vector pBIND (being equivalent to 1) o f the constructs 
shown in a) ±S.E.M.
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Figure 11
460 470 480 490 500
1 * I  I)• # # # #* #(
Homo sapiens 
Pan troglodytes
TEEGLFSQKSFLVLGFSNENESNIANIIKENAGKIMSLLSR
TEEGLFSQKSFLVLGFSNENESNIANIIKENAGKIMSLLSR
Canis familiaris TEEGLFSQKSFLVLGFSNENESNIANIIRENAGKVVSLQSR
Mus musculus 
Rattus rattus 
Gallus gallus
REEGLFSQKSFLVLGFSVENKCNIVDIIREHAGKIVSLPSR
PEEGLFSQKSFLVLGFSVENECNIVNIIREHAGKIVSLPSR
LDEGLFARKRFLLLGFGEEDESCIADLIKEHAGKTVPLQSR
Indicates hydrophobic residue
Figure 11: Sequence similarity across the Activation Domain is conserved across 
species. ClustalW™ sequence alignment o f TopBPI amino acid residues spanning 
the activation domain, • indicates a hydrophobic residue which is conserved.* 
indicates a residue which is conserved across species,: indicates a residue in which 
the charge of that residue is conserved across species.
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3.1.2 A Repression Domain within BRCT2 Represses the Activation 
Domain
The GAL4-TopBPl fusion TopBPI 2-591 contains the activation domain identified 
within amino acids 460-500 (3.1.1) but it shows no increase in transcriptional activity 
compared to the empty vector pBIND (Figure 7b). This indicated that there was 
possibly a repressor element within amino acids 2-258 which was acting upon the 
activation domain to repress its activity within this construct. To investigate this 
hypothesis a further a series of TopBPI constructs containing BRCT domain 
deletions were cloned into pBIND (Figure 12a), and the ability o f these fusion 
proteins to activate transcription from the pG51uc luciferase reporter was assayed as 
previously described, the results are shown in Figure 12b. The removal of first and 
second BRCT domains from TopBPI 2-591 does not restore the transcriptional 
activity seen by TopBPI 253-591 (Figure 9b). However this repressor domain was 
revealed using further tmncations; Figure 13a shows the regions covered by these 
fusion proteins. TopBPI 181-591 shows a significant increase in fold activation 
compared to pBIND a level which is similar to that seen by TopBPI 253-591; 
however TopBPI 113-591 shows no increase in transcription indicating that the 
repressor domain lies within amino acids 113-181, this region between amino acids 
113 and 181 maps directly to BRCT2 of TopBPI, indicating that BRCT2 is the 
region which represses the activation domain.
101
C h a p te r  3 -R esu lts
However; if this was the only repressor element acting upon the activation domain 
within amino acids 460-470, TopBPI 2-591 A BRCT2 should show an increase in 
transcriptional activity as it contains the activation domain but not the BRCT2 
repressor domain, however this is not the result observed. TopBPI 2-591 A BRCT2 
does not show an increase in transcription (Figure 12b). One possibility is that there 
is an additional repressor element within amino acids 2-113 incorporating the first 
BRCT domain, which is also repressing the activity of the activation domain within 
the TopBPI 2-591 A BRCT2 fusion, but not the ability o f TopBPI 181-591 to 
activate transcription. Figure 14 shows the expression of the GAL4-TopBPl fusion 
proteins described in Figures 10, 12 and 13 using the anti-GAL4 DBD antibody. The 
expression of each fusion protein was confirmed in repeat experiments.
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Figure 12
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Figure 12: The Activation Domain is Repressed by an adjacent Repressor 
Domain, a) Schematic representation of the GAL4-TopBPl fusion proteins, numbers 
correspond to amino acid number, shaded boxes indicate the regions covered by 
BRCT domains. The predicted size of these fusion proteins is indicated on the right 
of the diagram, b) Luciferase assay showing the mean fold effect against the empty 
vector pBIND (being equivalent to 1), in transcriptional activity o f the GAL4- 
TopBPl BRCT deletion fusion proteins indicated in a) ± S.E.M.
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Figure 13
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Figure 13: The Repressor Domain maps directly to BRCT2. a) Schematic 
representation of the GAL4-TopBPl fusion proteins, shaded boxes indicate the 
regions containing BRCT domains, numbers correspond to amino acid number. The 
predicted size o f these fusion proteins in kDa is indicated on the right o f the diagram,
b) Luciferase assay showing the mean fold effect change in transcription of the 
GAL4-TopBPl fusion proteins shown in a) against the empty vector pBIND (being 
equivalent to 1) ± S.E.M.
106
Figure 14
Plasmid
Chapter 3-Results
Û
I
Plasmid
II
CM CM g;1— h- 1— h-o O o o O oa: CH o i on on onm CO m 00 CO CO
< < < < O ) m00 00 oo in inin in in C 3 ) O ) cn AS' S' S' “? in inCM CM CM CM CM CM CM CM
a . Q . Q . Q . CL n . Q . n.o O O O O o o oh - 1 - t - 1- t - h - h -
«
Q .O
107
C h a p te r  3 -R esu l ts
Figure 14: Expression of GAL4-TopBPl fusion proteins. Western blot showing 
the expression o f the GAL4-TopBPI fusion proteins indicated in Figures 10, 12, and 
13). The plasmids were transfected into 293T cells and the protein lysates harvested 
as described (2.2.2.7.). Equal amounts of each lysates were then separated by SDS- 
PAGE and the fusion proteins detected using anti-GAL4 DBD antibody (2.2.1.17.). 
The location of the molecular weight marker (kDa) is shown on the left o f each blot.
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The repression of the activation domain by BRCT2 could be due to either an 
intramolecular interaction, in which BRCT2 physically masks the activation domain 
supressing its activity, or the repression could be due to the recruitment of a repressor 
complex to the site o f the activator. To study which o f these two possibilities is more 
likely, TopBPI 2-258 which contains the supressor was cloned in frame with the 
transcriptional activator VP 16 as a fusion protein with the GAL4 DBD (VP16Rep), 
as a control the VP 16 activation domain was cloned into GAL4 DBD (VP 16 
Activation Domain [VP16AD]). A diagrammatic representation of these fusion 
proteins is shown in Figure 15a. The ability o f these GAL4-TopBPl fusions to 
acitvate transcription from the pG51uc luciferase reporter was tested, and the results 
are shown in Figure 15b. As expected VP16 AD showed a strong 150 fold increase in 
transcription compared to GAL4 (pBIND) being equivalent to 1. VP16Rep showed a 
6.5 fold increase in transcription compared to pBEND and was able to supress over 
90% of the transcriptional activation o f the VP 16 AD (p = 0.0045) indicating that the 
repressor domain can suppress the ability of the adacent VP 16 to activate 
transcription. This result indicates that the mechanism in which the BRCT2 repressor 
domain represses the activation domain o f TopBPI (amino acids 460-500) is likey 
due to the recruitment o f a repressor complex and not by an intramocelular interaction 
as this repressor domain within TopBPI can also repress the transcriptional activity 
of the VP 16 transcriptional activation domain. The expression o f the fusion proteins 
(Figure 15a) is shown in Figure 16.
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To more fully understand the mechanism of repression a luciferase transcription 
assay was carried out in which the cells were treated with trichostatin A (TSA) three 
hours prior to harvesting. TSA is a histone deactyltransferase (HDAC) inhibitor; 
these inhibtors cause a build up o f acetylated histones, and result in an open 
chi-omatin state which is associated with transcriptional activation (Figure 17a) 
(Review Ekwall et a t  2005). Figure 17b shows .the fold change in transcription from 
the pG51uc reporter of the GAL4-TopBPl fusion proteins compared to the empty 
vector pBIND. In this experiment TopBPI 2-591 contains both the activation domain 
(amino acids 460-470) and the repression domain (amino acids 113-181), TopBPI 2- 
258 contains only the repression domain and TopBPI 253-591 only the activation 
domain. When treated with TSA pBIND shows a significant (p=0.023) increase in 
transcription compared to untreated cells, indicating that the GAL4 DNA binding 
domain has an activation domain kept silent by adacent repressor elements under the 
control of HDACs as they are revealed with TSA treatment. TSA did not alleviate the 
repression of the activation domain indicating that repression is HDAC independent.
It is possible that the activity o f the activation domain may function in a histone 
acetyltransferase dependent (HAT) manner. Although chromatin activation and 
silencing will be discussed in more detail in chapter 3.2, the results presented here 
aim to ascertain if the TopBPI activation/repression domains identified contain any 
HDAC or HAT activity. FIAT enzymes acetylate the core histones and are 
characterised according to the histone acetylated (Kimura et a l  2005). This 
acétylation of the core histones results in the formation of a more “open” chromatin
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structure providing access for other chromatin remodelling proteins, DNA damage 
proteins and transcriptional machinary. Recent evidence has shown that HAT 
enzymes also acetylate a larger number of substrates not just core histones (Yang et 
a l 2007). Therefore the GAL4-TopBPl repressor and activator fusions were tested 
for HAT activity (2.2.1.24.) in 293T cells. In this assay the 293T cells were 
transfected with the GAL4-TopBPl expression plasmids indicated in Figure 18, total 
cell lysates were prepared and immunoprecipitated (as described 2.2.2.7 and 2.2.1.20) 
using the anti-GAL4 antibody and the immunoprecipitate was used in this HAT 
assay. This assay indirectly measures the de-acetylation of acetyl-Coenzyme A to 
produce free CoA. The results are shown in Figure 18, active recombinant HAT 
serves as a positive control, and following a 60 minute incubation with the acetyl- 
CoA substrate shows a clear increase in HAT activity. However GAL4 alone 
(pBIND), TopBPI 253-591 and TopBPI 2-591 show no increase in HAT activity 
with the addition of the substrate although these constructs do have a higher basal 
activity than the negative control, indicating that the transcriptional activation and 
repression is HAT independent.
I l l
Figure 15
Chapter 3-Results
a)
VP16 AD
147—I
GAL4 VP16 Activation Domain
  __- ■'"(irfrBMnti Mmn i ■ i -  i  i t  f i - 1 - t h  r
21KD
VP16 Rep GAL4 — r VP 16 Activation Domain 1 45kD
b)
40 I
6.5 
VP16 Rep Top 2-258
0.9 
Top 2-591
D
Top 253-591
1.0
pBIND
Plasmid
112
C h a p te r  3 -R esu its
Figure 15: Transcriptional Repression by BRCT2 is likely due to the 
recruitm ent o f a Repressor com plex, a) Schematic representation o f the GAL4- 
VP16 fusion (VP 16 AD), and GAL4-VP16-TopBP 1 2-258 (VP16Rep) fusion 
proteins. Numbers correspond to the start and end amino acid o f each segment of the 
fusion, the predicted size o f these proteins in kDa is shown on the right of the 
diagram. Shaded boxes in VP16Rep indicate the location of BRCT domains within 
the TopBPI sequence, b) Luciferase assay showing the mean fold effect against the 
empty vector pBIND (being equivalent to 1), in transcriptional activity of the 
constructs indicated in a), +/- S.E.M. This experiment was repeated three times in 
duplicate.
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Figure 16; Protein Expression o f VP16-GAL4 Fusion Proteins. Western blot 
showing the expression of the VP16-GAL4 fusion proteins indicated in 15a) using 
anti“GAL4 DBD antibody. The location of the molecular weight marker (kDa) is 
shown on the left of the diagram as a control.
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Figure 17: BRCT4 and BRCT2 Domains do not contain any intrinsic HDAC  
activity, a) Diagram showing the mechanism of HDAC and HAT activity. HAT 
enzymes facilitate the acétylation o f core histones resulting in an “open” chromatin 
structure allowing access for transcription factors and DNA repair proteins. HDAC 
remove the acetyl groups resulting in a “closed” chromatin structure, b) Luqiferase 
assay of GAL4-TopBPl fusion proteins TopBPI amino acids 2-258, 2-591 and 253- 
591, either untreated or treated with 300ng/ml Trichostatin A for 3 hours prior to 
harvesting. Results are shown as relative light units (RLU) per pg of total protein in 
lysates, the activation and repression domains show no HDAC activity.
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Figure 18
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Figure 18: BRCT4 and BRCT2 Transcriptional domains do not contain any 
HAT activity. Histone acetyltransferase assay (2.2.1.24.), showing the mean 
absorbance at 450nm following the addition of the substrate (Time zero). This 
experiment was carried out in duplicate three times and this graph shows the mean 
±S.E.M.
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3.1.3 Identification of a Transcriptional Repression Domain within 
BRCT5
As shown in Figure 7b TopBPI 586-1435 repressed transcription from the pG51uc 
luciferase reporter. pG51uc was designed for the study of transcriptional activation 
and has a low background promoter activity; therefore a second luciferase reporter 
was constructed for the study of transcriptional repression with a more active 
promoter. The reporter ptkGAL46E2 contains the GAL4 binding domain from 
pG51uc upstream of a thymidine kinase promoter (2.1.9.), a diagrammatic 
representation o f this luciferase reporter is shown in Figure 19. The incorporation of 
the E2 binding sites provides a more versatile reporter for future experiments 
investigating the role of TopBPI in HPV16 E2 transactivation. Figure 20 shows the 
ability o f the initial GAL4-TopBPl fusion proteins (Figure 7a) to regulate 
transcription from the ptkGAL46E2 luciferase reporter in 293T cells. Compared to 
the empty vector (pBIND), TopBPI 586-1435 shows a 10 fold repression (p = 0.01), 
a repression stronger than the 5 fold observed using pG51uc (Figure 7b) therefore 
ptkGAE46E2 was used as the luciferase reporter for all assays in this chapter. 
However, as shown in Figure 8 TopBPI 586-1435 is poorly expressed compared to 
the other GAL4-TopBPl fusion proteins. To determine if this repressive effect was 
merely due to lower levels of protein, a titration of TopBPI 586-1435 was carried out 
in 293T cells and the luciferase activity quantified as a fold effect against the reporter, 
ptkGAL46E2 being equivalent to 1 (Figure 21). Over a 20 fold range in concentration
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the transcriptional repression shown by TopBPI 586-1435 increased as the 
concentration increased, increasing from a 5 fold repression at 0.1 pg to a 15 fold 
repression at 2pg compared to the empty vector pBIND, indicating that the repressive 
activity contained within this construct is not due to the poor expression of the protein 
but a function of this region. Unlike TopBPI 586-1435, the GAL4-TopBPl fusion 
protein 798-1435 shows a reduced repressive activity compared to pBIND, indicating 
a repression domain is situated within TopBPI amino acids 586 and 798. To 
characterise the location of this repression domain further a series o f GAL4-TopBPl 
truncations focusing on the region within TopBPI amino acids 586-798 were 
constructed (Figure 22a), and the activity of these constructs to regulate transcription 
is shown in Figure 22b. TopBPI 586-1435 shows a 10 fold repression; however 
TopBPI 635 and 710-1435 do not show a strong repressive activity indicating that 
the repression domain lies within amino acids 586-635. This region partly 
encompasses the fifth BRCT domain; amino acids 606-656. There is further evidence 
to support BRCT 5 as the region containing this repressor domain; as shown in Figure 
22b, the removal of BRCT 5 from TopBPI 586-1435 (TopBPI ABRCT5) alleviates 
the repressive activity of this construct. The results for GAL4-TopBPl (amino acids) 
586-803 in the luciferase transcription assays is also shown in Figure 22b, although 
transcriptional repression by this construct is less than that observed for TopBPI 586- 
1435, the deletion of BRCT5 from TopBPI 586-803 further reinforces the result seen 
for TopBPI 586-1435, as the deletion o f BRCT5 completely removes any 
transcriptional repression. The expression of the fusion proteins indicated in Figure 
22a is shown in Figure 23.
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Figure 19
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Figure 19: ptkGAL46E2 Luciferase Reporter. Diagrammatic representation o f the 
luciferase reporter construct designed and cloned for the study o f  transcriptional 
repression. Five GAL4 binding sites (Orange Box) from pGSluc were cloned in 
frame into the reporter construct ptk6E2 (Vance et al. 1999). ptk6E2 luciferase 
activity (Green Arrow) is driven by the HSV thymidine kinase promoter from 
nucleotide 75-199 (Red Box) containing the TATA box downstream o f six 
consecutive E2 binding sites (Blue Box) (Appendix page 339-349).
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Figure 20: Identification of a Second Transcriptional Repression Domain.
Luciferase assay showing the mean activity normalised against pBIND (Equivalent to 
1) o f  the initial constructs shown in Figure 7a, using the reporter construct 
ptkGAL46E2 (Figure 19) ± S.E.M. Top 586-1435 shows a stronger repression using 
the ptkGAL46E2 luciferase reporter than was observed using pG5luc (Figure 7b).
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Figure 21: Repression by TopBPI 586-1435 is not due to a lower level o f Protein.
Titration o f pBIND, TopBPI 586-1435 and TopBPI 798-1435 over a 20 fold range 
showing the repression o f TopBPI 586-1435 throughout this range. Results are 
shown as a mean fold effect against ptkGAL46E2 (Equivalent to 1) ±S.E.M. This 
experiment was carried out three times in duplicate.
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Figure 22: BRCT5 is responsible for Transcriptional Repression, a) Schematic 
representation of the GAL4-TopBPl fusion proteins. Shaded boxes indicate the 
regions covered by BRCT domains, and numbers correspond to amino acid number, 
b) Luciferase assay showing the mean fold effect change in transcription against the 
empty vector pBIND (being equivalent to 1), ± S.E.M of the constructs indicated in 
a).
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Figure 23: Protein Expression o f G A L4-TopBPl Fusion Proteins, a) Western blot 
showing the expression o f  the GAL4-TopBPl fusion proteins indicated in Figure 22a 
using anti-GAL4 DBD antibody. The location o f  the molecular weight marker (kDa) 
is shown on the left o f  the blot.
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3.1.4 The Transcriptional Repression Domain within BRCT5 can 
Repress the Activation Domain
The work described in chapter 3.1.2 suggested that the transcriptional activation 
domain within amino acids 460-500 is suppressed by the recruitment o f a repressor 
complex (Figure 15). Chapter 3.1.3 identified a second repressor domain within 
BRCT5; therefore we tested whether BRCT5 could repress the adjacent activation 
domain. To investigate this a TopBPI sequence was cloned into pBIND to create a 
GAL4-TopBPl fusion protein containing the activation domain (amino acids 460- 
591) and the repression domain within BRCT5 (Figure 24a). The expression of this 
protein is shown in Figure 24b, using the anti-GAL4 DBD antibody. The ability of 
this fusion protein to activate transcription for the ptkGAL46E2 luciferase reporter 
was tested in 293T cells (Figure 24c). TopBPI 460-591 shows a significant 30 fold 
increase in transcriptional activation as previously shown in Figure 10b; however 
TopBPI 460-675 shows no increase in transcription indicating that the repressor 
domain contained within BRCT5 can also repress the activation domain within 
BRCT4 when placed in cis.
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Figure 24: The BRCT5 R epressor is D om inant over the BRCT4 Transcriptional 
Activation, a) Schematic representation o f the GAL4-TopBPl fusion proteins. The 
predicted size of these proteins in kDa is shown on the right of each construct. 
Shaded boxes indicate the areas containing BRCT domains, numbers correspond to 
amino acid number, b) Western blot showing the expression of the GAL4-TopBPl 
fusion proteins indicated in a) using anti-GAL4 DBD antibody. The location of the 
molecular weight marker is shown on the left. The expression of TopBPI 460-591 
was shown previously (Figure 14). c) Luciferase transcription assay showing the 
mean fold change in transcription of the constructs indicates in a) normalised against 
the empty vector pBIND (being equivalent to 1) ± S.E.M.
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3.1.5 The Domains identified within BRCT2 and BRCT4 are 
functionally conserved in Yeast
In order to determine the functional conservation of the repressor domain within 
BRCT2 and the activation domain within amino acids 460-500 of TopBPI, the ability 
of these domains to function in yeast was tested. TopBPI sequences encoding amino 
acids 2-591, 2-258 and 253-591 were cloned into the yeast expression vector 
pGBKT7 to create yeast expression vectors encoding GAL4-TopBPl fusion proteins 
(Figure 25a). These plasmids were transformed into the yeast strain AH 109 (2.2.3.4), 
and plated out onto SC-Trp plates. Cell lysates were then prepared using a TCA 
preparation as described (2.2.3.2) and the proteins were separated by SDS-PAGE and 
probed for the presence of the GAL4 DBD (Figure 25b) to check the expression of 
these proteins in yeast. The predicated size o f the GAL4-TopBPl fusions is indicated 
by an *, although it is o f note that in the case o f TopBPI 2-258 although there is a 
band at the correct size, a larger protein is more evident.
The ability o f these fusion proteins to act as activators/repressors of transcription was 
tested in yeast using replica plating (2.2.3.6). The HIS3 and ADE2 genes are under 
the control of the GAL4 DNA binding sequences therefore only TopBPI sequences 
which activate transcription would permit growth on the adenine and histidine amino 
acid depleted plates. Several clones expressing these GAL4-TopBPl proteins were 
tested for their ability to grow on SC-Trp-His, Sc-Trp-Ade and SC-Trp-His-Ade
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amino acid dropout plates. An example of the initial screen is shown in Figure 26, 
plate A shows the growth of all clones on SC-Trp media, B; SC-Trp-Ade, C; SC-Trp- 
His and D; SC-Trp-His-Ade amino acid dropout media. 2 clones for TopBPI 253-591 
were tested but however only one of showed growth on all dropout media plates, 
however this clone did not express the fusion protein. A master plate is shown in 
Figure 26b, showing the location of each clone. GAL4-TopBPl fusions 2-258, 2-591 
and TopBPI 253-591 clone I were spotted onto SC-Trp and SC-Trp-His-Ade plates 
with pGBKT7 to confirm the results shown in Figure 26, the results are shown in 
Figure 27, only the TopBPI sequence 253-591 allowed growth on the triple dropout 
medium, demonstrating that the activator within this region which was initially 
identified in mammalian cells (3.1.1) also functions in yeast.
The activity of the repressor domain identified within BRCT2 is also conserved in 
yeast. TopBPI 2-591 showed no growth on the triple dropout medium, even though 
this construct contains the activation domain within TopBPI 253-591, mimicking the 
result seen in the luciferase transcription assay in mammalian cells (Figure 7b, and 
Figure 9b). This result was confirmed using a liquid P-GAL assay (2.2.3.3) as the 
data shows (Figure 28) TopBPI 253-591 shows a 4 fold increase in activity. The p- 
GAL assay also suggests that the repressor domain can actively repress the yeast 
promoter as the activity of the TopBPI 2-258 construct was lower than the activity of 
TopBPI 2-591 similar to the initial observation in 293T cells (Figure 7b).
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Figure 25; TopBPI Activation and Repression Domains are C onseived  in Yeast.
a) Diagrammatic representation of the TopBPI constructs cloned into the yeast 
expression vector pGBKT7. Blue boxes correspond to BRCT domains and numbers 
correspond to amino acid number. The predicted size of the proteins is indicated on 
the right o f the diagram, b) Western blot extracts from pGBKT7 lysates were 
harvested (2,2.3.3) and separated by SDS-PAGE and probed using anti-GAL4 DBD 
antibody. * indicates the predicted size of the proteins.
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Figure 26: Yeast Reporter Activation Screen, a) Example of dropout media 
reporter screen, numbers of correspond to the amino acid start and end o f TopBPI 
present in the GAL4 fusion a diagrammatic representation o f the TopBPI-GAL4 
fusions is show in Figure 19. A) Sc-Trp plate B) Sc-Trp-Ade, C) Sc-Trp-His D) Sc- 
Trp-His-Ade. A master template is shown in b) indicating the location of the clones 
spotted onto the media dropout plates. Note only TopBPI amino acids 253-591 
shows any growth on the dropout media plates indicating that this construct can 
activate transcription in yeast.
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Figure 27: TopBPI Activation Domain functions in Yeast. Plate A) Sc-Trp media 
(Full complement), Plate B) Sc-Trp-His-Ade dropout media (Deficient in 
tryptophan, adenine and histidine). Numerals correspond to the clones spotted, each 
clone has six repeat spots per plate; I represents pGBKT7, II; TopBPI 2-591, 111; 
TopBPI 253-591, IV; TopBPI 2-258. All constructs including the empty vector 
grew on the full complement plate; however, growth is only present on the TopBPI 
253-591 clone on the triple dropout plate indicating transcriptional activation.
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Figure 28: BRCT2 Repression also functions to repress the Activation Domain 
in Yeast. The ability o f  the fusion proteins to activate transcription in yeast was 
tested directly by monitoring levels o f  P-galactosidase activity. The promoter 
controlling the expression o f this protein is controlled by GAL4 DNA binding sites. 
The results are expressed as optical density units following the P-galactosidase 
assay.
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3.1.6 Summary Chapter 3.1
TopBPI has roles in DNA damage signalling and repair and can act as both a 
transcriptional co-activator (Boner et a l  2002) and a transcriptional co-repressor 
(Liu et a l 2003). Although the role o f TopBPI in the DNA damage response and 
chromatin modification will be discussed in more detail in chapter 3.2, the results 
presented here have identified three domains within TopBPI which regulate 
transcription.
Figure 29a summarises the location of these transcriptional regulatory domains. A 
transcriptional activation domain lies between amino acids 460 and 500, partly 
encompassing the BRCT4 domain. This region of TopBPI is rich in hydrophobic 
and acidic amino acids (Figure 11), characteristic of other transcriptional activation 
domains (Roberts et a l  1993). This is also similar to the amino acid content of the 
BRCAl transactivation domain. Figure 29b shows a ClustalW sequence alignment 
o f the TopBPI and BRCAl transactivation domains. Flydrophobic residues which 
are conserved between the two are indicated by •, and conserved residues are 
indicated by *. BRCT4 of TopBPI lies within amino acids 466 and 546, which 
partly includes the activation domain similar to the BRCAl activation domain which 
contains a BRCT domain (amino acids 1642-1736).
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The transcriptional activation domain is suppressed by an adjacent repressor domain 
which maps directly to BRCT2. This repressor domain represses the transcriptional 
activation potential of BRCT4 most likely via the recruitment o f a repressor complex 
and not by an intramolecular interaction. This is demonstrated in Figure 15 where 
the TopBPI repressor was able to repress over 90% of VP 16 transcriptional activity. 
The activation domain is also repressed by a second repressor domain, which exists 
on the C-terminal side of the BRCT4 activation domain (Figure 24). This repressor 
domain is a significantly stronger repressor than the BRCT2 repressor domain, 
repressing transcription over 10 fold compared to GAL4 (pBIND) alone (Figure 22).
Both the activation domain and the repressor domain contained within BRCT2 
function in yeast (Figure 27), another feature similar to BRCAl and other activation 
domains (Miyake et al. 2000). TopBPI has a potential role in the generation of 
breast carcinomas, having aberrant expression in a significant number o f tumours 
(Going et a l  2007). BRCAl mutations in cancers are often found in the 
transactivation domain o f BRCAl, which was identified using a similar GAL4 
fusion protein assay (Monterio et a l 1996, 1997). It is unlikely given the 
significance o f the BRCAl mutations within the activation domain and their role in 
tumour suppression and transcriptional regulation that the TopBPI domains 
identified here are an artefact of this established assay.
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Figure 29
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Figure 29: Schematic Representation o f the Activator and Repressor domains 
identified, a) Blue boxes correspond to the location o f BRCT domain, black 
numbers indicate the first and last amino acid contained within that BRCT domain. 
Red numbers and dash boxes indicate the first and last residue o f TopBPI contained 
in each o f the transcriptional-activation/repression domain, b) Sequence alignment 
TopBPI (amino acids 450-500) and BRCAl (amino acids 1560-1863) activation 
domains. • indicates a conserved hydrophobic residue, * indicates residues which are 
conserved, : indicate residues in which the charge o f the residue is conserved. A 
conserved serine residue is highlighted by a green *, and a conserved proline is 
highlighted by a red *.
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3.2 TopBPI: DNA Damage and Chromatin Modification
3.2.1. Repression by BRCT5 is Dependent on Brgl but Independent 
of Brm.
Chapter 3.1 discussed the identification o f three transcriptional modification 
domains within TopBPI; an activation domain within amino acids 460-500, partly 
encompassing BRCT4, which is repressed by two adjacent repressor domains 
contained within BRCT2 and BRCT5. However the transcriptional activity of these 
domains is not universal to all cell lines; the activity of the GAL4-TopBPl fusion 
proteins initially investigated (Figure 7a), was tested in C33a cells and the results are 
shown in Figure 30. The GAL4-TopBPl fusion protein TopBPI amino acids 586- 
1435, which contains the repressor domain within BRCT5, shows no repression in 
C33a cells; indeed it shows a two fold increase in transcription unlike the result 
previously observed in 293T cells (Figure 7b).
The modification of chromatin may be required for the functions of TopBPI in 
transcriptional regulation and DNA damage repair (As discussed chapter 1.6.). The 
chromatin remodeller SWI/SNF was originally identified in yeast as a set o f positive 
regulators of the HO gene (SWI; mating switch type) and the SUC2 gene (SNF; 
sucrose non-fermenting). The SWI/SNF mutliprotein complex consists of 10-12
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subunits and modifies chromatin in an ATP dependent manner, by disrupting 
histone-DNA interactions. This complex either contains Brm (Brahma) or Brgl 
(Brahma related gene 1) as the central ATPase catalytic subunit; C33a cells lack 
significant Brgl and Brm activity (Muchardt et al. 1993).
Previous work on TopBPI has shown an interaction with Brgl/Brm  repressing the 
E2F1 activity (Liu et a l 2004). Therefore the ability of the repressor domain within 
BRCT5 to regulate transcription in the Brgl/Brm  compromised C33a cell line was 
tested. Figure 31 shows a titration of GAL4-TopBPl 586-1435, GAL4-TopBPl 
798-1435 and pBIND in C33a cells. Over a two hundred fold range o f plasmid 
concentrations, keeping the reporter plasmid (ptkGAL46E2) constant at Ipg, 
TopBPI 586-1435 failed to repress transcription in C33a cells. These results 
suggested that transcriptional repression by BRCT5 could be mediated by the 
actions of either Brgl or Brm; or both. In order to investigate this hypothesis further, 
Brgl was restored to C33a by co-transfecting a Brg wild type expression plasmid 
(Muchardt et a l 1993), the GAL4-TopBPl fusions and pTKGAL46E2. The results 
o f this luciferase assay are shown in Figure 32; the data shows the mean of at least 
three experiments carried out in duplicate ± S.E.M. In this experiment the addition 
of Brgl (wt) to C33a significantly restored the transeriptional repression (p= 0.035) 
observed previously in 293T suggesting that repression is dependent on Brgl. Figure 
33 shows the same experiment in C33a eells with the addition o f an ATPase mutant 
Brgl plasmid (Brgl (-/-) Muchardt et al 1993), this plasmid did not restore 
repression by BRCT5, indicating that the ATPase enzymatic activity of Brgl is
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essential for transcriptional repression by TopBPI BRCT5. As the repression 
domain lies within BRCT5, Figures 32 and 33 also show the results for the TopBPI 
BRCT5 deletion construct (GAL4-TopBPl 586-1435 A BRCT5), this construct 
shows no repressive activity and is not effected by either the addition of Brgl (wt) or 
Brgl (-/-).
To confirm the results seen in C33a cells similar experiments were carried out in 
293T cells (a cell line which is not Brgl or Brm compromised), with the addition of 
the Brgl dominant negative (-/-) (Figure 34) and wild type plasmids (wt) (Figure 
35). The addition of the Brgl (-/-) ATPase mutant plasmid to 293T disrupts 
transcriptional repression by TopBPI 586-1435, but has no effect on either TopBPI 
A BRCT5 or pBIND. The addition of Brgl (wt) to 293T further confirms these 
results, as seen in Figure 35, when Brgl (wt) is co-transfected with the GAL4- 
TopBPl repressor construct Top 586-1435, even in Brgl positive 293T cells the 
repressive activity o f TopBPI 586-1435 is increased. The addition of Brgl (wt) has 
no statistically significant effect on the activity o f GAL4-TopBPl 586-1435 A 
BRCT5, in HEK293T or C33a cells indicating that transcriptional repression is 
dependent on Brgl and BRCT5 of TopBPI.
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Figure 30
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Figure 30: Transcriptional Repression is not present in C33a. Luciferase assay 
showing the fold effect against the empty vector pBIND (being equivalent to 1), in 
transcriptional activity o f  the GAL4-TopBPl constructs indicated in Figure 5b in 
C33a cells. All luciferase assays were carried out in duplicate and repeated at least 
three times; this graph shows the mean o f  the triplicate experiments, ±  S.E.M.
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Figure 31: Titration o f  G A L4-TopBPl 586-1435, G AL4-TopBPl 798-1435 and 
pBIND in C33a. Luciferase assay showing the fold effect against the luciferase 
reporter pTKGAL46E2 (being equivalent to 1), in transcriptional activity o f  the 
empty vector pBIND and the GAL4-TopBPl constructs 586-1435, and 798-1435 
across varing concentrations. This graph shows the mean o f triplicate experiments 
carried out in duplicate ± S.E.M.
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Figure 32: The Addition o f B rgl (wt) restores Transcriptional Repression in 
C33a. Luciferase assay showing the fold effect against the empty vector pBIND 
(being equivalent to 1), in transcriptional activity o f  the GAL4-TopBPl constructs 
amino acids 586-1435, and 586-1435 A BRCT5, with and without the addition o f  
Brgl (wt) in C33a cells. This experiment was carried out at least three times in 
duplicate; this graph shows the mean o f  the triplicate experiments, ± S.E.M.
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Figure 33: The Addition o f B rgl (-/-) has no Effect on Transcriptional 
Repression in C33a. Luciferase assay showing the fold effect against the empty 
vector pBIND (being equivalent to 1), in transcriptional activity o f  the GAL4- 
TopBPl constructs amino acids 586-1435, and 586-1435 A BRCT5, with and 
without the addition o f the Brgl dominant negative plasmid (-/-) in C33a cells. This 
experiment was carried out at least three times in duplicate; this graph shows the 
mean o f  the triplicate experiments, ± S.E.M.
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Figure 34: The Addition o f B rg l (-/-) removes Transcriptional Repression in 
B rg l positive 293T cells. Luciferase assay showing the fold effect against the 
empty vector pBFND (being equivalent to 1), in transcriptional activity o f  the GAL4- 
TopBPl constructs amino acids 586-1435, and 586-1435 A BRCT5, with and 
without the addition o f  the Brgl dominant negative plasmid (-/-), in 293T cells. This 
experiment was carried out at least three times in duplicate; this graph shows the 
mean o f  the triplicate experiments, ± S.E.M.
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Figure 35: The Addition o f B rgl (wt) increases Transcriptional Repression in 
B rgl positive 293T cells. Luciferase assay showing the fold effect against the 
empty vector pBIND (being equivalent to 1), in transcriptional activity o f  the GAL4- 
TopBPl constructs amino acids 586-1435, and 586-1435 A BRCT5, with and 
without the addition o f  Brgl (wt) in 293T cells. This experiment was carried out at 
least three times in duplicate; this graph shows the mean o f  the triplicate 
experiments, ± S.E.M.
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As Brgl is essential for BRCT5 repression, the role of the SW l/SNF Brm ATPase 
subunit was also tested. Similar experiments as those described for Brgl were 
carried out using a Brm wild type expression plasmid (Brm (wt)) and a Brm ATPase 
mutant plasmid (Brm (-/-) Muchardt et a l  1993). The result for the luciferase 
transcription assay in 293T cells using these Brm expression plasmids is shown in 
Figure 36a. Unlike the results observed using Brgl, the addition of the Brm (-/-) 
ATPase mutant plasmid does not alleviate repression, and the addition of Brm (wt) 
does not increase repression by GAL4-TopBP 1 amino acids 586-1435 when 
compared to the empty vector pBIND. These results indicated that although 
repression by BRCT5 is dependent on Brgl it is independent of the Brgl homo log 
Brm. However in these assays the control plasmid lacking BRCT5 does show an 
increase in transcriptional repression with the addition of the Brm (wt) and Brm (-/-) 
plasmids. This is a non-specific effect as it does not depend on the ATPase function 
of Brm.
The addition of Brm (wt) to C33a also does not restore repression (Figure 36b) 
unlike the effect previously seen by restoring Brgl (wt) to this cell line (Figure 32). 
The addition of Brm (-/-) was tested as a control and has no effect on TopBPl 
transcriptional repression in C33a (Figure 36b). It has been shown previously that 
TopBPl repression of E2F1 is dependent on both Brgl and Brm when TopBPl is 
overexpressed (Liu et a l  2004), therefore as a control the effect of Brm on E2F1 
transcriptional activity using a p73 luciferase reporter plasmid was tested (Figure 
37). In 293T cells E2F1 shows a 20 fold increase in transcriptional activation, which
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is increased to 70 fold with the addition of Brm (when normalised against the p73 
luciferase reporter (being equivalent to 1). Similar experiments were performed in 
C33a cells with the addition of Brm (wt). Although the fold increase in transcription 
by E2F1 when normalised against the p73 luciferase reporter (being equivalent to 1) 
is lower than that observed in 293T cells (Figure 37a); 5 fold compared to 20 fold. 
The addition of Brm (wt) has the sqjne effect increasing E2F1 transcription from 5 to 
20 fold in C33a cells. These experiments demonstrate that that the Brm (wt) 
expression plasmid is expressing a functional protein in both cell lines. Although 
this increase in E2F1 transcriptional activation when Brm is overexpressed is the 
opposite of the previously published result (Lui et al. 2004), showing repression 
following Brm, different reporter plasmids were used in these experiments which 
may account for the different result.
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Figure 36: Brm is not Essential for Transcriptional Repression in 293T cells.
Luciferase assay showing the fold effect against the empty vector pBIND (being 
equivalent to 1), in transcriptional activity o f the GAL4-TopBPl constructs amino 
acids 586-1435, and 586-1435 A BRCT5, with and without the addition of Brm (wt) 
and Brm (-/-) in 293T cells. This experiment was earried out at least three times in 
duplicate; this graph shows the mean of the triplicate experiments, ± S.E.M. 
b)Luciferase assay showing the fold effect against the empty vector pBIND (being 
equivalent to 1), in transcriptional activity of the GAL4-TopBPl constructs amino 
acids 586-1435, and 586-1435 A BRCT5, with and without the addition o f Brm (wt) 
or Brm (-/-) in C33a cells. This experiment was carried out at least tliree times in 
duplicate; this graph shows the mean of the triplicate experiments, ± S.E.M.
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Figure 37: The Brm  (wt) plasmid expresses a functional protein and increases 
E2F1 Transcriptional Activity in 293T and C33a cell lines, a) Luciferase assay 
showing the fold effect against the p73 luciferase reporter (being equivalent to 1), in 
transcriptional activity o f the E2FI with and without the addition of Brm (wt) in 
293T cells. This experiment was carried out at least three times in duplicate; this 
graph shows the mean of the triplicate experiments, ± S.E.M. b) Luciferase assay 
showing the fold effect against the p73 luciferase reporter (being equivalent to 1), in 
transcriptional activity o f the E2F1 with and without the addition of Brm (wt) in 
C33a cells. This experiment was carried out at least three times in duplicate; this 
graph shows the mean of the triplicate experiments, ± S.E.M.
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3.2.2. Brgl Physically Interacts with TopBPl via BRCTS
It has been shown previously that Brgl can interact with TopBPl following DNA 
damage (Liu et a l 2004). To test whether TopBPl-Brgl interaction could be 
detected in non-damaged cells 293T protein extracts were prepared and 
immunoprecipitated (2.2.2.20.) using anti-TopBPl antibody (R1180, see materials 
and methods 2.2.1.) and pre-immune serum as a control (Boner et a l  2002). The 
resultant blot was probed with anti-Brgl (H-88); and as Figure 38a shows TopBPl 
and Brgl do interact in non-damaged cells, as endogenous TopBPl can 
immunoprecipitate endogenous Brgl in undamaged 293T cell lysates.
To investigate whether the transcriptional modification domains identified in 
Chapter 3.1 were the regions responsible for the TopBPl-Brgl interaction, 
immunoprécipitation experiments were carried out using the GAL4-DBD antibody, 
the GAL4-TopBPl fusion proteins (Figure 38b). To narrow down the region 
responsible for the interaction three GAL4-TopBPl fusion proteins were chosen; 
TopBPl 2-591, TopBPl 253-914 and TopBPl 798-1435 (Numbers correspond to 
TopBPl amino acids number). Figure 7a shows the regions o f TopBPl covered by 
these GAL4-TopBPl fusions, taken together these constructs cover the full length 
protein. As shown in Figure 38b, all three constructs can immunoprecipitate Brgl 
using the anti-GAL4 DBD antibody, and this binding of Brgl is specific as GAL4 
alone (pBIND) poorly immunoprecipitates Brgl. These results suggest there are at
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least two Brgl interactions domains on TopBPl. It was decided to specifically test 
whether Brgl can interact with the repressor domain encoded by BRCTS. To do this 
the GAL4-TopBPl fusion proteins; GAL4-TopBPl 586-803 and GAL4-TopBPl 
586-803 A BRCTS (Figure 22a) were used. GAL4-TopBPl 586-803 shows a 5 fold 
repression o f transcription and the deletion of BRCT5 removes over 80% of this 
repression (Figure 22b). Figure 39a shows a luciferase transcription assay using 
these GAL4-TopBPl fusions, with the addition of either Brgl (wt) or Brgl (-/-) in 
293T cells. Similar to the results shown in Figure 34 and 35, repression is dependent 
on BRCT5 and the addition of Brgl (-/-) removes transcriptional repression. Figure 
39b shows that the expression of these fusion proteins is not altered following the 
addition of either the Brgl (wt) or Brgl (-/-) plasmids. An immunoprécipitation 
reaction using the anti-GAL4 DBD antibody to immunoprecipitate GAL4 (pBIND), 
GAL4-TopBPl 586-803 and 586-803 A BRCTS, was performed in 293T cells to test 
the Brgl-BRCTS interaction. The blot was probed with anti-Brgl antibody (H-88). 
As Figure 40a shows TopBPl amino acids 586-803 show an interaction with Brgl, 
and the removal of BRCTS completely removes this interaction between TopBPl 
and B rg l. However, the GAL4 DBD antibody had too much background when 
trying to show the GAL4 protein inputs. Therefore, Figure 40b shows a western blot 
using the same protein lysates used in Figure 40 to show the expression o f the 
GAL4/GAL4-TopBP 1 fusion proteins. Although GAL4 alone (pBIND) does bind 
Brgl, it is clear when comparing the results for GAL4-TopBPl 586-803 and GAL4- 
TopBPl 586-803 A BRCTS that binding of Brgl is significantly reduced with the 
deletion of BRCTS, suggesting BRCTS is essential for the Brgl-TopBPl interaction.
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Figure 38
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Figure 38: T opB Pl interacts with B rg l. a) 293T cells were harvested and 
immunoprecipitated with anti-TopBPI antibody (R1180) and a pre-immune serum 
(2.2.1.20.); this lysate was separated on an SDS-PAGE gel and probed with anti- 
Brgl antibody (H-88). b) 293T cells were transfected with the GAL4-TopBPl 
constructs indicated above the blot as described (2.2.2.2.) harvested and 
immunoprecipitated with the anti-GAL4-DBD antibody (2.2.1.20.); this lysate was 
separated on an SDS-PAGE gel and probed with anti-Brgl antibody (H-88). The 
molecular weight marker is shown on the left o f the each blot (kDa). I and IP 
indicate the lanes in which the inputs and immunoprécipitation were separated 
respectively.
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Figure 39: G A L4-TopBPl 586-803 ± BRCTS Transcriptional Repression is 
Dependent on B rg l. a) Luciferase assay showing the fold effect against the empty 
vector pBIND (being equivalent to 1), in transcriptional activity of the GAL4- 
TopBPl constructs amino acids 586-803, and 586-803 A BRCTS, with and without 
the addition either the Brgl (wt) or the Brgl (-/-) plasmids. This experiment was 
carried out at least three times in duplicate; this graph shows the mean of the 
triplicate experiments, ± S.E.M. b) Western blot showing the expression o f the 
GAL4-TopBPl fusion proteins Top 586-803 and Top 586-803 A BRCT5, and 
pBIND in either untreated 293T cells or cells co-transfected with Brgl (wt) or 
B rg l(-/-). This blot was probed with the anti-GAL4-DBD antibody, and the location 
o f the molecular weight markers (kDa) is shown in the left of the blot.
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Figure 40
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Figure 40: B rg l interacts directly with T opB P l via BRCTS. a) 293T cells were 
transfected as described (2.2.2.2.) with the GAL4 constructs indicated above the 
blot, harvested and immunoprecipitated with anti-GAL4-DBD antibody (2.2.1.20.); 
this lysate was separated on an SDS-PAGE gel and probed with anti-Brgl antibody 
(H-88); the molecular weight marker is shown on the left o f the blot. I and IP 
indicate the lanes in which the inputs and immunoprécipitation were separated 
respectively, b) The lysates used in the immunoprécipitation experiment in a) were 
separated on a SDS-PAGE gel and probed with anti-GAL4-DBD antibody to show 
expression of the input GAL4-TopBPl fusion proteins, the molecular weight marker 
is shown on the left o f the blot.
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To further investigate this endogenous interaction between TopBPl and Brgl 
chromatin immunoprécipitation (ChIP) assays using 293T cell extracts were carried 
out as described (2.2.1.22.) to determine the co-occupancy of TopBPl and Brgl on 
the p73 promoter, an E2F1 responsive promoter (Pediconi et a l  2003). As shown in 
Figure 41 p73 promoter sequences (A), but not p-actin (B) promoter sequences, were 
detected in TopBPl and Brgl immunoprecipitates, confirming that not only do 
TopBPl and Brgl interact via BRCT5 but that these proteins are recruited to the 
same promoters.
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Figure 41
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Figure 41: T opB Pl and B rgl are recruited to the same Prom oter. Chromatin 
Immunoprécipitation (ChIP) was performed (2.2.1.22.) using antibodies against 
TopBPl (R 1180) and Brgl (H-88) as indicated. The HPV16 E2 antibody (TVG261), 
and a mock immunoprécipitation were used as negative controls. A negative PCR 
reaction is also shown. The precipitated DNA was amplified using two primers 
derived from the p73 promoter (A) and the P-actin promoter (B). The input 
represented 10% o f the total chromatin added to each immunoprécipitation reaction.
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3.2.3. DNA Damage Regulation of Brgl Dependent Transcriptional 
Repression via BRCTS
TopBPl is involved in all several areas of the DNA damage response; DNA damage 
recognition (Makinemi et a l  2001), signalling (Yamane et a l  2002) and repair (Lee 
et a l  2007). Brgl is also implicated in regulating the DNA damage response and 
having shown a direct interaction between BRCTS and Brgl (Figure 40a) the ability 
o f DNA damage to regulate the Brgl-BRCTS interaction was investigated. To do 
this the effect o f DNA damage on BRCTS transcriptional repression was tested. 
293T cells were transfected with the GAL4-TopBPl repressor construct Top 586- 
803 ± BRCTS as described (2.2.2.2.). The cells were then damaged with 20Gy from 
a Co^° source four hours prior to harvesting and the luciferase activity was assayed 
as previously described (2.2.2.8.). As Figure 42 shows the transcriptional repressive 
activity of TopBPl amino acids 586-803 is significantly alleviated following DNA 
damage (p = 0.031), when normalised against the empty vector pBIND being 
equivalent to 1. This alleviation o f repression is specific to this repressor domain 
within BRCT5 as the BRCT5 deletion construct (GAL4-TopBP 1 amino acids 586- 
803 A BRCT5), shows no change in activity following DNA damage. The 
transcriptional activation domain (Chapter 3.1.1) is not effected the same way by 
DNA damage; GAL4-TopBPl 460-591 shows a 35 fold increase in transcription in 
untreated cells when compared to the empty vector pBIND and shows no change in 
transcriptional activity following DNA damage (p = 0.865) (Figure 43).
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Figure 42
■ Untreated
■ 20Oy
586-803-BRCT5
Figure 42: Transcriptional Repression by BRCTS is Alleviated following DNA  
Damage. Luciferase assay showing the fold effect against the empty vector pBIND 
(being equivalent to 1), in transcriptional activity o f  the GAL4-TopBPl constructs 
amino acids 586-803, and 586-803 A BRCTS, ± 20Gy gamma irradiation. This 
experiment was carried out at least three times in duplicate; this graph shows the 
mean o f  the triplicate experiments, ± S.E.M.
165
Figure 43
Chapter 3-Results
I Untreated 
■ 20Gy
pBIND Top 460-591
Figure 43: The Activity o f the Activation Domain is not Affected by DNA  
Damage. Luciferase assay showing the fold effect against the empty vector pBIND 
(being equivalent to 1), in transcriptional activity o f the GAL4-TopBPl construct 
amino acids 460-591 which encompasses the transcriptional activation domain 
previously identified (3.1.1), with and without a 20Gy gamma irradiation dose. This 
experiment was carried out at least three times in duplicate; this graph shows the 
mean o f  the triplicate experiments, ± S.E.M.
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To investigate the role of Brgl in this response by BRCTS following DNA damage 
similar experiments were performed in C33a cells. As Figure 44 shows C33a cells 
were, transfected with 586-803 ± the addition o f the Brgl (wt) plasmid. In untreated 
cells similar to previous observations the addition of Brgl restores transcriptional 
repression by BRCTS. Following DNA damage this transcriptional repression in the 
presence of Brgl is alleviated mimicking the results seen in 293T following DNA 
damage.
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Figure 44: Alleviation o f Repression Following DNA Damage is Dependent on 
B rg l. Luciferase assay showing the fold effect against the empty vector pBIND 
(being equivalent to 1), in transcriptional activity o f  GAL4-TopBPl amino acids 
586-803, ± 20Gy gamma irradiation ±  Brg (wt) in C33a cells. This experiment was 
carried out at least three times in duplicate; this graph shows the mean o f the 
triplicate experiments, ± S.E.M.
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3.2.4 Investigating which DNA Damage kinase mediates the 
regulation of BRCT5-Brgl interaction.
In an attempt to determine the mechanism of Brgl dependent repression via BRCTS 
the PIKK. inhibitors; caffeine, wortmannin and LY294002 were used (2.2.2.8.) in 
transcription assays. These drugs are general inhibitors of the DNA damage kinases 
ATM, ATR and DNA-PK.
Figure 45 shows the results using caffeine (lOmM) in 293T cells ± 20Gy. The 
treatment of these cells with caffeine alleviates repression by GAL4-TopBPl 586- 
803 even in undamaged cells (Figure 45a). Following irradiation the repression by 
BRCTS is alleviated in cells not treated with caffeine, although this alleviation 
following damage is reduced in the presence of caffeine. These results suggested 
that repression by BRCTS is mediated by ATM, ATR or DNA-PK in undamaged 
cells. GAL4~TopBPl 586-803 A BRCTS, is not significantly effected by gamma 
irradiation or caffeine (Figure 45b).
Similar experiments were carried out in 293T cells treated with either wortmannin 
(lOOmM) or LY294002 (lOOpM) (2.2.2.8.). The results are shown in Figure 46; this 
experiment shows the mean of at least three independent experiments carried out in 
duplicate ± S.E.M. Transcriptional repression is alleviated following the addition of 
both of these inhibitors, irrespective o f DNA damage or not although not to the same
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extent as with caffeine where activation is observed. The fungal metabolite 
wortmannin inhibits ATM and DNA-PK but at the concentration used in this 
experiment, ATR is not inhibited. The inhibitory effects of LY294002 are less well 
understood, phosphorylation o f S I39 on y-H2AX which is dependent on ATM is 
inhibited following treatment with LY294002.
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Figure 45: Caffeine Alleviates Transcriptional Repression by BRGT5 in 
Undamaged Cells, a) Luciferase transcription assay showing; the fold effect against 
the empty vector pBIND (being equivalent to 1), in transcriptional activity of the 
GAL4-TopBPl repressor construct amino acids 586-803, in 293T cells treated* with 
lOinM caffeine 2 hours prior to damage (20Gy gamma irradiation).This experiment 
was carried out at least three times in duplicate; this graph shows the mean of the 
triplicate experiments, ± S.E.M. b) Luciferase transcription assay showing the fold 
effect against the empty vector pBIND (being equivalent to 1), in transcriptional 
activity of the GAL4-TopBPl construct amino acids 586-803 A BRCT5, in 293T 
cells treated with lOmM caffeine 2 hours prior to damage (20Gy gamma 
irradiation).This experiment was carried out at least three times in duplicate; this 
graph shows the mean of the triplicate experiments, ± S.E.M.
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Figure 46
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Figure 46: Wortmannin and LY294002 Alleviate Transcriptional Repression by 
BRCT5 in Undamaged Cells. Luciferase transcription assay showing the fold 
effect against the empty vector pBIND (being equivalent to 1), in transcriptional 
activity o f the GAL4-TopBPl repressor construct amino acids 586-1435, in 293T 
cells treated with either 20pM LY294002, or 5pM wortmannin 2 hours prior to 
damage (20Gy). This experiment was carried out at least three times in duplicate; 
this graph shows the mean of the triplicate experiments, ± S.E.M.
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3.2.5. Alleviation of Transcriptional Repression is not a Universal 
DNA Damage Response
Gamma irradiation causes distinct double strand breaks in DNA however, ultra 
violet radiation and the repair of this type o f damage proceeds via a distinctly 
different mechanism involving different signal and repair proteins (Introduction 
1.1,3). UV forms pyrimidine dimers in DNA which are repaired by NER. To 
investigate if BRCT5 transcriptional repression and the alleviation of this repression 
following DNA damage was mediated by a specific type o f DNA damage, 
transcription assays were performed following UV damage.
293T cells were transfected with the GAL4-TopBPl repressor construct TopBPl 
amino acids 586-1435 and pBIND. 36 hours post transfection the cells were treated 
with 0i02kJ/m^ UVB and harvested at various time points thereafter. As Figure 47 
shows unlike gamma irradiation, DNA damage induced by UVB does not result in 
alleviation of TopBPl BRCT5 transcriptional repression, indicating that alleviation 
o f repression shows some selectivity depending upon the type of DNA damage 
induced.
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Figure 47
Time (hours)
-pBIND -*-586-1435
Figure 47: Alleviation o f Repression is not a Universal DNA Dam age Response, 
and is not present in UVB Damaged Cells. Luciferase transcription assay 
following UVB irradiation. Transcriptional activity o f the GAL4-TopBPl repressor 
construct (amino acids 586-1435) was assayed following 0.02kJ/m2 UVB. Cells 
were harvested following damage at the time points indicated. The results are shown 
as relative light units (RLU). This experiment was carried out at least three times in 
duplicate; this graph shows the mean o f  the triplicate experiments, ±  S.E.M.
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3.2.6 Summary Chapter 3.2.
The modification o f chromatin is essential for DNA replication, chromosome 
recombination^ gene expression and DNA damage repair. This chapter has identified 
that the transcriptional repression domain contained within BRCT5 (3.1.3) and the 
transcriptional repressive function of this region is dependent on the chromatin 
remodeller Brgl; the addition the dominant negative Brgl (-/-) in Brgl positive 
293T cells results in a loss of transcriptional repression (Figure 34), and the 
reconstitution of Brg (wt) to the Brgl compromised C33a cell line results in 
transcriptional repression by Top 586-1435 (Figure 32). The results have also 
shown that this effect of Brgl is specific to BRCT5 (Figures 34 and 35) and that the 
levels of the GAL4-TopBPl fusion proteins is not altered with the addition o f either 
Brgl (wt) or Brgl (-/-) (Figure 39b).
Although SWI/SNF can contain either Brgl or Brm as the central catalytic ATPase 
core of the multi-protein. Figure 36 showed that although transcriptional repression 
by BRCT5 is dependent on Brgl it is independent of Brm. Although Brgl and Brm 
were historically associated with transcriptional activation (Muchardt et al. 2001) 
there is increasing evidence for their role in transcriptional repression (Battaglioli et 
a l  2002). The interaction between Brgl and TopBPl following DNA damage has 
been shown previously (Liu et a l 2004) however in Figure 38, it is clear that
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endogenous TopBPl can immunoprecipitate endogenous Brgl in undamaged cell 
lysates. Brgl is involved in mediating transcription repression by BRCT5 and as 
Figure 40 demonstrated BRCT5 and Brgl physically interact, the GAL4-TopBPl 
586-803 repressor construct can immunoprecipitate Brgl, but this interaction is 
abrogated in the BRCT5 GAL4-TopBPl deletion construct. Repression by BRCT5 
is alleviated following gamma irradiation (Figure 42) but not following ultra violet 
irradiation (Figure 47).
Chromatin remodelling enzymes have an essential role to play in the DNA damage 
response allowing access for repair proteins to the site of damage (Park et a l 2006). 
The results shown in C33a cells suggested that alleviation o f BRCT5 repression is 
dependent on Brgl (Figure 44), This change in transcriptional activity following 
gamma irradiation is not a generic effect on TopBPl transcriptional modification 
domains, as the activation domain within BRCT4 previously identified (3.1.1) shows 
no change in activity following gamma irradiation (Figure 43). To investigate the 
mechanism of this Bfgl-BRCT5 response to DNA damage, general PIKK inhibitors 
were used (Figures 45, and 46) to inhibit the checkpoint kinases ATM, ATR and 
DNA-PK in transcription assays. These inhibitors alleviated repression in the 
absence of DNA damage, suggesting that repression in untreated cells and the 
alleviation of repression following DNA damage is dependent on one of these 
kinases. More specific kinase inhibitors are required to determine which of these 
enzymes are required for mediating repression and then alleviating repression 
following DNA damage.
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3.3 Investigation of the Genes Regulated by TopBPl
So far the results have shown that TopBPl is a potential transcription factor, 
therefore we wanted to identify transcriptional targets by rumiing a gene expression 
microarray in TopBPl knockdown cells. To do this we needed to use a cell line in 
which the knockdown of TopBPl did not immediately affect the cell cycle, to allow 
comparable gene expression analysis. This chapter describes the results obtained to 
do this.
3.3.1 TopBPl is not always essential for Cell Growth and 
Replication
TopBPl is involved in DNA replication; physically interacting with the primary 
leading stand DNA polymerase, DNA polymerase 8 (Makinemi et a l  2001) and 
directly associating with chromatin during DNA replication (Kim et a l  2005). 
Topoisomerase 118, which TopBPl was originally identified in association with, is 
also essential for replication, catalysing essential topological changes in DNA during 
this process. This evidence suggests that TopBPl may play an essential role in DNA 
replication. To investigate the role of TopBPl in DNA replication the ability of 
different cell lines to replicate in the absence of TopBPl was tested by knocking out
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TopBPl in cultured cells using specific small interfering RNA (siRNA) targeted 
against TopBPl (2.2.2.3.). Cell growth in these cells was measured using a MTT (3- 
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell viability assay 
(2.2.2.6.). For all experiments using siRNA targeted against TopBPl, siRNA 
oligonucleotides against luciferase, and a mock transfection (lipofectamine only) 
were also used as experimental controls. The MTT assay provides a direct measure 
o f metabolically active cells in culture, the yellow MTT substrate is reduced in the 
mitochondria o f metabolically active cells form insoluble purple formazan crystals, 
which are then solubilised in DMSO and the absorbance reading at 570nm gives a 
direct measure of cell viability.
Five cell lines were chosen to test; HEK293T, U 20S, MRC5, MCF7 and HeLa. 
Figure 48 shows the MTT assay results for MRC5 and HeLa cells where TopBPl 
expression was knocked down. MRC5 (a) and HeLa (b) cells treated with siTopBPl 
stopped growing at 24hours and 36hours respectively. This stunted growth curve in 
the TopBPl knockdowns is significantly different from the siluciferase growth 
curves for both'cell lines (MRC5, p=0.031, and HeLa, p = 0.022) indicating that the 
arrest o f cell growth in these cells is due to the knockdown of TopBPl and not an 
effect o f  the siRNA transfection.
However not all cell lines seem to require TopBPl for replication as some cell lines 
tested showed no change in cell growth in the absence o f TopBPl. As Figure 49 
shows MCF7 (a), 293T (b) and U 20S (c) cell lines showed no reduction in cell
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growth when TopBPl was-knocked down compared to the growth curves o f the 
siluciferase and mock controls.
As Figure 48 and 49 show these assays were carried out over four days; the 
expression of TopBPl during these four days following siRNA treatment (either 
siTopBPl or siluciferase). is shown in Figure 50. These cell lysates were harvested at 
the same time points as the MTT assay readings were taken, and were transfected 
using the same siRNA/lipofectamine cocktails. The TopBPl siRNA knockdown is 
more effective in certain cell lines; noticeably more efficient in 293T (Figure 50a) 
and MCF7 (b) cells and to a lesser extent U 20S (c). In contrast the effect of the 
siRNA in MRC5 (d) and HeLa (e) cells is less efficient but as Figure 48 shows this 
these cells are more sensitive to the knockdown of TopBPl as it has a more 
profound effect their growth. In this experiment the Hela and MRC5 cell lines have 
a lower level of TopBPl, and even though the knockdown is less efficient it is 
possible that as the level o f  TopBPl in these cell is lines is already low, the 
knockdown results in a critically low level o f TopBPl with which the cells cannot 
survive. From the data presented here it is unclear why certain cell lines can grow in 
the absence of TopBPl and others cannot although this will be discussed later. These 
experiments seemingly contradict previous observations, which demonstrated that 
TopBPl was essential for DNA replication, as siTopBPl treated cells arrested at G1 
phase (Jeon e/ al  2007), however different cell lines and siRNA’s were used in these 
experiments which may account for different results.
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To analyse the cell cycle effect of the TopBPl knockout further FACs analysis was 
carried out in cells either treated with siTopBPl, siluciferase or a mock 
(Lipofectamine only 2.2,2,3.). The results are shown in Figure 51, MCF7 cells were 
siRNA treated and synchronised with aphidicolin for 16 hours to induce an early S- 
phase arrest (2.2.1.21.). The cells were then either left arrested or released and 
harvested for FACs analysis four hours following release. As panel A shows the 
knockdown of TopBPl has no effect on the cell cycle compared to either the mock 
or luciferase siRNA in unsynchronized cells. The aphidicolin induced an S-phase 
arrest in all tliree samples (Panel B) and following release, the TopBPl knockout 
cells show no significant change in cell cycle from the controls and still progress 
(Panel C) although perhaps at a slower rate.
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Figure 48: M CR5 and H ela Cells Cannot Grow in the absence o f T opB Pl. a)
MRC5 cells were treated with either siTopBPl, siluciferase or a mock siRNA, as 
described (2.2.2.3.). The cell viability was measured using the MTT assay (as 
described 2.2.2.6.) at the time points indicated. This experiment was carried out 
three times in duplicate and this data shows the mean ± S.E.M. for the repeat 
experiments, b) Hela cells were treated with either siTopBPl, siluciferase or a mock 
siRNA, as described (2.2.2.3.). The cell viability was then measured using the MTT 
assay (2.2.2.6.) at the time points indicated. This experiment was carried out three
times in duplicate and this data shows the mean ±  S.E.M. for the repeat experiments.
Students paired T Test, siluciferase against siTopBPl.
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Figure 49: TopBPl is not Essential for Cell Growth in all Cell Lines, a) MCF7 
cells were treated with either siTopBPl, siluciferase or a mock siRNA, as described 
(2.2.2.3 .). The cell viability was measured using the MTT assay (2.2.2.6.) at the time 
points indicated. This experiment was carried out three times in duplicate and this 
data shows the mean ±  S.E.M: for the repeat experiments, b) 293T cells were treated 
with either siTopBPl, siluciferase or a mock siRNA, as described (2.2.2.3.). The cell 
viability was measured using the MTT assay (2.2.2.6.) at the time points indicated. 
This experiment was carried out three times in duplicate and this data shows the 
mean ± S.E.M, for the repeat experiments, a) U 20S cells were treated with either 
siTopBPl, siluciferase or a mock siRNA, as described (2.2.2.3.). The cell viability 
was measured using the MTT assay (2.2.2.6.) at the time points indicated. This 
experiment was carried out three times in duplicate and this data shows the mean ± 
S.E.M. for the repeat experiments. * Student paired T-Test results for siluciferase 
against siTopBPl, there is no significant difference between the growth of the 
siluciferase and siTopBPl treated cells in 293T (p= 0.968), MCF7 (p= 0.894) or 
U 20S (p=0.981) in this assay, indicating that TopBPl is not essential for replication 
in these cell lines.
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Figure 50: T opB P l Expression Levels following siRNA Treatment. Total Cell 
lysates were harvested at the time points indicated and; equal amounts o f protein 
were separated on a SDS-PAGE gel (2.2.1.17.), the resultant blot was probed for the 
presence;, of TopBPl and y^ubulin as a loading control. The expression of these 
proteins following, either siTopBPl or siluciferase transfection over the time course 
(hours) are shown. Expression o f these two proteins was examined from each cell 
line previously used in the MTT assays (Figure 48 and 49); a) 293T, b) MCF7, c) 
U 20S, d) MRG5 and e) Hela cells.
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Figure 51 : The Cell Cycle is not effected by T opB Pl knock down. FACS analysis 
of synchronized and unsynchronized MCF7 cells. The siRNA transfected into the 
cells is indicated at the top of the figure, either siTopBPl, siluciferase or a mock 
(lipofectamine only as a control). A) Cells were left untreated, no synchronization. 
B) Cells treated with aphidicholin for 16 hours but not released. A clear early S 
phase arrest can be observed the siRNA samples following aphidicolin treatment. C) 
Cells treated with aphidicolin for 16 hours and released for 4 hours before harvesting 
for FACS analysis. Both siTopBPl and siluciferase treated cells proceed through S- 
phase and are not arrested. This experiment was performed twice in triplicate and the 
profiles shown here are representative o f those obtained for all repeats.
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3.3.2 Long Term Survival is Abolished when TopBPl is knocked 
down
Although MCF7, 293T and U 20S cell lines showed no change in cell viability 
following TopBPl knockdown (3.3.1), these MTT assays were carried out over. 96 
hours. It is possible that although cells might replicate for this length of time, a 
longer period in the absence o f TopBPl might result in cell death; perhaps by 
accumulation of damage.
To assay if TopBPl is essential for replication over a longer period o f time, crystal 
violet colony survival assays were carried out over 14 days (2.2.2.5.). MCF7 cells 
were chosen because they were originally derived from a breast adenocarcinoma and 
therefore any results would show more biological significance in the context of 
TopBPl and breast cancer. In these assays TopBPl was knocked down using 
TopBPl targeted siRNA and similarly to the previous MTT assays; siluciferase and 
mock (lipofectamine only) controls were also used. The results for the colony 
survival assay are shown in Figure 52. Photographs of the stained colonies which 
remained at Day 14 are shown in Figure 52. This experiment was carried out three 
times in duplicate; this figure shows one of the duplicate plates from the same repeat 
experiment. It is visually very clear that knocking down TopBPl expression has a 
profound effect on MCF7 cell growth over longer time periods than those previously 
investigated using the MTT assay (3.3.1).
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Table 8 shows the mean colony survival numbers ± S.E.M. for the triplicate 
experiments, following siRNA treatm ent There is no significant change in colony 
survival when comparing the mock and siluciferase transfected cells (p=0.08), 
indicating as a control the siluciferase has no effect on the cell survival. Compared 
to the mock transfected cells only 10% survived in the TopBPl knocked down 
samples (p =0.00004) and 13% compared to the siluciferase (p =0.0004). It is 
possible that the 10% of cells which do survive were not affected by the TopBPl 
targeted siRNA, as shown in Figure 50b the TopBPl knockout is not complete, 
therefore the percentage of cells which do survive may contain TopBPl.
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Figure 52: TopBPl is Essential for the Long Term survival of MCF7 cells.
Photographs from MCF7 colony survival assay. These experiments were carried out 
three times in duplicate. The plates shown here are single duplicates from the same 
repeat experiment and are representative o f  those obtained for the three experiments.
A) MCF7 cells were plated out and mock transfected (lipofectamine only control).
B) MCF7 cells transfected with anti-luciferase siRNA. C) MCF7 cells transfected 
with anti-TopBPl siRNA. All colonies were visualized 14 days following siRNA 
treatment using a 0.5% crystal violet solution (2.2.2.5.).
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T a b le s
’ Mock siRNA Luciferase SiRNA TodBPP
Mean Colony Number Day 14 541 429 57
Standard Error 27.94 40.09 4.80
T-Tesf* 0.0892 4.081E-06
T-Test** 0.0004
Table 8: M ean colony Survival num ber following siRNA treatm ent in M CF7 
cells. This data shows the mean colony number/plate ± S.E.M for each siRNA oligo 
knockdown from the triplicate experiments. MCF7 eells were either transfected with 
a mock siRNA, anti-TopBPI siRNA or anti-luciferase siRNA as described (2.2.2.3.), 
and the colonies were visualised at day 14 using a 0.5% ciystal violet solution. * 
indicates a paired T-Test between the siluciferase or siTopBPl and the mock data. 
** indicates a paired T-Test between the siTopBPl and siluciferase data.
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3.3.3; Experimental Design and Controls
In order to investigate the genes regulated by TopBPl, microarray experiment was 
performed, in which TopBPl was knocked down using siRNA. The experimental 
design is shown in Figure 53. MCF7 cells were chosen for this experiment as they 
are a breast carcinoma cell line and therefore provide a model for studying the role 
of TopBPl and breast cancer than other cell lines and as shown in Chapter 3.3.2. 
these cells still grow following TopBPl knockdown and the cell cycle is not 
effected, allowing a comparable gene expression profile. TopBPl was knocked out 
in these cells using small interfering RNA (as described 2.2.2.3.); and similar to the 
previous experiments a mock siRNA targeted against luciferase was used as a 
siRNA control. Figure 54a shows the reduction in TopBPl protein expression which 
results following siTopBPl transfection. TopBPl expression is reduced compared to 
the siluciferase control (Blot A). The luciferase control siRNA had no adverse effect 
on TopBPl expression compared to the mock siRNA (lipofectamine only). The total 
cell lysates used in this experiment were harvested 48hours following siRNA 
treatment; the same time point at which the RNA was extracted for the microarray, 
therefore serving as a control for the microarray samples, confirming that TopBPl 
expression was knocked down when the RNA was harvested. The same blot was 
probed with anti-y-tubulin as a loading control (Figure 54a, blot B).
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As TopBPl is a DNA damage response protein, three separate gene expression 
profiles were determined from the experimental data; 1) Genes regulated by 
TopBPl, 2) Genes regulated by DNA damage and 3) Genes regulated by TopBPl 
following DNA damage. To test if MCF7 cells respond and signal a DNA damage 
response following the dose o f gamma irradiation given in this experiment (IGy) the 
phosphorylation of y-H2AX was determined using immunofluorescence (2.2.4.1. 
12.). y-H2AX is phosphorylated at S139 in response to DNA damage (1.5.1.). 
Therefore MCF7 cells were stained with a phospho S I39 specific anti-y-H2AX 
antibody. Cells were plated out on coverslips, and either damaged (IGy) or left 
untreated (Control) and stained with DAPI and phosphorylated y-H2AX. The images 
are shown in Figure 54b; following DNA damage MCF7 cells do show the induction 
o f y-H2AX foci demonstrating a DNA damage response.
195
Figure 53
Chapter 3-Results
MCF7
aLuciferase siRNAaTopBPl siRNA Time Ohrs
Time 46hrs
OGy1Gy1Gy OGy
Harvest Total RNA (Triplicates) 
Time 48hrs
Aflymetrix^'^ Human Exon Array
Figure 53: Experim ental Design o f M icroarray. Diagrammatic representation 
showing the treatments o f each microarray sample; MCF7 cells were either 
transfected with siTopBPl or siluciferase, and damaged (IG y) or left untreated 
(OGy). These four RNA samples represent one repeat. Three repeats were taken for 
this experiment resulting in 12 RNA samples and 12 arrays in total.
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Figure 54: M CF7 controls for M icroarray, a) Western blot showing TopBPl 
expression knock down; MCF7 cells were transfected with anti-TopBPl, anti- 
iuciferase siRNA or mock (lipofectamine only) (2.2.2.3.)- Cell lysates were 
harvested at day 3 (the same time RNA was harvested), and the proteins separated 
using SD8-PAGE gel and the resultant blot was probed for the presence o f TopBPl 
using a monoclonal TopBPl antibody (BD Transduction Laboratories), Blot A. Blot 
B shows the expression o f y-tubulin (GTU-88, Abeam) as a loading control, b) 
MCF7 immunofluorescence staining following DNA damage. MCF7 cells were 
plated out onto glass coverslips; 3 days later the cells were either damaged (IGy) or 
untreated (Control, OGy), fixed and stained (as described 2.2.4.1/2,). Coverslips 
were stained with the DNA damage marker y-F12AX and DAPI to stain the nuclei. 
Panels A: DAPI only, B: y-FI2AX, C: Merge of two images. The staining of both 
control (undamaged) and damaged MCF7 is shown, showing that following DNA 
damage MCF7 form y~H2AX foci.
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To.extract the RNA MCF7 cells were plated out and either siTopBPl or siluciferase 
treated. 48 hours later, the cells were either left untreated or damaged (IGy), and the 
RNA was harvested 4 hours later using Qiagen RNAeasy RNA extraction kit (as 
described 2.2.1.23.). This experiment was carried out three times, resulting in 3 
repeat RNA samples for each condition (Figure 53). The concentration o f RNA in 
each sample was measured (2.2.1.2.) as a minimum of 1.5pg RNA was required per 
sample to perform the array. The quantity and quality of the 12 RNA samples was 
further analysed by Jing Wang (Sir Henry Welcome Functional Genomics Facility 
(SHWFGF), University o f Glasgow) using a 21000 Agilent Bioanalyser. The DNA 
was prepared using GeneChip cDNA synthesis and amplification kit (Affymetrix) 
also performed' by Jing Wang (SHWFGF) and analysed using Affymetrix Exon 
Array software by Dr. Pawel Herzyk (SHWFGF).
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33.4. Data Analysis
Analysis o f the microarray core data was performed using ArrayAssist® software 
(Affymetrix). ArrayAssist® software is specifically designed for the analysis of 
Affymetrix Exon microarray chip data, and in this section data analysis was 
performed only to the level o f gene expression. The core data was log transformed, 
instead of using linear data in order to perform the analysis using this software. Log 
transformation of the data makes the distribution, of the data more symmetrical 
around the mean of the population, which reduces the influence o f outliers and 
reduces the variance within the replicates.
3.3 4.1. Quality Controls
Before any gene expression analysis (3.4;5) was performed, the quality of the 12 
arrays was tested using the ArrayAssist® software. These quality controls are an 
essential process in the analysis o f the data; an array which fails these controls might 
alter the gene expression levels giving'rise to false results. The first quality control 
run on this software was the poly-A control which monitors the entire labeling 
process. These controls were incorporated into the array at the start o f the sample 
preparation process (Performed Jing Wang, SHWFGF). The GeneChip® Poly-A 
RNA Control kit (Affymetrix) contains a mixture of lys, phe, thr and trp (Bacillus
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subtilis genes cloned into pBluescript vectors), at increasing concentrations 
1:100)000, 1:50,000, 1:25,000, and 1:7,500 respectively relative to the total RNA in 
sample. Each of the 12 arrays is represented on the plot (Figure 55a) and the legend 
shows the array information (siTopBPl or siluciferase), untreated or damaged (IGy) 
and the repeat number (01, 02 or 03) for each array. These Poly-A controls provide 
exogenous positive controls to monitor the handling of the samples during 
preparation and as Figure 55a shows these internal controls all show the same trend 
(increasing concentration) on the plot therefore the samples were all treated in the 
same way and the gene expression profiles can be compared with confidence.
The second quality control performed was the hybridisation control; this plot gives 
a representation o f the quality of hybridisation, measuring the intensities helps to 
monitor the entire labeling process independently o f the starting RNA. The 
GeneChip® Eukaryotic Hybridisation control kit (Affymetrix) contains a mixture of 
biotin-labelled cRNA transcripts [bioB (1.5pM), bioC (5pM), bioD (25pM) and ere 
(lOpM)]. These controls are added to hybridisation cocktail of the 12 arrays, and 
provide a method of comparing the replicates within the experiment for example, a 
degraded RNA sample or a sample that has not amplified correctly will show a 
lower intensity compared to the other repeats. All 12 arrays are represented in the 
plot (Figure 55b) and there are no arrays within this experiment, which do not follow 
the same hybridisation profile as the other repeats. These quality controls confirmed 
that further analysis of the arrays could take place without any repeat arrays being 
performed.
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Figure 55
a)
b)
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Figure 55: M icroarray Q uality Controls, a) Poly-A internal control plot showing 
the signal intensities for each o f the poly-A controls, from each o f the 12 arrays. The 
information for each array is shown in the legend below; siRNA 
(TopBPl/Lueiferase), DNA damage (untreated/ IGy) and repeat number (01, 02 and 
03). b) Hybridisation plot for all 12 arrays. Array information is given in the legend 
as in a).
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3.3.5. Genes Regulated by TopBPl
Analysis of the genes regulated by TopBPl was perforrned using two Affymetrix 
Exon Microarray Software packages; ArrayAssist and Rank Products (RP (Breitlang 
et a l  2004), carried out by Pawel Herzyek (SHWFGF). Both analysis methods used 
a low level normalisation using Robust Multichip Average (RMA), described by 
Irizary et a l  2003, to correct the background levels for all probe sets, reducing non­
specific binding signals. These two methods o f analysis resulted in two sets of 
significant genes which were regulated by TopBPl. Only those genes which were 
significantly changed following both methods of analysis are shown in this chapter.
Table 9 shows the genes which are down regulated in the TopBPl knock down cells 
by 1.5 fold or more, and those which have a p value of 0.05 or below, TopBPl has 
the highest fold change, as would be expected and serves as a control for the siRNA. 
Table 10 shows the genes which are up regulated in the absence of TopBPl. 
Considering, the roles o f TopBPl in the DNA damage response, transcription and 
cell cycle control, there are some genes within these lists which participate in these 
processes and are significantly regulated by TopBPl. For example; proteins 
involved' in transcriptional'regulation include; p3 00/CBP-associated factor ((PCAF), 
Reid et a l  1998), RAD23 homolog B (Yokoi et a l  2000) and three inhibitors of 
DNA binding (ID) homologues are significantly down regulated in the absence of 
TopBPl ((DB2, IDT, and ID3).
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There are also several genes regulated by TopBPl which are involved in cell cycle 
control these include; S-phase kinase-assoeiated protein 2 (SKP2), MAX 
dimérisation protein 1 (M XDl), SET domain containing protein 7 and 8 ((SETD7) 
Couture et a l 2005).and the death associated protein 3 (DAP3) which plays a role in 
both transcriptional activation and apoptosis (Hulkko et a l  2000).
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Table 9
Transcript Id IGene ID | Gene p-value 1 Fold
2695941 NMs007027 TOPBPl // topoisonierase'(DNA') ITbindinR protein 1 2.33Er07 • -4.855
; 3151943 NM’ 032026 TATDNl-// TatD DNase domain' containing 1 , 2,08E-02 -4.280
2363074 NR 002190 StJMOTpseudogene 3 4.77E-02 , -3.634
2947040 NM 021066 HIST1H2AJ // histohe 1; H2aj 3:8iE-02 ' -3.426
3991889 NM 003928 CXXl //G A A X bo»! 3.SSEtOS -2.831
2468622 NM 001039 D2B I I  inliibitor o f DNA binding 2B, dominant negative helix-Ioop helix; LG8E,03 -2.517
3568603 NM 002083 GPX27/ glutathione.peroxidase2  (gastrointestinal). 1.67E,04 -2.385
3273484 NM 015155 LARP57/ La ribonucleoprotein domain family, member 5 7 1.32Ei03 -2.287
2781813 NM- 024090 ELOVL67/BLOVL family, membér-,6, elongation of long chain fatty acids ■ 6.05E-04 -2.182
3564919 NM, 006832 PLEKHei // pleckstrin homology domain containing,-family C 5.35E.05 -2.176
3815399 NM; 20127-7 CNN2-// calponin.2' 2.92E,04 . -2.096
2836665 NM.'024632 SAE30L // SAP30-like 4.94E-06 ; -2.064
3627076 NM; 004330 BNIP2’// BCL2/adenovirus ElB; l9kDa interacting protein 2 4:86E-05 -2.057
3136413 NM 017813 IMP ADI // inositol monophosphatase domain containing 1 9.82E-08 -2.040
2931683 NM 024573 C6orI2I I // chromosome 6 open reading frame 211 7.1ÜE.06 -L989
2859667 NM 197941 ADAMTS6 / / ADAMmietallopeptidase with thrombospondin type I motif 1.25E-03 -1.988
4004819 NM;006520 iDYNLT37/dynein, lighfchain, Tctex-type 3 , 3.07E-04 -1.976
266003C NM 033029 Leishmanolysin-like (metallopeptidase M8 family) 4.23E-02 -1.966
2487549 NM 002357 MXDl / / MAX dimerization protein 1 9.79E-05 -1.963
3543756 NM 031427 :G14orfl6 8 7 /chromosome Idmpen reading frame 168 1.Ü3E-Û2 -1.899
2401.493 NM 002167 ID3 H  inhibitor o f DNA binding 3, dominant negative helix-loop-helix 7.18E-04 -1.826
3034027 NM 005494 DNAJB6 //DnaJr(Hsp40) homolog, subfamily B; member,6 8.10E-03 -1.755
3316344 NM 173 584 EFCAB4A // ER-hand calcium binding domain 4A 4.27E-03 -1.746
2613441 NM 003884 PCAF // p300/CBP-associated factor 2.98E-04 -1.742
! 2817053 NM 004866 SCAMPI //secretory carrier membrane protein 1 3.75E-04 -1.722
: 2400373 NM 003760 EIF4G3 // eukaryotic translation initiation factor 4 gamma, 3 1.87E-03 -1.711
2777412 NM 032906 PIGY II  phosphatidylinositol glycan, class Y 2.45E-04 -1.703
3268274 NM 021622 PLEKHAl // pleckstrin homology domain containing, family A 2.71E-03 -1.681
' .  2866704 NM 020801 ARRDG3 // arrestin domain containing 3 1.17E-02 -1.679
3535922 NM 145251 STYX // serine/threonine/tyrosine interacting protein 4.72E-04 -1.670
2777070 NM 016245 DHRS8 // dehydrogenase/reductase (SDR family) member 8 5.61E-03 -1.670
3237088 NM 003473 STAM // signal transducing adaptor molecule (SH3 domain and IT AM motif) 1.23E-05 -1.669
3185498 NM 001860 SLC31A2 // solute, carrier family 31 (copper transporters), member 2 4.G5E-04 -1.667
2361036 NM 033657 DAP3 // death associated protein 3 6.20E-05 -1.664
3473331 NM 024738 G12orf49 //chromosome 12 open reading frame49 2.82E-06 -1.657
2694786 NM 003925 MethyUCpG.binding domain protein 4 (MBD4) 4.63E-02 -1.650
4045665 NM 020672 S100A14 // SiOO calcium binding protein;A14 1.S7E-02 -1.644
2722291 NM 018317 TBC1D19'//TBCI domain family, member 19 6.92E-03 -1.626
3881391 NM 002165 IDT// inhibitor o f DNA bindingT , dominant-negative helix-loop-helix l,31E-02 -1,615
2548274 NM 003162 STRN // striatin, calmodulin binding protein 1.59E-Ü4 -1,605
2910477 NM 033481 FBX09 ■// H-box protein,9 8.44E-04 -1.599
273675C N M '001865 Cytochrome c oxidase subunit V ila COX7A2'. 2.55E-02 -1.596
2786658 NM ’ 03064! SET. domain containing (lysine methyltfansferase) 7 3.03E-02 -1.594
2423017 XM 930999 LOC642939 // hypothetical protein LOC642939 3.G4E-03 -1.593
2876257 NM: 001033 SARIB7/ SARI gene homolog B (S. cereyisiae) 1.67E-02 -1.593
2356425 XM»942453 LOC652793 // similar to PDZ domain containing 1 4.70E-03 -1.589
3791996 NM 198833 SERPINB8 // serpin peptidase,inhibitor, clade B (ovalbumin) 2.43E-03 -1.585
3232944 NM -001040 AKRICL2 // aldo-keto reductase family 1, member C-like 2 6.96E-03 -1.581
2793346 NM 000958 Prostaglandin E synthase 3 4.93E-02 -1.575
4000456 NM 024087 ASB9 //.hnkyrin repeat and SOCS boxtcontaining.9 3.27E-02 -1.575
2940920 NM 004280 EEFIEL// eukaryotic translation elongation lactonl epsilon I 3.74E-02 -1.559
3299469 NM 144590 ANKRD227/ ankyrin repeat domain 22- 1.26E-03 -1.558
2957462 NM: 001512 GSTA4 7/ glutathione S-trans(erase A4 7.5ÎE-03 -1.555
3845620 NM 017797 BTBD2 // BTB (POZ) domain containing 2 3.87E.04 -1.549
2921338 NM 014891 PDGFA associated protein 1 (PDAPl), 4.67E-02 -1.540
2450855 NM 012396 PHLDA3, // pleckstrin HomolOgy-like domain, family A, member 3 7.26E-04 -1.540
3183757 NM 002874 RAD23B // RAD23 homolog B 1.43E-04 -1.529
2442103 NM 000696 ALDH9A1 // aldehyde dehydrogenase 9 family, member A l 1.49E-05 -1.521
2457988 NM 016096 ZNF706 // zinc finger protein 706 6.02E-03 -1.515
3012677 NM 032120 DKFZP564O0523 //hypothetical proteinDRFZp564O0523 7.72E-03 -1.512
2786657 NM 030648 SETD7-// SET domain containing (lysine methyltransferase) 7 2.54E-03 -1.508
2806520 NM 005983 S-phase kinase-associated protein 2 (p45) (SKP2), 3.35E-02 -1.505
2926476 NM 004865 TBPLl //TBP-like 1 1.31E-02 -1.500
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Table 9: Genes Down RegulatedTolldwing siT opB Pl This table shows the genes 
which are down regulated; in the siTopBPl samples. These transcripts were obtained 
by retaining those with a p value of 0.05 or below, and those with a fold change of 
1.5 or above. Analysis of significant genes was performed using two exon 
microarray software packages; ArrayAssist and RP, and as discussed earlier the data 
presented here represents transcripts which were significantly changed following 
analysis with both software programs.
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Table 10
Transcript ID Gene ID j Gene p-value 1 Fold
2359352 NM 178430 L’eE2E)7/ late coniified envelope 2D, 9.6300E-05 5.6772
3403414 NM 199286 DPP A3 // developmental pluripotency associated 3 1.9338E-03 2.7132
3416834 NM 054104 OR6C3 H  olfactory receptor, family 6, subfamily G, member 3 3.8087E-03 2,6674
2814154 AP073520 SERFIA // smalTEDRR-rich facton 1A ( telombric) ■ 3.5893E-02 ; 2.1977
3583362 NM 001005 OR4Mlr// olfactoiy; receptor, family 4, subfamily M| member. 1 ■ 4.S222E-02 2.0657
3318253 NM: 001004 OR51L1 //olfactoryaecepton family 51, subfamily. L, member 1 1.8145E-02 ; 2.0439
3881045 XM 945478 RP13-401N8..2 // hypothetical gene, supported by BG042812 1.7967E-02 ' 1.9337
3866831 NM 019855 GABP57/ calcium binding protein 5 5.2304E-03 1.9305
2828146 NM 020240 CDC42 small effector 2 1.8561E-04 1.9052 ,
33169'87 NM 001012 KRTAP5-6;// keratin associated protein 5-6 2.0196E-02 1.8709
3360333 NM 001005 OR51A4 // olfactoiy receptor; family 51, subfamily A, member 4 1.9039E-03 1.8435
3360486 NM; 033179 OR51B41// olfactory receptor, family 51, subfamily B, member 4 9.8707E-03 1.8288
3865867 NM: 001002 IGFL4.7/ insulin growth factor-like family member 4 1.6376E-02 1.8240
4047607 NM 024850 BTNB8 //.butyrophilimlike 8 4.8262E-02 1.7976
3928477 NM 203405 RRTAP26rl.// keratin associated protein 1.7762E-02 1.7887
3684548 AK1261667 LOG94431 // RNA polymerase I tianscription factor RRN3-like 4.3336E-02 1.7761
3713539 XM 942620 LOG6528947/ similar to RIKEN cDNA 1810036124 isoform 1 2.9916E-02 1.7670
3288482 NM 001006 LRRC18 // leucine rich repeat containing 18 8.1088E-03 1.7511
: 3195238 NM 000832 GRINl // glutamate receptor, ionotropic, N-methyl D-aspartate 1 1.9991E-02 1.7317
3977886 NM 174961 SSX87/ synovial sarcoma, X  breakpoint 8 1.0934E-02 1.7289
3883542 NM 032194 BXDCl / / brix domain containing 1 3.4389E-02 1.7261
3330551 XM 941859 LOC652421 //  similar to tripartite motif protein 39 1.7836E-02 1.7068
3361238 NM 003700 OR2D2 // olfactory receptor, family 2, subfamily D, member 2 3.3984E-02 1.7043
3386038 XM 930197 LOC399937 // similar to RING finger protein 18 I.8292E-02 1.7003
3250650 NM 001743 CALM2 // calmodulin 2 (phosphorylase kinase, delta) 4.8102E-02 1.6981
3919033 NM 006933 SLC5A3 // solute carrier family 5 (inositol transporters), member 3 1.9Ü72E-04 1.6969
3662086 NM 032935 MT4 // metallotliionein IV 3.8902E-02 1,6810
3330786 NM 001004 OR5L2 // olfactory receptor, family 5, subfamily L, member 2 4.5987E-02 1.6716
3755848 XM 927734 LOC653498 // similar to TBCl domain family, member 3B 1.1066E-02 1.6627
2792459 BC066960 GKP3 // glycerol kinase pseudogene 3 2.5149E-02 1.6582
3955483 NM 001001 bA9Fl 1 .1 // hypothetical LOC255349 8.8643E-03 1.6537
2887930 NM 001004 FLJ16I71 //FLJ16171 protein 3.0117E-02 1.6508
2362230 NM 030893 CDIE 7/ C D le molecule 3.4151E-03 1.6395
3369755 NM 207428 Cl lorf55 // chromosome 11 open reading frame 55 2.7072E-02 1.6258
; 2547090 NM 020382 SET domain containing (lysine methyltransferase) 8 (SETD8), 3.2100E-02 1.6123
3160658 NM 004170 SL C lA l // solute carrier family 1 (neuronal/epithelial high affinity) 2.0587E-02 1.6034
3558145 NM 014430 CIDEB // cell death-inducing DFFA-like effector b 1.8421E-02 1.6011
3595594 NM; 020980 AQP9 // aquaporin 9 ' 1.9613E-02 1.5981
3399922 XM 942369 I0SEC3 / /1 0  motif and Sec7 domain 3 3.4510E-02 1,5877
381-5082 NM 0206371 FGF22 // fibroblast growth factor 22 1.3786E-02 1.5787
3318141 NM ’001004 OR52M1 // olfactory receptor, family 52, subfamily M, member 1 2.240 lE-02 1.5778
3568485 XM 929192 ;LOG653716 // similar to spectrin, beta, eiythrocytic 4.2987E-02 1.5731
3721251 NM 031962 KRTAP9-3 // keratin associated protein 9-3 1.26S4E-02 1.5667
3904858 NM 021081 GHRH // growth hormone releasing hormone 2.44S0E-02 1.5649
3923896 NM 198699 KRTAP l 0-12 // keratin associated protein 10-12 4.1818E-03 1.5633
3957207 NM 001037 LOG6529687/ hypothetical protein LOC652968 1.3500E-05 1.5594
3373046 NM 001005 OR4C127/olfactoiy.receptor, family 4, subfamily C, member 12 2.8680B-02 1.5580
3535780 NM 000956 PTGER2'// prostaglandin E receptor 2 (subtype EP2), 53kDa 3.2035E-02 1.5531
3013255 XM. 928928 PEG 10 //  paternally expressed 10 2.6448E-03 1,5527
3474787 AK096009 / ÂR096009 // C12orf27 // chromosome 12 open reading frame 27 1.8024E-02 1.5522
3361523 NM. 001004 OR10A67/ olfactoiy receptor, family 10, subfamily A, member 6 2.9964E-03 1.5480
3399379 NM 174927 ’SPATA19 //spermatogenesis associated 19 1.3472E-02 1.5468
3472389 NM, 022363 LHX5 // LIM homeobox 5 1.0772E-02 1.5445
3699390 NM. 001025 CTRB2 // chymotrypsinogen B2 1.2Ô53E-02 1.5439
3299578 NM 003956 GH25H // cholesterol 25-hydroxylase 2.4815E-02 1.5374
3815710 NM 001405 EFNA2 // ephrin-A2 1.1037E-04 1.5324
3523978 NM 000452 ;SLC10A2 // solute carr ier family 10 2.1421E-02 1.5315
3680249 NM 021247 PRM3 // protamine 3 3.2606E-02 1.5295
3882823 NM, 001672 ASIP // agouti signaling protein, nonagouti homolog (mouse) 1.9534E-02 1.5216
2939232 NM 001069 TUBB2A // tubulin, beta 2A 1.6548E-02 1.5210
3989062 NM 032498 PEPP-2 // PEPP subfamily gene 2 2.092 lE-02 1.5198
3331150 NM; 001005 LRRC55 // leucine rich repeat containing 55 1.2855E-02 1.5160
3527641 NM 006683 FAM12A // family with sequence similarity 12, member A 2.5245E-02 1.5085
3487824 NM ’ OOIOIC C13orf21 // chromosome 13 open reading frame 21 4.6915E-02 1.5004
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Table 10: Genes Up Regulated following siT opB Pl. This table shows the genes 
which are up regulated in the siTopBPl samples. These transcripts were obtained by 
retaining those with a p value of 0.05 or below, and those with a fold change of 1.5 
or above. Analysis o f significant genes was performed using two exon microarray 
software packages; ArrayAssist and RP, and as discussed earlier the data presented 
here represents transcripts which were significantly changed following analysis with 
both software programs.
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33.6. Genes Regulated by DNA Damage
The second gene list which was extracted from the microarray data was the genes 
which were either down regulated or up regulated by DNA Damage in the presence 
of TopBPl. As described earlier (3.3.5.) this analysis was performed using two 
Affymetrix Exon Microarray Software packages; ArrayAssist and Rank Products 
(RP), carried out by SHWFGF), and only those genes which were significantly 
changed in both methods are shown in this chapter. Table 11 shows the genes which 
are down regulated following DNA damage by -1.5 fold or more, and those which 
have a p value o f 0.05 or below. Table 12 shows the genes which are up regulated 
following DNA damage, under the same restrictions. Although these DNA damage 
regulated genes will be discussed in more detail later (Chapter 4.3.3.) it is reassuring 
that genes involved in the DNA damage response are present in the significant 
transcript lists. For example; N-myc interactor (involved in apoptosis and interacts 
with BRGAl (Li et a l  2002)), excision repair cross complementing 8 (Groisman et 
a l  2003), inhibitor of growth family member 2 (Nagashima et a l 2001) and 
programmed cell death 10 (Plummer et a l 2005).
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Table 11
Transcrip t ID: GBHe-IDi G en e - p -value i Fold
2047O4D NM 021066 HIST1H2AJ '// histone 1 .H 2 a |n 3.14E-02 -3.64366
2461,717 NR. 002955 SN0RA14A // small nucleolar RNA, H/ACA box 14A- 5.83E-06 -2.45154
334801,1 XM.499315 5004425737/ similar to postmelotlc seqreqation increased 2-llke 2 Ï.36E-D2 -2.1666
2979246 NM1130900 RAETIL // retinolc a d d  early transcript 1L 1.29E-02 -2.13007
3038617 NM. 002489 NDUFA47/ NADH detivdroqenase (ubiquinone) 1 alpha subcomplex, 4 ' 5.74E-0B -2.09816
2468622 NM 001039 1D2B // Inhibitor of.DNA bindinq 2B, dominant neqatlve helix-ioop-heiix? 4.87E-03 -2.04186
: 3208356 NM 199244 FOXD4L4 // forkhead box D4-like 4 2.16E-02 -1.99427
' 2944025 NM 000367 TPMT 7/ thiopurine S-methvltransferase* 2.68E-02 -1.94849
: 3717034 XR 000654 5 0 0400590  // hypothetical L 00400590 9.50E-03 -1.93935
2707359 NM 201261 DNAJ019 // DnaJ (Hsp40) homolog, subfamily C, m em ber 19 1.41E-02 -1.93282
3025433 XM 935707 5 0  0441282 // similar to aldo-keto reductase family 1, m em ber 810 1.93E-02 -1,90769
3053380 NM; 024498 ZNF117 //z in c  finger protein 117 (HPF9) 1.26E-02 -1.90524
2768145 NM 017845 C0MMD8 // OOMM domain containing 8 9.65E-03 -1.88148
2403470 NM 014280 DNAJ08 // DnaJ (Hsp40) homolog, subfamily 0 , m em ber 8 1.02E-03 -1,87412
2382781 XM1938194 5 0 0 1 2 7 6 0 2 7 /hypothetical protein 5 0 0127602 1.77E-02 -1,84088
Î 2832387 NM 019120 PCDHB8 // protocadherin beta 8 6.06E-04 -1.8268
2566645 NM.: 138798 5001295317 / hypothetical protein BC018453 3.98E-02 -1.79283
: 23636,18 NM :001035 8DMC // succinate dehydrogenase complex, subunit 0 2.42E-02 -1.7871
> 2815139 NM: 138782 FC H 02 // FOM domain oniy 2 7.96E-04 -1.76403
2580955 NM 004688 NMI:// N-myc (and STAT) interactor 4.90E-O2 -1.75748
2380785 NM 138794 5YP5A51 // lysophosphollpase-like 1 2.45E-02 -1.75313
2522598 NM 002491 NDUFB3 // NÀDH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 1.87E-02 -1.74339
2466493 NM 033213 ZNF670 // zinc finger protein 670 3.21 E-04 -1.73009
2587747 NM' 004882 OIR // 0BF1 interacting corepressor 8.88E-03 -1.72636
3826504 NM 133473 ZNF431 / / zinc finger protein 431 7.12E-04 -1.7217
i 2418451 NM 001889 CRYZ7/ crystaliln, zeta (quinone reductase) 8.37E-03 -1.71511
3107828 XM 031334 , similar to pleckstrin homology domain containing 1.55E-02 -1.69534
2940920 NM 004280 EEF1E1 / / eukaryotic translation elongation factor 1 epslion 1 1.85E-02 -1.69128
2389130 XM 936697 hypothetical protein 50C647651 1.3 IE-02 -1.68908
2836886 NM 014180 MRP522 // mitochondrial ribosomal protein 522 2.68E-02 -1.68379
2603897 NM 145702 TIGD1 / / tiqqer transposable elem ent derived 1 6.95E-04 -1.67963
2773545 NM 001729 BTC // betacallulin 4.40E-03 -1.67331
2966232 NM 017421 COQS // coenzym e Q3 homolog, methyltransferase 3.32E-02 -1.67088
2424148 XM 926707 50G 642617 //hypothetical protein 50C 642617 3.49E-03 -1.60509
2858668 NM 001007 ERCC8 // exdsion repair cross-complementing 5.71 E-03 -1.66371
3004665 XM1927547 50C 653473 // similar to Zinc finger protein 588 2.84E-04 -1.65677
2875634 NM 017665 ZGCHC10 / / zinc finger, CCHC domain containing 10 1.49E-02 -1.64921
2559696 NM 016058 TPRKB //TP53RK  binding protein 1.42E-03 -1.64637
2783473 NM 001001 LOC4Û1152 // HCV F-transactivated protein 1 1.87E-02 -1.64398
r. 3504054 NM 001039 ZMYM5II zinc finger, MYM-type 5 8.34E-03 -1.63464
; 2612930 NM 012198 GCA // grancaldn, EF-hand caldum  binding protein 2.35E-03 -1.62732
2589291 NM 003319 T IN  II titin 4.92E-02 -1.6256
2740005 NM 016648 HDGMA18P // HDCMA18P protein 6.48E-04 -1.62199
2704188 NM 145859 PDGD10 // program med cell death 10 7.1 IE-03 -1.6182
3870135 NM: 032584 ZNF347 / / zinc finger protein 347 5.91 E-03 -1.61748
2361241 NM I014017 MAPBPIP7/ mitogen-activated protein-binding protein-interacting protein 4.83E-02 -1.61583
2810395 NM 153706 M GG 33648 II hypothetical protein MGG33648 2.05E-02 -1.61307
2534564 NM 080678 UBE2F / / ubiquitin-conjugatinq enzym e E2F (putative) 3.B2E-02 -1.61292
282198:1 NM 108507 TMEM15 7 7 /transm em brane protein 157 4.04E-03 -1.60153
2514497 NMiil 44711 K5H5237/ kelch'llke 23 (Drosophila) 2.73E-02 -1.59794
2813481 NM 001799 CD K7I I  cydih-dependent kinase 7 5.96E-03 -1.59464
2788143 NM 014885 ANAPC10 // an ap h ase  promoting complex subunit 10 5.02E-03 -1.59362
■ 2517737 NM: 019091 P5EKHA3II pleckstrin homology domain containing, family A 1.83E-04 -1.5918
2603597 NM 002601 PDE6D II phosphodiesterase 6 0 , cGM P-spedfic, rod, delta 3.03E-Q3 -1.59159
2761151 NM 001017 RAB287/ RAB28, m em ber RAS oncogene family 2.83E-03 -1.58788
3139950 NM 016027 5ACTB2 // lactam ase, beta  2 1.13E-02 -1.5862
3018535 XM 935514 5 0 C 6 5 3 8 3 6 I I  similar to B-cell receptor-associated protein 29 3.48E-Q3 -1.58202
2763952 NM f001564 IN G 2 // inhibitor of growth family, m em ber 2 1.82E-02 -1.5783
2366132 NM 001031 TIPR57/TiP41, TOR signalling pathway regulator-like 7.42E-03 -1.57395
2745067 NM .153702 E5MOD2 //. E5MO/CED-12 domain containing 2 5.73E-D3 -1.57038
2544179 NM 016047 SF 3B 14 II splicing factor 3 8 .1 4  kOa subunit 8.88E-03 -1.56703
2633631 NM 020202 NM_ 020202 // N IT2 II  nitrilase family, m em ber 2 1.89E-02 -1.56602
2429842 XM_944043 50C 148766 //hypothetical 50C148766 6.44E-04 -1.5659
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Table 11 continued
T ran sc rip t ID. ' G ene-ID G e n e . p-value- Fold
2374956 NM ,006335 :TIMM17A // tran slocase:o f inner mitochondrial m em brane 17 homolog A 4.-47E.02 -1.56551
2423625 NM 002061 GCLM.// g |u tam atercyste ine  ligasb, modifier subunit 1.41 E-Û2 -L 56536
2415728 NM 032027 TM2D17/.TM2 dom ain containing l ; 2;19E-04 -1 .55812
2422885 XM_937148 LOG646821 //'sim ilar to  cytoplasm ic beta-actin 2.31 EiQ2 -1.55798
3569690 XM, 113763 c i4 o rf1 2 6  // ch rom osom e 14 open reading fram e 126 1 ,2 2 E T 0 2 -1 .55633
2469094 NM 005680 TAF1B // TATA box binding protein (TBP)-'associated factor. 6 .87E-03 -1 ,55569
2946714 NMk 080593 H IST 1H 2B K //histone,1f H2bk 6.31 E-03 ' -1 .56534
2960872 N M ii 38441 C6orf150 / / ch rom osom e 6 open  reading fram e ISO 8 20E -03 -1.55461
2702154 NM10071D7 SSR3;//<signar seq u e n c e  receptor, gam m a 5.83E-03 -1.55105
2627080 NM; 020685 G3orf14 //ch ro m o so m e 3 open  reading fram e 14 7:36E-04 -1:55023
3183219 NM 1207647 FSD1L //fibronectin .type III and  SPR Y  dom ain containing 1-like // 2.42 E-02 -1.55
3391265 NM 1001562 IL18V/ in teiieukindS  (interferon-gam m a-inducing factor) 3.46E-03 -1 .54999
2700500 NM.;.016094 C0M M D 2 //G 0M M .dom ain  containing 2 2.54E-03 -1.5485
2691421 N M i006287 TFPI // tissue  facto r pathw ay inhibitor 1.15E-02 -1.54581
3976450 NM; 205856 R R 11-38023 .2  // PNPK 6288 9.13E-03 -1 ,54525
2792127 NM 000909 NPY1R // neuropep tide Y recep to r Y1 1.76E-02 -1 .54256
3857105 NMl 003430 Z N F 9 1 //z in c  finger protein 91 //1 9 p 1 3 .1 -p 1 2 //7 6 4 4 ///X M _ 9 2 9 8 6 4.85E-02 -1.54189
2878446 NM 1002488 NDUFA2'// NADH d ehyd rogenase 4.68E-02 -1.5416
2474071 NM&012326 MAPRE3 //.m icro tubuie-assoctated  protein, RP/EB family, m e m b e rs 1.99E-03 -1.54123
2829542 NMi.152409 C5orf24 // ch rom osom e 6 open  reading fram e 24 1.07E-03 -1.53748
2483016 NM.. 080667 CCDC.104 / / cPiled-coil dom ain containing 104 1.84E-02 -1.53519
2780656 NM_.020395 IN T S 12// Integrator com plex subunit 12 9.21 E-03 -1.53413
2711034 NM_ 178496 C3orf59 // ch rom osom e 3 o pen  reading  fram e 59 1.08E-02 -1.53101
2898562 NM_018473 THEM2 // th io es te ra se  superfam ily m em ber 2 1.85E-02 -1.53074
3721124 NM_145274 TMEM99 // tran sm em brane protein 99 6.78E-03 -1 .52994
2448971 NM. 015984 UCHÜ5 // ubiquitin carboxyl-term inal hydrolase L5 1.20E-02 -1 .52883
2924619 NM 138571 HINT3 // histidine triad nucleotide bindinq protein 3 2.96E-03 -1.52864
2472914 NM _181713 UBXD4 // UBX dom ain containing 4 / 3.14E-03 -1.52859
2746269 NM. 007080 LSM6 // LSM6 hom olog, U6 small nuclear RNA assoc ia ted 2.71Ë-02 -1.52745
2871717 NM  152549 GGDG112 // cotled-coil dom ain containing 112 1.36E-02 -1.52676
2546285 NM. 017910 F LJ20628 // hypothetical protein FLJ20628 1.36E-02 -1.62613
3536396 NM. 006568 CGRRF1 // cell growth regulator with ring finger dom ain 1 1.55E-02 -1.52489
2351817 NM. 001688 ATP5F1 // ATP syn th ase , H+ transporting, mitochondrial FO com plex. 3.34E-02 -1.52054
3387171 NM 016403 H SPC148 // hypothetical protein H SPC 148 / 1.50E-02 -1.51749
3790479 NM 033280 S E C 11L 3//S E C 11-like  3 (S. cereyisiae) 1.38E-02 -1 .51392
3104323 NM...016010 C8orf70 // ch rom osom e 8 open  reading  fram e 70 2.71 E-02 -1 .51276
2809423 NM 003950 F2RL3 // coagulation factor II (thrombin) receptor-like 3 3.62E-02 -1.51091
3070658 NM. 005000 NDUFA5 // NADH deh y d ro g en ase  (ubiquinone) 3.19E-02 -1.50726
2875419 NM..007054 KIF3A // kinesin.family m em ber 3A 1.24E-02 -1.50306
Table 11: Genes Down-regulated Following DNA damage: This table list the 
genes which were significantly (p<0.05) up-regulated (Fold >1.5) following DNA 
damage. Analysis of significant genes was performed using two exon micro array 
software packages; ArrayAssist and RP, and as discussed earlier the data presented 
here represents transcripts which were significantly changed following analysis with 
both software programs.
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Table 12
Transcript ID G ene-ID  1 1 p-vatue 1 Fold
2329131 N M  002143 HPCA II hippocaldn 2.48E^03 Ï 1.60407
2335048 X M '940223 LO C654164II similar, to cytochrome R450, family 4, subfamily A 8.63E:03 ; 1.81121
2359352 NM:,1 78430 LCE2D //la te  cornlfied envelope 2D ' 1:72E-03 ; 3.06409
2359377 NM; 178428 LCE2A II late (X)mlfied erivelope‘2A 3.06E-02 1.64486
2359431 NM 178354 LCE1F II late cornlfied envelope IF 3.33E-02 ' 1.99373
2359691 NM' 002963. 8100 calcium binding, protein A77psorlasln 1) T54E-02 , 1.52063
2362230 N M 030893 GD1E II CD1e moiecuie 6.36E-03 , 1.55475
2362537 NMV002D01 FCER1A7/;Fc fragment of IqE, high affinity 1, receptor 2.51 E-02 1.60225
2387606 AK0563497/ CHRM3 II cholinergic receptor: muscarinic 3 2.10E-03 1.90611
2398146 N M '198546 NM 198546 /7SPATA21 // sperm atogenesis associated 2 1 111 p36.13 //374955 III B 1.38E-02 1.51583
2407496 NM( 002699 NM 002699 //. P 0 U 3 F 1 IIPO U  domain, class 3, transcription factor 1 // 1p34.1 II 5.83E-03 1.57182
2542420 N M ;145260 0SR17/,odd-skipped re la ted :! (Drosophila) 7.28E-03 1.50743
2560881 XM^942076 LOC647278 //.similar to Leucinerrich repeal transm em brane 9.13E-G3 1.52413
2564816 X R'000661 LOG150759 //.hypothetical pYotein LOC150759 5.51 E-03 1.84772
. 2576608 XM:497877 LOC391444 II hypothetical LOC391444 1.47E-Q2 1.51492
2611546 NM: 001998 F B lN 2 //fibu lih2 ' 8.41 E-04 1,50848
2672442 NM? 000258 MYL3 // myosin, light polypeptide 3, 9.79E-03 1.60956
2748605 NM;004744 LRAT7/ lecithin retinoi acyltransferase 1.3 IE-02 1.54331
2779199 NM: 000667 ADH1A7 /aicohoi dehydrogenase 1A (class 1), alpha polypeptide 3.70E-03 1.75928
2792459 BG0669607/ QKP3 //.'glycerol kinase pseudoqene 3 4.22E-02 1.55971
2795904 NM: 153008 F U 30277 II hypothetical protein FLJ30277 6.43E-03 1.9022
2892734 AF2106507/ G6orf50 //.chromosome 6 open reading frame 50 4.83E-02 1.51919
2903777 AY3836277/ G G N B P l// gametogenetln binding protein 1 3.99E-02 1.86137
.• 2937625 NM ' 025002 C6orf208 I I  chrom osom e 6,open reading frame 208 2.61 E-02 1.55386
2939232 NM 001069 TUBB2A7/ tubulin, beta 2A 1.54E-02 1.53082
3013952 NM 020186 ACN9 // ACN9 homolog (S. cereulsiae) 1.63E-02 1.53382
3029434 NM 0010041 OR2F2 // olfactory receptor, family 2, subfamily F, m em ber 2 1.93E-02 1.60358
3031573 NM 018384 G1MAP57/ G TPase, IMAP family member 5 6.01 E-03 1.51344
3040465 NM 152774 MGC42090 // hypothetical protein MGC42090 3,71 E-02 1.63035
3086809 NM 020844 KIAA1456 // K1AA1456 protein 2.55E-03 1.5009
3147699 NM .080651 THRAP6 // thyroid hormone receptor associated protein 6 5.19E-D3 1.50023
3185953 NM 0010401 LOC286334 // hypothetical protein LOC286334 5,1 IE-03 1.62499
3191674 NMr,021619 PRDM12 //P R  domain containing 12 2,7QE-02 1.5813
3203524 NRt002B23 AQP7P2 //aquaporin 7 pseudoqene 2 3.71 E-03 1.52919
3218209 NM:'147180 PPP3R2 // protein phosphatase 3 (formerly 28), requlatoty subunit B 2.77E-02 1.60975
3218496 NM; 001004' OR13C2 //olfactory receptor, family 13, subfamily C, member 2 2.00E-02 1.9015
3250650 NM'-001743 CALM2 // calmodulin 2 (phosphorylase kinase, delta) 1.07E-02 2.12126
3316987 NM 001012' KRTAP5-6II keratin associated protein 5-6 7.58E-03 2.1555
3318589 NM '001005 O R 52W 1 II olfactory receptor, family 52, subfamily W, member 1 3.49E-02 1.82922
3322638 NM.f054031 MRGPRX3I I  MAS-reiated GPR, m em ber X3 3.5 IE-03 1.57167
■ 3330693 NMk001004 tOR4C167/ olfactory receptor, family 4, subfamily G, m em ber 16 4.17E-02 1.61851
;  3335124 NM 145719 TIGD3 // tigger transposable elem ent derived 3 2.95E-03 2.00658
3360486 NMA033179 OR51B47/ olfactory receptor, family 51, subfamily B, m em ber 4 2.93E-02 1.60868
3369755 NM--2D7428 C l 1 orf55 // chrom osom e 11 open reading fram e 55 2.44E-02 1.64566
3373411 NM: 001004' 0R5R1 // olfactory receptor, family 5, subfamily R, member 1 1.73E-02 1.52718
- 3386038 XM;930197 U OC399937 II similar to,RING finger protein 18 4.02E-02 1.55195
. 3395691 NM: 001040 SCN3B //sodium  channel, voltaqe-qaled, type III, beta 1.98E-02 1.53521
3416834 NM.; 054104 OR6G37/ olfactory,receptor, family 6, subfamily C, member 3 2.42E-02 1.96589
; 3420316 N M '003483 HMGA2II high mobility group AT-hook 2 4.03E-02 1.51217
3437780 NM; 007197 frizzled homolog 10 (Drosophila) 4.33E-03 , 1.55502
. 3455478 NM'fl 73086 KRT6E7/keratin 6E 9.21 E-03 1.51392
3487,824 NM-001010 C13orf21 II  chrom osom e 13 open reading frame 21 3.44E-02 1.55294
, 3527831 NM; 032572 ribonuctease, RN&se A family, 7 7.69E-03 1.56213
3595594 NM3020980 A Q P9 II  aquaporin 9 3.14E-02 1.52149
3652749 NM; 006043 H838T2 //iheparan sulfate (glucosamine) 3-0-sulfotransferase 2 7.03Ê-03 1.51991
3680223 NM 002761 PR M 1//protam ine 1 2.24E-02 1.59504
: 3680249 NM /021247 PR M 3 II protamine 3 3.86E-02 1.5026
'■ 3715476 NR 002181 P P Y 2 II pancreatic polypeptide 2 7.50E-04 1.51708
3756668 XM,927544 LO G644398II similar to keratin associated protein 3,1 8.44E-04 1,6271
3815006 NM 005317 GZMM II granzym e M (lymphocyte m et-ase 1) 2.89Ê-03 1.54881
3817651 BC090884 // C l9orf30 //chrom osom e 19 open reading frame 30 4.56E-03 1.5287
3866831 NM 019855 CABP5 / / calcium binding protein 5 2.65E-02 1.59926
3867660 NM 006179 NTF5 // heurotrophin 5 (neurotrophin 4/5) 7.08E-03 1.71782
3882387 NM-5130852 PLUNC // palate, lung and nasal epithelium carcinoma associated 2.22E-02 1.56414
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Table 12 continued
Transcript ID f  Gene-ID G ene p-.valuo. Fold
3886994 NM 080753 WFDG10A // WAR four-dIsulfidë core domain 10A 2.08E-02 1:51182
,■ 3904858 NM 021081 GHRH // arowth'hormone.releasing hormone : 2.48E-02 1.56304
3923850 AJ566385//, KRTAP10-77/ keratin associated protein 10-7. 2.13Ë-02 1.93746
3923896 NM 198699 KRTAPl0 -1 2 '//keratin associated protein 10-12 2.94E-03 1.60892
3934573 NM 198688 KRTAPl0-6 //keratin associated protein 10-6, . 1.64E-02 1:54809
; 3944210 NM 014310 RASD2I I RASD familV, m em ber 1. . 1.18E-02 1.98583
• 3960605 NM 004981 KCNJ4 // potassium inwardIv-rectifvlnq ,channel/subfamily J. 8/15E-03 1:59144
. 3963913 BG009388// LOC5541747/hVBOthe1icall!:OG554174: 1.22E-02 1.59612
■ 3977886 NM 174961 SSXSf// synovial sarcom a, X breakpoint 8 ; 7Æ6E-.03 1.7943
, 4007899 NM 003179 SYR // synaptophvsin' 2.65Et03 1.55649
, 4010768 NM 018684 KIAA1166 // KIAA1166.//Xql1J1- . 3.08E-04 1.63738
4016396 NM 0010061 TGEAL8 //transcription elongatlonTaclorA/SliV-like B- u 4,81 E-02 . 1.52951
4046481 XM 930939 LOG6530667/ similar.to Inhibitor of growth.family, member 5 7.75E-03 . 1.60623
4047607 NM 024850 BTNL8 //butyrophilln-like 8 3.54E-Û2 1.89014
4052962 XM 942429 L0C652779 / / similar to Killen.cell lmmunoqlobulln4ike receptor 20 3.30E-02 1.58969
Table 12: Genes Up-regulated Following DNA damage: This table list the genes 
which were significantly (p<0.05) up-regulated (Fold >1.5) following DNA damage. 
Analysis of significant genes was performed using two exon microarray software 
packages; ArrayAssist and KP, and as discussed earlier the data presented here 
represents transcripts which were significantly changed following analysis with both 
software programs.
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3.3.7. Genes Regulated by TopBPl following DNA Damage
The final gene list which was extracted from the microarray data was the genes 
which were either down regulated'or up regulated by DNA Damage in the absence 
of TopBPl. Table 13a shows the genes which are upregulated following DNA 
damage by (>1.5 fold) with a p value of <0.05. Table 13b shows the genes which 
are down regulated following DNA damage, under the same restrictions. Figure 56a 
shows a Venn diagram linking the three datasets A) Genes regulated by TopBPl B) 
Genes regulated by DNA damage and C) Genes regulated by TopBPl following 
DNA damage. The overlap between the gene sets is o f interest; for example there are 
5 genes which appear in both damage sets (TopBPl/siTopBPl) but the expression of 
these five genes changes significantly. This data is shown in Figure 56b. Olfactory 
receptor family6, calcium binding protein 5, calmodulin 2, tigger transposable 
element 2 and tubulin: beta 2A are all upregulated following DNA damage in the 
presence o f TopBPl however in the absence of TopBPl these genes are significantly 
downregulated. Calmodulin and calcium signalling are both associated with estrogen 
receptor signalling in breast cancer (Li et al. 2007) and the possible role of TopBPl 
will be discussed later.
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Tablé 13
a)
Gene-^ lD Gene p value. Fold
■XM' 375007 L0G4OOÛ93 // hypothetical gene supported by AK123815 : 0.013887 2.31487
NML176890. TAS2R50 // taste receptor, typei2, member 50 0.007936 2.12575
NM„181600 KRTAPl 3^ 47/ keratin associated protein 13-4 0.028409 1.74752NM-021992- TMSL8 // thymosin-like. 8: 0.013781 1.71973NMt003654 GHSTt//carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 0.020645 1.61119
NM 017445! H2BFS // H2B histone family, member S 0.004945 1.60915NM? 080817 GPR827/ G protein-coupled receptor 82 0:006616 1.58925NMii 98089 ZNF155':// zinc finger protein 155,(pHZ-96) 0.029217 1.58528NM1178547 ZBTB80S //zinc finger and;BTB domain containing 8 opposite strand 0.025251 1.57371XM* 294521? FLJ4395Û // FU43950 protein 0.032546 1.56334XM 939596' UOC646996//.similar to RAB42', member RAS homolog family 0.044272 1.54958NM_001008397 L0C493869 // similar to RIKEN cDNA 2310016G16 0.047753 1.54602NMM71998 RAB39BV/ RAB39B, member RAS oncogene family 0.043521 1.54206NMi002723 PRB4 //proline-rich protein BstNI subfamily 4 0.016628 1.52426
NM 0^01355 L DDT // D-dopachrome tautomerase 0.01409 1.51348
b)
Gene-ID Gene p value Fold
NM 003552 0R1D4 // olfactory receptor, family 1, subfamily D, member 4 0.006111 -2.75981
XM 943969 KRTAP2-2 // keratin associated protein 2-2 0.01689 -2.32292
XM 929003 LOC646Û437/similar to CG32346-PB, isoform B 0.013304 -2.20422XM/927258 LOC644005 // hypothetical protein LOC644005 0.012403 -2.00166
AK023372 FLJ13310 //.hypothetical protein FLJ13310 0.005105 -1.7843
NMII 76882 TAS2R40 // taste receptor,type 2, member 40 0.025566 -1.77994
NM! 014743 KIAA0232 //'KIAA0232 gene product 0.013125 -1.74686
NM1199286 DPPA3Î//developmental pluripotency associated 3 0.04122 -1.7088
NMI032498 PEPP-2 //’PEPP subfamily.gene 2 0.006436 -1.70539
NM. 002667 PLN //phospholambanr 0.002106 -1.63511
NM 00103938 G8orf777/;ohromosomet8 open reading frame 77 0.000755 -1.6188
NMV;203406' KRTAP26r1 // keratin associated protein 0.042714 -1.60093
AK075204 FLJ907237/ hypothetical protein FU90723 0.020559 -1.57087
NM. 00100166 ;bA9F1c1.17/ hypothetical LOC255349 0.015491 -1.56587
NM 0:14474 SMBDIX3B.// sphingomyelin phosphodiesterase, acid-like 3B 0.003049 -1.55337
Table 13: Genes Regulated by T opB Pl following DNA damage, a) This table 
lists the genes which were significantly (p<0.05) up-regulated (Fold>1.5) by 
TopBPl following DNA damage, b) This table lists the genes which were 
significantly (p<0.05) down-regulated (Fold>1.5) by TopBPl following DNA 
damage.
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F igure 56
a)
Djunisf
Tf4
A
TopBPX
46
61 f
A3
30
b)
Damage (TopBPl) Damage (siTopBPl)
r A Y A .
G e n e  ID G e n e D-value Efild D -value Efild
N M _054104  
N M _019855  
N M _001743  
N m I i 4 5 7 1 9  
NM 0 0 1 0 6 9
0 R 6 C 3  I I  o lfacto ry  re c e p to r , fam ily 6, sub fam ily  0 ,  m e m b e r  3
C A B P 5 I I  ca lc ium  b ind ing  p ro te in  5
CALM 2 I I  ca lm odu lin  2 (p h o s p h o ry la s e  k in a se , d e lta )
T IG D 3 I I  tig g e r  tr a n s p o s a b le  e le m e n t d e r iv ed  3 
TU BB2A  // tubulin , b e ta  2A
0 .0 2 4 1 5
0 .0 2 6 5 3
0 .0 1 0 7 0
0 .0 0 2 9 5
0 .0 1 5 4 2
1 .9 6 5 8 9
1 .5 9 9 2 6
2 .1 2 1 2 6
2 .0 0 8 5 81JHM7
0 .0 0 2 6 5
0 .0 0 8 8 5
0 .0 4 3 6 5
0 .0 3 2 4 4
0 .0 1 6 9 9
-2 .8 4 4 6 0
-1 .8 1 2 9 4
-1 .7 2 2 3 0
-1dS3303
.-1 -5 1 7 3 f i.
Figure 56: Venn Diagram o f Three Gene Expression Data Sets. This diagram 
shows the number o f genes in each data set, A) TopBPl, B) Damage and C) TopBPl 
following Damage. The overlaps between these sets are also shown, a-d. b) This 
table shows the genes which change in TopBPl knockout cells following damage. 
(p<0.05) fold change-<-1.5, >1.5).
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3.3.8. Pathway Analysis
Pathway analysis was performed using DAVID (Database for Annotation, 
Visualization and Integrated* Discovery Edition), a pathway analysis program 
freely available from DAVID Bioinformatics Resources 2007, National Institute of 
Allergy and Infectious Diseases (NIAID), NIH (http://david.abcc.ncifcrf.gov). 
DAVID was first published in 2003 (Dennis et a l  2003) and since then has been 
cited in over 900 scientific publications.
In order to perform the pathway analysis for the genes regulated by TopBPl and the 
genes regulated by DNA damage, significant genes (p <0.05) were uploaded into the 
DAVID functional annotation tool. This tool uses the human genome as a 
background reading (30,000 total background genes). The effect o f the significant 
genes uploaded is then tested against this background to return a significance value 
for pathways effected within this gene list. An example of this pathway analysis is as 
follows; 40 genes are involved in the p53 signalling pathway. The loaded gene list 
contains 300 genes, 3 o f which are involved in the p53 pathway. Therefore the tool 
analyses if 3 genes /300 (Sample) is random compared to 40 genes/30,000 
(Background). This gives a p value o f 0.001, therefore it is not random and the p53 
pathway is significantly altered.
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3.3.8.1. Pathways predicted to be significantly effected by TopBPl
This pathway analysis was performed using the genes which were significantly 
changed (both up-regulated and down-regulated) following siTopBPl treatment. 
Table 14 shows the pathways which were identified as being significantly (p<0.05) 
effected by the TopBPl knock down. As the table shows there are eight pathways 
effected, the percentage of significant genes involved in this pathway is given as 
well as the p-value for each pathway. The possible implication o f TopBPl and 
these pathways will be discussed later (4.3.2.1,), however, there are several 
interesting results considering the roles o f TopBPl discussed earlier in breast cancer, 
replication and transcription. The MAPK kinase pathway is significantly altered; as 
this pathway is affected in a wide range o f cancers including breast cancer (Dhillon 
et a l  2007).
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Table 14
Pathw ay %
G enes
P -va lu e
r Sprouty Regulation of Tyrosine Kinase Signals 0.2 0.0041
2 ' p38MAPK Signaling Pathway 0.3 0.0042
3 Gap Junction 0.8 0.0043
4 Inositol Phosphate Metabolism 0.6 0.0053
5- MAPK Signaling Pathway 1.7 0.0059
6 Cell Cycle 0.9 0.0095
7 Estrogen-responsive Protein Efp controls Cell Cycle and Breast 
Tumour Growth
0.2 0.0096
8 Lysine Degradation 0.5 0.0321
Table 14: Pathways Effected by T opB P l knockdown: This table shows the 
pathways which are significantly changed following the TopBPl knockdown. The 
percentage of genes from the total significant gene population is given. p= Fischer 
Exact, significant pathways were identified as those with a significance value o f 0.05 
or less.
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The following tables in this section list the genes which are changed^ in each of the 
eight identified pathways following the TopBPl knockdown; Table 15 lists the 
genes involved in Sprouty regulation of tyrosine kinase signals (Pathway 1), Table 
16; genes altered in p38 MAPK signaling pathway (Pathway 2), Table 17; genes 
changed within gap junctions (3), Table 18; genes altered in the metabolism of 
Inosito 1 phosphate (4) following TopBPl knockdown. Table 19 lists the genes which 
are effected by the knockdown of TopBPl and that are involved in the MAPK 
signaling pathway (5). Table 20 lists the genes changed within the cell cycle, Table 
21 lists genes involved in estrogen-responsive Efp cell cycle control and breast 
cancer and Table 22 list the genes involved in lysine degradation which are 
significantly altered in siTopBPl treated samples.
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Table 15
Gene P-Value Fold
1 Cas-Br-M (murine) ecotropic retroviral transforming 
sequence 0.01572 1.26455
2 v-Ha-ras Harvey rat sarcoma viral oncogene homolog 0.00572 1.12195
3 mitogen-activated protein kinase kinase 1 0.03719 -1.15154
4 v-raf-1 murine leukemia viral oncogene homolog 1 0.00098 -1.20107
Table 15. Genes changed within the Sprouty Regulation o f Tyrosine Kinase 
Signals Pathway (1). This table lists the genes which were significantly changed in 
the TopBPl knockout samples and that were identified using DAVID as having a 
significant effect on the sprouty regulation o f the tyrosine kinase signaling pathway. 
The p-value and fold change for each gene are also given.
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Table 16
Gene P-Value Fold
, 1 mitogen-activated protein kinase kinase kinase 5 0.00693 -1.21284
2 mitogen-activated protein kinase kinase kinase 7 0.00030 -1.14143
3 ribosomal protein S6 kinase, 90kDa, polypeptide 5 0.00794 -1.36597
4 v-death-associated protein 6 0.04135 -1.18875
5 ' TNF receptor-associated factor 2 0.01145 1.0887
6 v-Ha-ras Harvey rat sarcoma viral oncogene homolog 0.00572 1.12195
7 cAMP responsive element binding protein 1 0.0111 -1.1037
8 potassium voltage-gated channel, subfamily H 0.0140 1.196
9 transforming growth factor, beta receptor I 0.00017 1.47149
Table 16. Genes changed within the p38 M A PK  Signalling Pathway (2). This 
table lists the genes which were significantly changed in the TopBPl knockout 
samples and that were identified using DAVID as having a significant effect on the 
p38 MAPK signaling pathway. The p-value and fold change for each gene are also 
given.
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Gene P-Value Fold
1 . casein kinase 1, delta 0.0300 1.07749
2 casein kinase 1, epsilon 0.03396 1.07469
3 mitogen-activated protein kinase kinase 5 0.03024 -1.16659
4' CDC20 cell division cycle 20 homo log 0.00482 1.28839
■5 cell division cycle 2, G1 to S and G2 to M 0.04257 1.28291
6 protein kinase, cAMP-dependent, catalytic, beta 0.01016 -1.16981
7 tubulin, beta 3 0.00243 -1.09104
8 adenylate cyclase 1 (brain) 0.03813 -1.07511
9 guanylate cyclase 1, soluble, alpha 2 0.02674 1.12141
10 , mitogen-activated protein kinase kinase 1 0.03710 -1.15154
11 mitogen-activated protein kinase kinase 2 0.01768 1.12798
12" v-raf-1 murine leukemia viral oncogene homo log 1 0.00098 -1.20107
13 v-Ha-ras Harvey rat sarcoma viral oncogene homolog 0.00572 1.12195
14 epidermal growth factor (beta-urogastrone) 0.03069 -1.18199
15 glutamate receptor, metabotropic 4 0.01832 -1.17231
16 glutamate receptor, metabotropie 7 0.04483 1.18655
17 phospholipase C, beta 3 (phosphatidylinositol-specific) 0.00948 1.07685
18 phospholipase G, beta 4 0.01501 -1.26094
19 inositol 1,4,5-triphosphate receptor, type 3 0.03460 -1.10961
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Table 17. List o f Genes changed following T opB P l knockout which are 
involved in Gap Junctions (3). This table lists the genes which were significantly 
changed in the TopBPl knockout samples and that were identified using DAVID as 
having a significant effect on GAP junctions. The p-value and fold change for each 
gene are also given.
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Table 18. Inositol Phosphate M etabolism  (4)
Gene P-Value Fold
1 inositol polyphosphate-5-phosphatase, 72 kDa 0.00220 1.17757
2 synaptojanin 2 0.00686 -1.13937
3 multiple inositol polyphosphate histidine phosphatase, 1 0.00034 1.32195
.4 inositol polypbosphate-5-phosphatase, 40kDa 0.00014 1.3776
5 skeletal muscle and kidney enriched inositol phosphatase 0.03232 1.08955
6 inositol polyphosphate-1 -phosphatase 0.01674 -1.27678
7 inositol polyphosphate-4-phosphatase, type I, 107kDa 0.00178 -1.09695
8 ’ inositol(myo)-l(or 4)-monophosphatase 2 0.0337 -1.11766
9’ ’ phosphatidylinositol-4-phosphate 5-kinase, type I, gamma 0.00831 1.11185
10 phospholipase C, beta 3 (phosphatidylinositol-specific) 0.00948 1.07685
11 : phospholipase C, beta 4 0.01501 -1.26094
Table 18. Genes changed following T opB P l knockdown which are involved in 
Inositol Phosphate M etabolism  (4). This table lists the genes which were 
significantly changed in the TopBPl knockout samples and that were identified 
using DAVID as having a significant effect on the metabolism of inositol phosphate. 
The p-value and fold change for each gene are also given.
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Table 19
Gene P-Value Fold
1 dual specificity phosphatase 3 0.00716 1.08341
2 stathmin 1/oncoprotein 18 0.04877 -1.10899
3 microtubule-associated protein tau 0.02882 1.10373
4 casein kinase 1, gamma 2 0.00053 1.11543
.5 cyclih G associated kinase 0.01006 1.08053
6 homeodomain interacting protein kinase 2 (HIPK2) 0.00321 -1.43692
7 eukaryotic elongation factor-2 kinase 0.00757 -1.12691
8 dual-specificity tyrosine-(Y)-phosphoryIation regulated 0.01747 -1.20236
9 mitogen-activated protein kinase kinase kinase 5 0.00693 -1.21284
10 mitogen-activated protein kinase kinase kinase 7 0.00030 -1.14143
11 nuclear factor of kappa light polypeptide gene 0.04655 -1.18042
12 mitogen-activated protein kinase kinase 1 0.03710 -1.15154
13 mitogen-activated protein kinase kinase 2 0.01768 1.12798
14 v-raf-1 murine leukemia viral oncogene homo log 1 0.00098 -1.20107
; 15 protein kinase, cAMP-dependent, catalytic, beta 0.01016 -1.16981
16 protein kinase, X-linked 0.04936 1.12373
17 v-akt murine thymoma viral oncogene homolog 2 0.00352 1.48933
18 RAS p21 protein activator 2 0.00637 -1.17921
19 v-Ha-ras Harvey rat sarcoma viral oncogene homolog 0.00572 1.12195
20 RAS guanyl releasing protein 1 0.00263 -1.48832
21 guanine nucleotide binding protein (G protein) alpha 12 0.02747 1.19497
22 fibroblast growth factor receptor 3 0.00094 1.17852
23 Epidermal growth factor (beta-urogastrone) 0.03069 -1.18199
24 mitogen-activated protein kinase kinase 5 0.03024 -1.16659
25 nemo-like kinase 4.85E-05 -1.20278
26 ribosomal protein 86 kinase, 90kDa, polypeptide 5 0.00794 -1.36597
,27 ELK4, ETS-domain protein (SRF accessory protein 1)
0.00319 -1.16125
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.28 tumor protein. p53 (Li-Fraumeni syndrome) 0.01833 -1.22855
29 growth arrest and DNA-damage-inducible, beta 0.02431 1.23731
30 death-associated protein 6 0.04135 -1.18875
31 TNF receptor-associated factor 2 0.01145 1.0887
32 caspase 9, apoptosis-related cysteine peptidase 0.01201 -1.23739
33 ' transforming growth factor, beta receptor I 0.00017 1.47149
34 transforming growth factor, beta receptor II (70/8 OkDa) 0.03717 -1.20264
35 activin A reeepton, type IB 0.01647 1.14405
36 interleukin 1 receptor, type I 0.00919 -1.40704
, 37 tumor necrosis factor receptor superfamily, member 1A 3.36E-05 -1.27299
38 p21 (CDKN1 A)-activated kinase 2 0.02760 -1.14114
39 arrestin, beta 1 0.01827 -1.1231
40 mitogen-activated protein kinase kinase kinase 3 0.00047 -1.31747
41 mitogen-activated protein kinase 9 / 0.00868 -1.14003
42 v-crk sarcoma virus CTIO oncogene homolog (avian) 0.00151 1.23123
43 jun D proto-oncogene 0.00466 -1.38914
44 v-jun sarcoma virus 17 oncogene homolog (avian) 0.01776 -1.18901
45 nuclear factor of activated T-cells 0.00153 -1.22522
46 protein phosphatase 3 (formerly 2B), catalytic subunit 0.01061 -1.19879
47- Filamin A, alpha (actin binding protein 280) 0.01102 -1.18805
48 v-rayc myelocytomatosis viral oncogene homolog (avian) 0.04363 -1.29962
Table 19. Genes changed following T opB P l knockdown which are involved in 
the M A PK  Signaling Pathway (5). This table lists the genes which were 
significantly changed in the TopBPl knockout samples and that were identified 
using DAVID as having a significant effect on the MAPK signaling pathway. The p- 
value and fold change for each gene are also given.
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Table 20
Gene P-Value Fold
1 origin recognition complex, subunit 6 like (yeast) 0.00534 1.25617
2 origin recognition complex, subunit 5-like (yeast) 0.00408 -1.23075
.3 MCM7 miniclii'omosome maintenance deficient 7 0.03190 1.11717
4 MCM6 minichromosome maintenance deficient 6 0.03255 -1.1038
5 Cell division cycle 2, G1 to S and G2 to M 0.04257 1.28291
6 v-abl Abelson murine leukemia viral oncogene homolog 1 0.03137 -1.09566
7 Polo-like kinase 1 (Drosophila) 0.023051 1.17961
8 E2F transcription factor 2 0.00011 -1.20265
9 E2F transcription factor 5, pi 30-binding 0.01953 1.30047
10 E2F transcription factor 6 0.03082 1.18788
11 histone deacetylase 1 0.00326 -1.19688
12 histone deacetylase 3 2.33E-05 1.61364
13 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 0.00605 -1.2345
14 S-phase kinase-associated protein 2 (p45) 0.00182 -1.43619
15 WEEl homolog (S. pombe) 0.01503 1.20016
16 Extra spindle poles like 1 (S. cerevisiae) 0.04431 1.19417
17 Growth arrest and DNA-damage-inducible, beta 0.02431 1.23731
18 tumor protein p53 (Li-Fraumeni syndrome) 0.01835 -1.22855
19 cyclin-dependent kinase inliibitor 1C (p57, Kip2) 0.04289 1.16848
20 cyclin-dependeiit kinase inhibitor 2C (p i8, inliibits CDK4) 0.04656 -1.12777
21 cyclin-dependent kinase inhibitor 2D(pl9,inhibits CDK4) 0.00290 1.17143
22 CDC20 cell division cycle 20 homolog (S. cerevisiae) 0.00482 1.28839
23 cyclin-dependent kinase 2 0.00834 1.11116
24 cyclin-dependent kinase 6 0.01274 -1.27104
25 cyclin D1 0.01029 1.06348
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Table 20 Genes Involved in the Cell Cycle w hich are altered by the knock down 
o f T opB Pl (6). This table lists the genes which were significantly changed in the 
TopBPl knockout samples and that were identified using DAVID as having a 
significant effect on the cell cycle. The p-value and fold change for each gene are 
also given.
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Table 21
Gene P-Value Fold
1 stratifin 0.00021 -1.0095
2 tripartite motif-containing 25 0.01092 1.1249
3 tumor protein p53 (Li-Fraumeni syndrome) 0.01835 -1.2285
Table 21 Genes whose expression is changed following siTopBPl that play a 
role in the estrogen-responsive protein and its control of the cell cycle and 
breast tnmour growth. (7). This table lists the genes whose expression is 
significantly changed in the pathway indicated within the TopBPl knockout. The p- 
value and fold change for each gene are also given.
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Table 22
Gene P-Value Fold
1 . aldehyde dehydrogenase 9 family, member A1 3.65E-06 -1.43023
2 nuclear receptor binding SET domain protein 1 0.03532 -1.18843
3 suppressor of variegation 3-9 homolog 1 (Drosophila) 0.04409 1.20376
4 SET domain containing (lysine methyltransferase) 7 0.00021 -1.53705
5 procollageii-lysine 1, 2-oxoglutarate 5-dioxygenase 1 0.01179 -1.30573
6 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 0.04975 -1.16235
;V proGollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 0.00162 -1.14653
8 , enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme 0.04687 -1.21743
9 glutaryl-Coenzyme A dehydrogenase / 0.00203 1.12358
lo­ ARDl homolog A, N-acetyltransferase (S. cerevisiae) 0.03030 1.13767
ll retinol dehydrogenase 11 (aIl-trans/9-cis/l 1-cis) 4.39E-05 1.23329
12 serine hydroxymethyltransferase 1 (soluble) 0.01059 -1.24662
13 pipecolic acid oxidase 0.04554 1.12762
14 dihydrolipoamide S-succinyltransferase 0.02315 1.14835
Table 22. Genes Involved in the Degradation of Lysine which are altered by the 
knock down of TopBPl (8). This table lists the genes which were significantly 
changed'in the TopBPl knockout samples and that were identified using DAVID as 
having a significant effect on the degradation of lysine. The p-value and fold change 
for each gene are also given.
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3.3 8.2. Pathways Predicted to be Significantly Effected by DNA 
damage
Similar to the results described in the previous section in which pathway analysis 
was performed to predict pathways which might be effected by TopBPl using the 
data obtained from the microarray (Chapter 3.3.8.1.), this chapter describes the 
pathways which are predicted to be effected by DNA damage. This pathway analysis 
was performed as described previously using only those genes which were 
significantly (p<0.05) changed (either up-regulated or down-regulated) following 
gamma irradiation. Table 23 shows the pathways which are predicted (using 
DAVID) to be significantly (p<0.05) altered following DNA damage. Five pathways 
were identified; I) Oxidative Stress Induced Gene Expression, 2) FAS Signalling 
Pathway, 3) The Proteosome, 4) Inositol Phosphate Metabolism and 5) Apoptosis. 
Although these pathways and the genes with altered expression will be discussed in 
Chapter 4.3.3., it is of interest that pathways associated with DNA damage and cell 
death were identified using this method of analysis. Tables 24-28 list the genes 
which were effected in each pathway, their fold change and significance (p-value).
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P a th w a y % G en es P -v a lu e
1 Oxidative Stress Induced Gene Expression via Nrf2 0.2 0.0021
2 FAS Signalling Pathway 0.3 0.0023
3 Proteosome 0.4 0.0039
4 Inositol Phosphate Metabolism 0.5 0.0044
5 Apoptosis 0.5 0.0483
Table 23: Pathways Effected by DNA Damage: This table shows the pathways 
which are significantly changed following DNA Damage. The percentage of genes 
from the total significant gene population is given. p= Fischer Exact, significant 
pathways were identified as those with a significance value of 0.05 or less.
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Table 24
Gene Fold p-value
1 crystallin, zeta (qiiinone reductase) -1.21427 0.00836
2 mitogen-activated protein kinase 14 -1.10558 0.01445
■3 v-maf musculoaponeurotic fibrosarcoma oncogene homolog K -1.05368 0.02529
4 cAMP responsive element binding protein 1 -1.10425 0.00042
5 kelch-like ECH-associated protein 1 -1.02067 0.04666
Table 24: Genes Involved in Oxidative Stress Induced Gene Expression ivhicli 
are altered following DNA Dam age (1). This table lists the genes which expression 
was significantly changed following DNA damage and that were identified using 
DAVID as having a significant effect on the oxidative stress pathways. The fold 
change for each gene and their significance is also given.
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Table 25
Gene Fold p-valiie
1 p21 (CDKN lA)-activated kinase 2 -1.10004 0.04883
2 mitogen-activated protein kinase kinase kinase 7 -1.09507 0.00078
3 adenomatosis polyposis coli -1.29148 0.00198
'4 CASP8 and FADD-like apoptosis regulator 1.00604 0.04625
5 receptor-interacting serine-thieonine kinase 2 -1.14571 0.00203
Table 25: Genes Involved in FAS Signalling Pathway which are altered 
following DNA Dam age (2). This table lists the genes which expression was 
significantly changed following DNA damage and that were identified using 
DAVID as having a significant effect on. the FAS signalling pathway. The fold 
change for each gene and their significance is also given.
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Table 26
Gene Fold p-value
1 proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 -1.11386 0.0304
.2 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 -1.0348 0.04513
3 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 -1.04948 0.01147
4 proteasome (prosome, macropain) 26S subunit, ATPase, 2 -1.04648 0.04666
5 proteasome (prosome, macropain) subunit, alpha type, 4 -1.05013 0.01599
6 proteasome (prosome, macropain) subunit, alpha type, 7 1.00605 0.03692
7 proteasome (prosome, macropain) subunit, alpha type, 5 -1.10178 0.00341
8 proteasome (prosome, macropain) subunit, alpha type, 3 -1.05101 0.03508
9 proteasome (prosome, macropain) subunit, beta type, 2 -1.08852 0.02477
10 proteasome (prosome, macropain) subunit, beta type, 4 -1.06895 0.00716
11 proteasome (prosome, macropain) subunit, beta type, 1 -1.07999 0.00327
Table 26. Genes Involved within the Proteosom e and whose Gene Expression is 
altered following DNA Dam age (3) This table lists the genes whose expression was 
significantly changed following DNA damage and that were identified using 
DAVID as having a significant effect on the degradation of lysine. The p-value and 
fold change for each gene are also given.
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Table 27
Gene Fold p-value
1 . multiple inositol polyphosphate histidine phosphatase, 1 -1.07247 0.01330
2 inositol polyphosphate-4-phosphatase, type I, 107kDa -1.03574 0.02142
3 Inositol (myo)-l(or 4)-monophosphatase 2 -1.01325 0.03994
4 ' Myo-inositol oxygenase 1.16080 0.03455
5 Meisl, myeloid ecotropic viral integration site 1 -1.06155 0.02704
6 phosphatidylinositol-4-phosphate 5-kinase, type I, gamma 1.03439 0.04006
7 phosphatidylinositol-4-phosphate 5-kinase, type I, beta -1.0819 0.01126
8 phospholipase C, beta 2 1.08451 0.04566
9 casein kinase 1, gamma 2 -1.03717 0.00205
10 casein kinase 1, gamma 3 -1.17524 0.03914
11 eukaryotic translation initiation factor 2-alpha kinase -1.14254 0.02699
12 phosphoinositide-3-kinase, catalytic, delta polypeptide 1.06016 0.03838
Table: 27: Genes changed following DNA Dam age which are involved in Inositol 
Phosphate M etabolism  (4). This table lists the genes which were significantly 
changed following DNA damage and that were identified using DAVID as having a 
significant effect on the metabolism of inositol phosphate. The p-value and fold 
change for each gene are also given.
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Table 28
Gene Fold p-value
1 protein phosphatase 3 (formerly 2B), catalytic subunit -1.17010 0.00269
2 protein phosphatase 3 (formerly 2B), regulatory subunit 1.24094 0.02765
3 v-rel reliculoendotheliosis viral oncogene homolog A, -1.02087* 0.01646
4 protein kinase, cAMP-dependent, regulatory, type II, -1.03442 0.04557
5 protein kinase, cAMP-dependent, regulatoiy, type II beta -1.13236 0.02263
6 protein kinase, cAMP-dependent, catalytic, beta -1.12834 0.03045
7 caspase 8, apoptosis-related cysteine peptidase -1.03997 0.04801
8 caspase 10, apoptosis-related cysteine peptidase 1.07863 0.00027
9 calpain 6 1.05458 0.00181
10 CASP8 and FADD-like apoptosis regulator 1.00604 0.04625
11 phosphoinositide-3-kinase, catalytic, delta polypeptide 1.06016 0.03838
12 phosphoinositide-3-kinase, regulatory subunit 2 1.09384 0.00788
. 13 TNF receptor-associated factor 2 1.06691 0.04653
14 receptor (TNFRSF)-interacting serine-threonine kinase 1 -1.13047 0.00670
15 tumor necrosis factor receptor super family, member 10c 1.13687 0.01284
16 tumor necrosis factor (TNF superfamily, member 2) 1.14243 0.02448
Table 28: Apoptosis genes that are altered following DNA Dam age (5). This 
table lists the genes which were significantly changed following DNA damage and 
that were identified using DAVID as having a significant effect apoptosis. The p- 
value and fold change for each gene are also given.
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3.3.S.3. Pathways Predicted to be significantly Effected by DNA 
damage following TopBPl knockout
Following the analysis of the pathways altered following DNA damage in the 
presence of TopBPl, pathway analysis was performed to predict the pathways 
effected by DNA damage in the TopBPl knockout samples. This pathway analysis 
was performed as described previously (3.3.8.) using only those genes which were 
significantly (p<0.05) changed (either up-regulated or down-regulated) following 
gamma irradiation. Table 29 shows the pathways which are predicted (using 
DAVID) to be significantly (p<0.05) altered following DNA damage in the absence 
of TopBPl. Seven pathways were identified; I) Androgen and Estrogen Metabolism, 
2) Biosynthesis of Steroids, 3) Aspirin Blocks Signalling involved in Platelet 
Activation, 4) Regulation o f Splicing Through Sam68, 5) Links between Pyk2 and 
Map Kinases, 6) Roles of P-arrestin Dependent recruitment o f Src Kinase and 7) 
Sprouty Regulation of Tyrosine Kinase Signals. The percentage of genes involved in 
each pathway and the p value according to the DAVID analysis is also shown. 
Tables 30 and 31 list the genes which are altered in the Androgen and Estrogen 
Metabolism, and the Biosynthesis o f Steroids pathways respectively. The genes 
altered in remaining pathways overlap considerably; therefore the genes altered in 
these pathways are shown as a combined table (Table 32).
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Table 29
P a th w a y % G en es P -v a lu e
1 Androgen and Estrogen Metabolism 0.8 0.0023
2 Biosynthesis o f Steroids 0.4 0.0493
3 Aspirin Blocks Signalling involved in Platelet Activation 0.4 0.0077
4 Regulation of Splicing Through Sam68 0.3 0.0024
5 Links between Pyk2 and Map Kinases 0.5 0.0021
6 Roles of p-arrestin Dependent recruitment o f Src Kinase 0.4 0.0078
7 Sprouty Regulation of Tyrosine Kinase Signals 0.4 0.0028
Table 29: Pathways Effected by T opB Pl following DNA Damage: This table 
shows the pathways which are significantly changed following DNA Damage in the 
absence of TopBPl. The percentage o f genes from the total significant gene 
population is given. p= Fischer Exact, significant pathways were identified as those 
with a significance value of 0.05 or less.
241
Chapter 3-Resiilts
Table 30
Gene P value Fold
1 Williams Beuren syndrome chromosome region 22
0.04415 1.14487
2 HemK methyltransferase family member 2
0.04494 1.30164
3 protein arginine methylti’ansferase 2
0.04116 1.13067
4 protein arginine methyltransferase 1
0.01564 1.23129
’ 5 protein arginine methyltransferase 7
0.02042 1.15939
6 3-hydroxybutyrate dehydrogenase, type 1
0.03972 1.20702
7 arylsulfatase E (chondrodysplasia punctata 1 )
0.01823 -1.25241
8 Beta-carotene dioxygenase 2
0.04542 -1.13379
Table 30: Genes involved in Androgen and Estrogen M etabolism  that are 
altered following DNA Dam age in T opB P l knockouts (1). This table lists the 
genes which were significantly changed following DNA damage and that were 
identified using DAVID as having a significant effect apoptosis. The p-value and 
fold change for each gene are also given.
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Table 31
Gene P value Fold
I farnesyl diphosphate synthase 0.02272 -1.3128
2 mevalonate kinase (mevalonic aciduria)
0.04403 1.1097
3 sterol-C5-desaturase (ERG3 delta^-S-desaturase homolog
0.01703 1.3112
4 cytochrome P450
0.02823 -1.3258
Table 31: Genes involved in the Biosynthesis o f Steroids that are altered  
following DNA Dam age in T opB P l knockouts (2). This table lists the genes which 
were significantly changed following DNA damage and that were identified using 
DAVID as having a significant effect apoptosis. The p-value and fold change for 
each gene are also given.
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Table 32
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3.3i9. Summary chapter 3.3.
The data presented here has shown that contrary to previously published data (Jeon et 
a l  2007) TopBPl is not essential for cell growth and replication in all cultured cell 
lines. Figure 48 showed that the primary cell line MRC5 and the immortalised HeLa 
cell: line cannot continue to grow when TopBPl is knocked down using siRNA, and 
this is specifically due to the reduction in TopBPl expression because the control 
lueiferase siRNA did not adversely effect cell growth in these cells. This is not 
however true of all cell lines tested, as Figure 49 shows 293T, MCF7, and U 20S cell 
lines can survive when TopBPl is knocked down as the growth of these cells shows 
no significant deviation from control cells, over a four day period. TopBPl is 
however essential for continued cell growth over longer time periods, as Figure 52 
showed; MCF7 cells in which TopBPl was knocked down could not survive over a 
14'day period. As TopBPl is essential for the DNA damage response and replication, 
it is possible that cells lacking TopBPl would be significantly more effected by DNA 
damage than controls, resulting in lower colony survival numbers in damaged cells.
Following these results, MCF7 cells were chosen for the study o f the genes regulated 
by TopBPl because in addition to TopBPl having no immediate effect on cell 
growth, this cell line is also a breast carcinoma cell line and therefore provides a 
model for studying TopBPl in breast cancer. TopBPl was knockdown in these cells 
and an exon microarray was carried out. Chapter 3.3.3. described the experimental
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plan and controls; the knockdown of TopBPl was efficient (Figure 54a) and had no 
effect on the cell cycle profile when compared to the si lueiferase controls (Figure 51). 
The data analysis performed using ArrayAssist software proved that the labeling 
process and hybridisation o f all 12 arrays was of a high standard (Figure 55) and that 
all sample repeats could be used in further analyses. The microarray data revealed 64 
genes which were significantly (p<0.05) down-regulated with a fold effect of <-1.5 
and 65 genes which were up-regulated by TopBPl resulting in a fold effect of >1.5 
(Table 9 and 10 respectively). Chapter 3.3.6. described the genes regulated by DNA 
damage and Chapter 3.3.7., further investigated these two data sets to provide a list of 
genes which are specifically regulated by TopBPl following DNA damage. Pathway 
analysis was performed using DAVID (as described (3.8.3.), this analysis revealed 
several pathways which are predicted by this software to be significantly effected by 
the knockdown of TopBPl (Table 14) and significantly changed following DNA 
damage in the presence and absence of TopBPl (Tables 23 and 29 respectively). 
These pathways and the possible role o f TopBPl will be discussed in more detail 
later; however these pathways might provide an insight into previously unknown 
functions of TopBPl.
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Chapter 4- Discussion
As discussed in Chapter 1.6 TopBPl is involved in transcription, replication and 
repair. The modification of chromatin is essential in mediating all these functions of 
TopBPl; the results presented here have identified three transcriptional regulatory 
domains within TopBPl which may mediate these functions via the modification of 
chromatin.
4.1 TopBPl Contains Transcriptional Modification Domains
Chapter 3.1 described the identification o f a transcriptional activation domain partly 
encompassing BRCT4 (Figure 9) which is repressed by two adjacent repression 
domains within BRCT5 (Figure 24) and BRCT2 (Figure 10). This discussion chapter 
will focus on the significance o f these domains in transcription and discuss the
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possible regulation of these domains by sumoylation, phosphorylation, and 
ubiquitination during transcription. Initiation and elongation of transcription occurs 
through a complex set of DNA-protein and protein-protein interactions, involving 
RNA polymerase II, transcription adaptors and regulators. These regulatory 
transcription factors bind DNA, or are recruited to DNA via protein-protein 
interactions, and act as transcriptional activators and repressors depending upon the 
specific complex. TopBPl is a possible transcription factor, as it has been shown to 
interact with both single stranded and double stranded DNA (Yaniane et al. 1999) 
RNA polymerase II (Yu et al. 2003). TopBPl co-activates transcription of the 
HPV16 transcription/replication protein E2 (Boner et al. 2002) and represses 
transcription of myc target genes via M izl (Herold et al. 2002). The data presented 
here has identified three transcriptional regulatoiy domains within TopBPl; an 
activation domain and two repression domains (Chapter 3.1) further supporting the 
role o f TopBPl as a potential transcription factor.
4.1.1 Transcriptional Activation Domains
Transcriptional activation domains are classified into three distinct groups depending 
upon their amino acids content; 1) rich in acidic amino acids, 2) glutamine (acidic) 
rich or 3) proline rich. As Figure 11 shows the aetivation domain identified in 
TopBPl (amino acids 460-500 (Figure 10)) is characteristic of an acidic activation 
domain, interspersed with hydrophobic amino acids, similar to the activation domain 
of VP 16 (Drysdale et al. 1995) and BRCAl (Flayes et a l 2000).
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To investigate the transcriptional activation domain further, the specific amino acids 
essential for TopBPl transcriptional activity could be investigated. Although TopBPl 
is an acidic activation domain it is unlikely that the acidic residues are the residues 
essential for activation. Studies of the VP 16 activation domain identified that 
mutations which removed the acidic amino acids still retained transcriptional 
activation (Cress and Triezenbery 1991) but mutation of the hydrophobic residues (V, 
L, M, F and L) are more important for activation function (mutation of the 
phenylalanine within VP 16 abolished transcriptional activation (Drysdale et al. 
1995)). These hydrophobic residues within the TopBPl activation domain are 
conserved between species (Figure 11). Therefore mutation of both the acidic 
(aspartic acid (D) and glutamic acid (E)) and hydrophobic residues (phenylalanine (F) 
valine (V) and leucine (L)) within the TopBPl activation domain might reveal the 
residues essential for function. The possible significance of the hydrophobic residues 
within the TopBPl activation domain is also suggested by previous studies of the 
BRCAl activation domain. Mutation o f hydrophobic residues L1780P and V1833E 
within the activation domain resulted in a loss of BRCT structure and transcriptional 
activation (Hayes et a l  2000).
The different classes of activation domains differ in their mechanism o f activation. 
Glutamine and proline rich activation domains only activate transcription from 
positions close to the TATA box (proximal) in contrast to acidic activation domains 
such as GAL4 and VP 16 which have the ability to activate transcription from both 
proximal and remote regions (Seipel et a l  1992). Chromatin immunoprécipitation 
experiments could be used to determine if  the TopBPl activation domain can activate
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transcription from both proximal and remote sequences as would be expected due to 
the amino acid content of the domain.
Recent research has shown that TopBPl may be involved in the development of 
breast cancer. Karppinen and colleagues screened polymorphisms within TopBPl to 
ascertain if similarly to BRCAl, TopBPl is a breast cancer predisposing gene. They 
identified a novel variant Arg309Cys which was found at a higher frequency in 
familial breast cancer patients compared to healthy controls (Karppinen et a l  2006). 
TopBPl is also aberrantly expressed in breast cancer (Going et a l  2007); in normal 
breast tissue the staining of TopBPl was nuclear however in breast cancer the 
staining was cytoplasmic in 15% and absent in 3% of cases. This cytoplasmic 
staining is similar to that obseiwed for BRCA l, which is often cytoplasmic in breast 
cancer (Yoshihawa et a l 1999). Karihtala et a l  2006 also showed that there was an 
increase in TopBPl expression levels in breast cancer which correlated with cancer 
progression.
BRCAl mutation studies have demonstrated the link between transcriptional activity 
and breast cancer; mutations within the transcriptional activation domain are often 
associated with disease-predisposing mutations which abolish transactivation by 
BRCAl. Figure 57 shows a sequence alignment o f BRCAl (amino acids 1550-1863) 
and TopBPl (amino acids 460-500) activation domains. Several o f the disease- 
associating mutations in BRCAl, which lie within the transcriptional activation 
domain and that result in a loss of transcriptional activity are highlighted (dash 
boxes). One such mutation; V1668del in BRCA l, introduces a stop codon suggesting
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that the sequence following this residue, which encompasses the transcriptional 
activation domain o f BRCAl is important for the function. This residue and the area 
surrounding it is conserved in TopBPl and similarly to BRCAl the alteration of this 
residue resulting in the insertion o f a stop codon would result in a TopBPl lacking 
transcriptional activation domain (red dash box).
Although similar studies have been performed with TopBPl, which identified 
TopBPl as a possible breast cancer susceptibility gene (Karppinen et al. 2006), this 
study used 125 familial breast cancer cancers and compared the results to patients 
with a non-hereditary breast cancer. It would be interesting to study the non-familial 
group and sequence TopBPl from the both the lesion and normal tissue from the 
same patient. Figures 27 and 28 demonstrated that the activation domain and the 
repression domain within BRCT2 are conserved in yeast, similar to the activation 
domain within BRCAl (Monterio et a l  1996, Hu et a l  2000). This provides a useful 
genetic tool to identify the residues within each domain essential for transcriptional 
regulation. Hu and collègues found that the residues within the predicted coil-coil 
m otif of BRCAl were essential for transcriptional activation. Although the structure 
of TopBPl has not yet determined, motifs of this nature could be predicted using 
PARACOIL program (Berger et a l  1995, http : dot. imgen.bcm.tmc.edu: 993 31 seq- 
search/struc-predict.html), the residues within this region could then be mutated and 
their transcriptional activity tested in both yeast and mammalian systems, using 
similar experiments to those described previously.
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Figure 57
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Figure 57: Disease Predisposing Mutations within BRCAl Activation Domain.
This diagram shows a sequence alignment of TopBPl (amino acids 460-500) and 
BRCAl (amino acids 1550-1863) transcriptional activation domains. Dashed boxes 
indicate the cancer pre-disposing residues within BRCAl, of interest is BRCAl 
V 1668 (Red dashed). A possible serine phosphoiylation target is indicated by green 
box and an adjacent conserved proline is indicated by a red box. * indicates residues 
which are conserved between the two activation domains. • indicates hydrophobic 
residues conserved residues and : indicates a position where the charge o f the residue 
is conserved.
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4.1.2. Regulation of TopBPl Activation and Repression Domains
Figure 15 suggested the repression domain within BRCT2 repressed the activation 
domain via the recruitment o f a repressor complex and not via an intramolecular 
interaction, as BRCT2 was able to repress the transcriptional activity of VP 16. 
However to be certain this would need to be confirmed with further experiments as 
the repression of the activation domain might still be via an intramolecular interaction 
because of the domain similarity between TopBPl and VP 16. Both domains consist 
of acidic activation domains with pockets of hydrophobic residues. It is possible that 
BRCT2 specifically binds to domains of this type. To confirm the recruitment of a 
repressor complex as the method of repression additional (BRCT2 repressor)- 
(activation domain X) fusion proteins using different types of activation domain 
(glutamine, proline rich) would need to be constructed and tested in similar 
luciferase assays. Nuclear versions of BRCT2 could also be over-expressed to 
determine if it can inhibit the transcriptional activation domain when placed in trans.
One possible method of TopBPl transcriptional repression might be via the 
recruitment of HDAC (histone deacetyltransferase). HDAC complexes are important 
in the regulation of gene expression. HDAC enzymes deacetylate histone H3 and H4, 
which results in a tighter chromatin state and the repression o f transcription. HDAC 
directly interact with several transcription factors including p53, E2F and NFkB 
(Mayo et al. 2003). As Figure 16 showed the treatment o f cells with the HDAC
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inhibitor (TSA) did not alleviate repression of the activation domain by BRCT2, 
therefore repression o f the activation domain is not via histone deacetylation.
A second method of transcriptional regulation tested in this thesis was the 
involvement of the HAT in transcriptional activation. The acétylation of the core 
histones results in a more “open” state providing access for DNA damage repair 
proteins, and transcriptional machinery. Figure 18 shows the BRCT2 repressor and 
the activation domain show no intrinsic HAT activity in the HAT activity assay tested 
however to confirm this result the HAT inhibitor garcinol, a polyisoprenylated 
benzophenone isolated from Garcinia indica could be used in the luciferase assays 
(Balasubramanyam et a l  2004).
However there are many post translation modifications of proteins such as 
phosphoiylation, ubiquitination, sumoylation and méthylation which play an essential 
role in the regulation of their target protein. The possible role of these modifications 
in the context of TopBPl transcriptional activity will be discussed further in this 
chapter.
4.1.2.1 TopBPl and Ubiquitination
One possible method of TopBPl regulation could be ubiquitination. Ubiquitin (Ub) is 
a small 76 amino acid protein which is tagged to target proteins to signal them for 
degradation by the 26S proteosome. Ubiquitination involves three enzymes, E l, E2 
and E3. Ub is activated by the ubiquitin activating enzyme E l (a reaction requiring
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ATP) (Figure 58). The Ub is then transferred to the Ub-conjugating enzyme E2 which 
transfers the Ub to the target protein via the Ub-ligase E3 (Varshavsky et al. 1997). 
There are two groups of human Ub ligases; 1) the HECT domain Ub-ligase enzymes 
and 2) the RING finger Ub-ligase E3 enzymes. The HECT-domain E3 ligases directly 
interact with Ub and transfer the Ub directly to the substrate, conversely the RING 
finger E3 ligases form complexes with the E2 conjugating enzyme and Ub, which 
then as a complex transfers Ub to the target protein (Figure 58).
TopBPl specifically interacts with the FIECT E3 ligase, hHYD {hyperplastic discs in 
Drosophila melanogaster) via amino acids 574 to 993 incorporating the BRCT5 
transcriptional repression domain and BRCT6 (Honda et al. 2002). This is a specific 
interaction with hHYD and not a general interaction with HECT domain ligases; as 
NEDD4, another member of the HECT domain E3 ligases does not 
immunoprecipitate with TopBPl. Honda and colleagues also showed that TopBPl 
was ubiquitinated and degraded by the proteosome, under “normal” conditions, 
however following gamma irradiation ubiquitination of TopBPl was reduced, 
implying that the regulation o f TopBPl by ubiquitination is essential for TopBPl 
response to DNA damage. hHYD activates Chk2 following DNA damage
(Henderson et al. 2006) and has shown abnormal expression im breast cancers; both a 
decrease (Fuja et al. 2004) and an increase in expression (Clancy et al. 2003) when 
comparing invasive breast cancers and normal breast tissue.
Many transcription factors are unstable and are constantly destroyed by ubiquitin- 
mediated proteolysis (Thomas et al. 2000) mediated by ubiquitination, as described
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TopBPl is also continually degraded by hHYD until required following DNA 
damage. Mutational analysis of transcriptional activation domains has revealed a 
close correlation between transcriptional activation and proteolysis. Salghetti et a l 
2000 showed that three transcriptional activation domains also acted as degrons, 
destabilising the LexA Protein in S cerevisiae, therefore linking transcriptional 
activation and ubiquitination. They suggested that Ub “licences” transcription factors 
by linking their activity to their destruction; E3 ligases interact with the 
transcriptional activator and simultaneously activate the transcription factor and target 
it for degradation. The phosphoiylation of the target protein is one mechanism which 
reduces the ability o f Ub ligases to ubiquitinated their target protein. TopBPl is 
phosphoiylated following DNA damage, preventing ubiquitination and therefore 
TopBPl degradation following DNA damage.
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Figure 58: Ubiquitination T opB Pl by HHYD is essential for T opB P l regulation 
under normal conditions. This diagram shows the method o f TopBPl 
ubiquitination via the HECT-domain containing E3 ligase hHYD.
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4.1.2.2 Transcriptional Regulation by Sumoylation
It is possible that TopBPl activity might be regulated by sumoylation. SUMO (small 
ubiquitin related modifier) is an llk D a  ubiquitin like protein, but unlike 
ubiquitination sumoylation does not lead to the degradation o f the target protein. 
Sumolyation does however regulate a wide variety o f cellular control processes; 
protein-protein interactions, nuclear localisation, and protein-DNA interactions (For 
review see Verger et al. 2003). In addition sumolyation has been shown to have both 
positive and negative effects on the activity of transcription factors; increasing the 
transcriptional activity of p53 but repressing the activity of c-Jun, and p300. 
Therefore SUMO may be involved in TopBPl transcriptional activation and 
repression (Review Girdwood et a l 2003).
SUMO is added to proteins in a similar way to the Ub pathway (Figure 61); it is 
activated in an ATP dependent manner by an E l enzyme (Uba2), and transferred to 
an E2 conjugating enzyme (Ubc9). However the two E3 ligase enzymes differ in the 
SUMO pathway from those used in the Ub pathway; the first is similar to the RING 
E3 ligase from the Ub pathway (PIAS, Schmidt et a l  2003), the second E3 ligase 
(RanBP2) is a component of the nuclear pore complex. Although SUMO can be 
transferred to the target protein without the cooperation o f an E3 ligase (Muller et al 
2001) the efficacy is greatly enhanced in the presence o f the E3 ligases, although the 
mechanism of action is still unknown.
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SUMO binds to a specific SUMO recognition sequence on the target protein, binding 
to a specific lysine residue within the target (Melchior et a l  2000). CBP/p300 
contains a transcriptional repression domain and this repressor domain contains a 
SUMO binding motif. The mutation of the lysine residue within this domain removed 
all repression suggesting that sumolyation has an essential role to play in 
transcriptional repression.
Sequence analysis o f the TopBPl transcriptional activation and repression domains 
(using SUMOplot™) identified two possible SUMO sites; one within the BRCT2 
repression domain (K137) (Figure 59a) and one site within the transcriptional 
activation domain (K469), (Figure 59b). It is possible that these domains are 
regulated by sumolyation and there are several ways in which SUMO might do this; 
1) by causing a conformational change in the TopBPl, resulting in alleviation of 
BRCT4 repression by BRCT2, 2) by changing the surface charge o f TopBPl which 
might physically mask BRCT2 binding site on BRCT4 or visa versa or 3) by 
changing the activation and repression domain binding partners, resulting in the 
recruitment of a repressor/activator complex. Sumoylation also functions to repress 
transcription by blocking acétylation and by competing for Ub target sites; for 
example IkB o is sumoylated and ubiquitinated at the same lysine therefore 
sumolyation stabilises the protein by inhibiting Ub and therefore inhibits the activity 
of the transcription factor N F -kB. As TopBPl is ubiquitinated by liHYD and then 
degraded, it might be possible that SUMO would stabilise TopBPl, preventing 
ubiquitination. This might be of particular importance following DNA damage 
(Discussed Chapter 4.2.).
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Future work could focus on these potential SUMO sites and investigate if indeed they 
are SUMO targets, by co-immunoprecipitation using SUMO antibodies. Does 
mutation of the predicted critical lysine residue (according to prediction Figure 62) 
within these SUMO motifs result in a loss of transcriptional repress ion/activation? Is 
TopBPl stabilised by sumolyation following DNA damage?
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Figure 59: Possible pliospliorylatioii sites and Sumolyation sites within the 
T opB P l activation and repression dom ains, a) Predicted serine (S), threonine (T) 
and tyrosine (Y) phosphorylation sites and sumolyation sites within the BRCT2 
repression domain amino acids 113-181. The number of each amino acid predicted to 
be phosphoiylated is also indicated, b) Predicted serine (S), threonine (T) and 
tyrosine (Y) phosphoiylation and sumolyation sites within the transcriptional 
activation domain amino acids 460 -500. The number of each amino acid predicted to 
be phosphoiylated is also indicated, c) Predicted serine (S), threonine (T) and tyrosine 
(Y) phosphorylation sites and sumolyation sites within the BRCT5 repression domain 
amino acids 586-606. The number o f each amino acid predicted to be phosphoiylated 
is also indicated. These predictions were carried out using NetPhos 2.0 
phosphorylation prediction tool (Centre for Biological sequence analysis (CBS), 
University o f Denmark). This software predicted the likelihood of phosphorylation of 
serine, tyrosine and threonine residues within TopBPl and returned a predicted score 
result. A higher score result indicates a more significant result, and the cut off for this 
analysis was taken as 0.75, residues with a score higher than 0.75 indicates a very 
likely phosphorylation site.
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4.1.2.3. Transcriptional Regulation by Phosphorylation
The regulation o f the domains identified in Chapter 3.1 may be facilitated by 
phosphorylation. As described previously the interaction of transcription factors with 
the basal transcription machinery and other transcription factors can be regulated by 
phosphorylation. There is evidence to support the regulation o f both transcriptional 
activators and repressors by phosphorylation. CREB (CRE response element binding 
protein) is an example of a transcriptional activator regulated by phosphorylation. 
CREB is phosphorylated at S I33 by PKA, which recruits CREB-binding protein 
(CBP) to link CREB to the basal transcriptional machinery (De Cesare et al. 1999). 
Similarly the retinoblastoma binding protein (RB) is an example of a transcriptional 
repressor which is regulated by phosphorylation; de-repression of E2F transcription is 
dependent on phosphorylation o f RB by CDK, and this phosphorylation is a key 
controller of the cell cycle.
The activation domain and repression domains within TopBPl might be regulated by 
phosphorylation, as Figure 59 shows there are several predicted phosphorylation sites 
(Serine, Tyrosine and Threonine) within these regions. These potential 
phosphorylation sites were predicted using NetPhos 2.0 phosphorylation prediction 
tool (Centre for Biological sequence analysis (CBS), University o f Denmark). Which 
predicted the likelihood o f phosphorylation of; serine, tyrosine and threonine residues 
within the TopBPl activation (Figure 59a) and repression domains (Figure 59b, and 
59c) and returned a predicted score result (Cut off for this analysis was taken as 0.75,
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residues with a score higher than 0.75 indicates a very likely phosphorylation site). It 
would be interesting to mutate these residues in future studies in order to determine if 
the repression o f the activation domain is regulated by phosphorylation, and if the 
transcriptional activity of the domains is altered following phosphorylation. The role 
of phosphorylation in the activation and amplification of signal transduction 
pathways is well documented. For example c-Jun is phosphoiylated within the 
transactivation domain by c-Jun NH^-terminal kinase (JNK) increasing its 
transcriptional activity (Review JNK Bogoyevitch et a l  2006).
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4.2 TopBPl interaction with Chromatin Remodellers
Chapter 3.1. described the identification o f chromatin modification domains by using 
GAL4 fusion proteins and monitoring transcriptional activity. These domains could 
be involved in replication, transcription and DNA damage repair. Chapter 3.2 showed 
that transcriptional repression by BRCT5 and the alleviation of it following DNA 
damage is dependent on the ATPase subunit o f the chromatin remodeller SWISNF, 
Brgl. The data presented also showed that TopBPl directly interacts with Brgl and 
that this interaction is dependent on BRCT5. The results discussed here focus on this 
relationship between these two proteins and the possible role their interaction may 
have in mediating TopBPl function.
4.2.1 SWISNF
The human SW12/SNF2 chromatin remodelling enzymes are a family of remodellers 
which can be further divided into 8 subtypes: 1) SNF2, 2) ISW l 3) CHDl 4) INO80 
5) ERCC6, 6) RAD53, 7) DDMl and 8) M OTl, according to the structural domains 
within the complexes for example ISW l contain SANT-like domains, CHDl 
chromatin remodellers contain chromodomains (Lusser et a l  2003, Eisen et a l  1995) 
and the SNF2 subfamily contain bromodomains. The chromatin remodellers 
destabilise the interaction between DNA and histones using ATP which results in the
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a more open chromatin state, which reveals binding sites for transcription factors and 
DNA damage repair proteins (Owen-Hughes et a l  1996).
SWISNF a SNF2 chromatin remodeller is a 2MDa complex (Peterson et a l 2000, 
Cote et a l 1994, Wang et a l  1996), which contains 10-12 subunits (Recht et a l 
1999). This complex hydrolyses 3 ATPs to displace approximately 52bp of DNA 
from the nucleosome to create a bulge (Zofall et a l 2006). The central catalytic 
ATPase core is either Brgl or Brm (Phelan et a l 1999, Tyler et a l  1999). Brgl and 
Brm interact with several cell cycle, transcriptional regulatory and repair proteins 
including, RB, p53, p l07, p i30, and BRCAl (Muchardt et a l  2001, Barker et a l 
2001, Bochar et a l 2000), c-myc (Grace et al. 1999), Cyciin E (Shanahan et a l  1999) 
CEBPB (CCAAT/enhancer binding protein-beta), HDAC4, LDBl (LIM Domain 
Binding 1), MXD4 (Max dimérisation protein 4), NFkB2 (Nuclear factor k  light 
enhancer in B cells) and TBX2 (T-Box 2). In addition these proteins are both either 
mutated or down regulated in approximately 10% of human cancer cell lines 
(DeCristofaro et a l  2001) and a variety o f human malignancies (Kiochendler et al 
2002) and heterozygote Brgl mice show a tumour phenotype and are susceptible to 
the formation of mammary tumours (Bultman et a l 2000). Therefore Brgl is 
implicated in many of the functions attributed to TopBPl; transcription and DNA 
damage signalling/repair.
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4.2.2. Brgl-BRCT5 and DNA Damage
Although Big and Brm are primarily associated with transcriptional activation, there 
is also evidence to suggest they are also involved in transcriptional repression. The 
transcriptional repressor REST represses transcription of neuronal genes in non­
neuronal cells, by binding specific repressor element 1 (REl) sites. Repression by 
REST is dependent HDAC and a co-repressor complex; CoREST. CoREST interacts 
with the SWISNF subunit BAF57 (Battaglioli et a l 2002) and is recruited along with 
REST and CoREST to REl sites. B rgl interacts with REST and is recruited to REl 
sites (Ooi et a l 2006), and this recruitment o f Brgl is dependent on an interaction 
between Brgl and the REST repression domains as expression of a REST dominant 
negative lacking the repression domain reduces Brgl recruitment to R El sites.
The cell cycle regulator E2F1 is stabilised by phosphoiylation by ATM (Lin et a l 
2001) and Chk2 (Stevens et a l 2003) following DNA damage. TopBPl was 
identified as an E2F1 interacting protein using a yeast two hybrid assay and was 
shown to interact with E2F1 via BRCT6 following ATM phosphorylation of E2F1. 
The function of this interaction was tested in E2F1 luciferase assays and showed that 
TopBPl represses the transcriptional activity o f E2F1 (Liu et a l  2003), however in 
several cell lines however repression was lost in Brgl and Brm compromised C33a 
cell lines (Liu et a l  2004). This data suggested that TopBPl regulates the 
transcriptional activities o f E2F1 during apoptosis and DNA damage via Brgl and 
Brm by recruiting Brgl and Brm to E2F1-responsive promoters,
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To investigate the role of Brgl in TopBPl BRCT5 transcriptional repression, 
luciferase transcription assays in the Brgl and Brm compromised cell line C33a were 
carried out (Figure 30). The results showed that transcriptional repression by BRCT 5 
is dependent on Brgl but independent o f Brm in several ways; 1) BRCT5 repression 
is absent in C33a cells 2) Addition of Brg (wt) but not Brm (wt) restores repression in 
C33a cells 3) Addition of Brg (-/-) but not Brm (-/-) alleviates repression in 293T 
cells and lastly 4) The addition of Brg (wt) to 293T cells increases repression. 
TopBPl and Brgl have been shown previously to interact following DNA damage 
(Liu et al. 2004), but as Figure 38a shows Brgl and TopBPl can physically interact 
in undamaged cells.
Repression by BRCT5 is alleviated following DNA damage (Figure 42) and this 
alleviation of repression is dependent on B rgl, as this effect is not observed in C33a 
cells until the addition of Brg (wt) (Figure 44). TopBPl contains no chromatin 
remodelling activities but does have eight BRCT domains as potential binding sites, 
therefore perhaps recruits Brgl via a direct interaction to the sites of DNA damage to 
allow access for repair. Immunoprécipitation experiments showed that the interaction 
between Brgl and one o f the TopBPl repressor regions is dependent on BRCT5 
(Figure 40), suggesting that Brgl mediated BRCT5 repression is dependent on a 
direct interaction between the two proteins. However further immunoprécipitation 
would need to be carried out to ascertain if the alleviation of repression following 
DNA damage is also dependent on a direct Brgl-TopBPl interaction. It is possible 
also that following DNA damage Brgl no longer binds TopBPl, and TopBPl
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changes its binding partners to respond to the damage, interacting with NBS and 
Rad9 to facilitate the signalling and repair of the damage.
TopBPl recruitment of Brgl and repression o f E2F1 transcription following DNA 
damage is dependent on the prior phosphorylation of E2F1 by ATM (Liu et al. 2004). 
TopBPl is phosphorylated following DNA damage on S345 by ATM, therefore to 
study the mechanism of Brgl-BRCT5 alleviation of repression following DNA 
damage the PIKK inhibitors; caffeine LY294002 and wortmannin were used in 
transcription assays (Figures 45 and 46).
The results suggested that transcriptional repression in un-damaged cells was 
dependent on one of these three kinases, as it was lost following their addition. This 
could be via several mechanisms for example 1 ) One of the kinases may regulate the 
Brgl protein to facilitate repression. 2) The phosphoiylation of BRCT5 by one of 
these kinases mediates the BRCT5-Brgl interaction which is essential for repression 
or 3) As well as Brgl, there is a PIKK dependent aspect to the BRCT5 repressor 
domain. It is possible that addition of these inhibitors disrupts the Brg-BRCT5 
interaction and that is why repression is alleviated in damaged cells. 
Immunoprécipitation reactions would need to be performed to test if Brgl and 
BRCT5 still directly interact following the inhibition of ATM, ATR and DNA-PK. 
As Figure 59c shows there are two predicted serine phosphorylation sites within the 
BRCT repression domain (S616, S654). Perhaps ATM, ATR, or DNA-PK 
phosphorylates BRCT5 at these residues to facilitate the interaction with Brgl 
(Figure 60a). The use o f more specific inhibitors such as: NU-66933 and KU55933
269
C h a p te r  4 - D iscuss ion
(KuDOS Pharmaceuticals Ltd), which specifically inhibit DNA-PK and ATM 
respectively which would be beneficial to dissect the kinase responsible repression. 
Once the specific kinase is identified using these inhibitors, creation o f TopBPl 
BRCT5 phosphorylation site mutants (S616, S654) followed by immunoprécipitation 
reactions with Brgl would confirm if the interaction between BRCT5 and Brgl is 
mediated by PIKK BRCT5 phosphorylation.
These series of experiments should be performed over a time course following DNA 
damage; as the literature suggests that the phosphorylation of H2AX and the 
signalling of the DNA damage response are dependent on the prior modification o f 
the surrounding chromatin (Ikura et al. 2007) by recruited chromatin remodellers. 
The phosphoiylation of H2AX is dependent on Brgl, as Brgl compromised cell lines 
show a reduction in yH2AX foci (Park et al. 2006). Following DNA damage 
TopBPl might initially bind Brgl and recruit it to the sites o f damage. Then 
following the initiation of the damage signal by phosphorylated H2AX, TopBPl may 
then change its binding partners to aid in the activation of the cell cycle checkpoints 
and DNA damage repair (Figure 60b) and no longer bind Brgl. Immunofluorescence 
experiments should be performed staining TopBPl and Brgl (and yH2AX as a 
control for damage) following DNA damage. This would be interesting if the cells 
were fixed and stained at various time points following DNA damage to see if 
TopBPl and Brgl initially co-localise and then perhaps dis-associate later on in the 
damage response. Although it has been previously shown that Brgl localises the sites 
o f DNA damage, represented by yH2AX foci (Park et al. 2006), the staining was only 
carried out 1 hour post damage. Although the length it takes for cells to respond to
270
Chapter 4 - Discussicm
damage, arrest, repair and then re-enter the cell cycle is varied, MCF7 cells for 
example show yH2AX foci 2 hours post damage but the repair protein XRCC4 is not 
recruited until 8 hours following damage.
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Figure 60: Model of TopBPl BRCT5-Brgl interaction in undamaged and 
damaged cells, a) In undamaged cells TopBPl is phosphoiylated by ATR, ATM or 
DNA-PK within BRCT5 (1) this phosphorylation of BRCT5 then mediates the 
BRCT5“Brgl interaction (2), to repress transcription (3). This would support the 
result observed when repression is alleviated following the addition of the PIKK 
inhibitors, b) Following DNA damage Brgl and TopBPl may still interact, as both 
proteins localise to yH2AX foci. Then following TopBPl phosphorylation (1), 
TopBPl changes its binding partners (2, 3) to respond to the damage signal and no 
longer binds Brgl (4).
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4.2.3. Repression is Independent of Brm
BRCT5 repression is dependent on Brgl but independent of Brm; the addition of Brm 
(wt) to Brm null C33a cells did not restore repression observed in 293T and the 
addition of Brm (-/-) did not alleviate repression as Brgl (-/-) showed (Figure 37). 
Although these two homologues do have both sequence (75% identical and 86% 
similar) and functional redundancies there are several distinct differences; 1) Brg 
specifically interacts with zinc finger proteins (Kadam et a l  2003) via the N-terminal 
which is absent in Brm 2) Brm interacts with ankyrin repeats containing proteins 
(Xue et a l  2000). 4) Brgl null mice are embryonic lethal (Bultman et al. 2000) in 
contrast to Brm null mice which are not, in fact their phenotypic characteristic is a 
tendency to gain weight (Reyes et a l  1998). 5) Brgl specifically represses 
transcription from the c-fos promoter (Murphy et a l  1999).
A functional Brgl and Brm are lost in a variety o f cancer cell lines (Muchardt et a l 
2001). B rgl in these lines is mutated but Brm is not (Wong et a l 2000). In fact 
treatment of these cell lines with the histone deacetylase inhibitor TSA resulted in 
Brm protein expression demonstrating that Brm is not mutated rather silenced in 
these cell lines. To confirm that Brm is not required for repression further luciferase 
transcription assays could be performed in C33a cells treated with TSA. These two 
proteins also differences in there expression during cell development; oocytes contain 
both Brgl and Brm however at the four cell stage when transcription starts the Brgl
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gene is expressed but no Brm mRNA was detected until later on in the blastocyst 
stage (Muchardt et al. 2001). Brm is found in cells that are removed from the cell 
cycle, and downregulated in cells which are actively proliferating where Brgl is 
expressed (Muchardt et al. 1999, Reyes et al. 1998, Machida et al. 2001). One 
explanation for the results observed is that the Brm expression plasmids do not 
encode a functional protein; however transfection of the Brm (wt) expression plasmid 
into C33a and 293T increased E2F1 transcription 3 fold demonstrating that a 
functional Brm protein is present. The preferential selection of Brgl over Brm could 
be due to the N-terminal region of Brgl a region not present in Brm. This N-terminal 
domain could be the region o f Brgl which interacts with BRCT5. To determine if this 
is the region within Brgl which binds TopBPl radioactively labelled TopBPl 
BRCT5 in vitro translation (IVT)’s could be incubated against GST-Brgl truncations, 
either incorporating or deleting the N-terminal domain.
These results have identified a functional interaction between TopBPl and Brgl. This 
interaction could be involved in mediating the DNA damage response and 
transcriptional regulatoiy functions of TopBPl. As discussed in the following 
Chapter, TopBPl is clearly involved in gene regulation following DNA damage.
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4 . 3  G e n e s  R e g u l a t e d  b y  T o p B P l
An investigation into the genes regulated by TopBPl (Chapter 3) was carried out; 
identification of these will potentially reveal novel genes involved in the DNA 
damage response and breast carcinogenesis. This study was composed o f two parts, 
firstly and an investigation into the effect o f the TopBPl knockdown on cell growth, 
and secondly the microarray and analysis.
4.3.1 TopBPl and Cell Growth
In order to perform the microarray following the knockdown of TopBPl, an 
investigation into the effect of the TopBPl knockdown on cell growth was carried 
out. This was an essential control for the microarray, to ensure that the cell cycle was 
not adversely affected and therefore the data retrieved from the microarray analysis 
was comparable. Figures 49 and 51 showed that contrary to previously published data 
(Jeon et a l 2007) TopBPl is not essential for cell growth in all cultured cell lines for 
a short period of time (4 days) although TopBPl is essential for cell growth over 
longer periods of time (Figure 52).
TopBPl is essential for signalling the DNA damage response interacting with NBSl 
and Rad9, and ultimately the activation of the cell cycle checkpoint and repair. It is
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therefore possible that cells lacking TopBPl cannot initiate these pathways and 
display a compromised DNA damage response, over time (14 day period) and as the 
damage accumulates and is not repaired the cells finally undergo apoptosis or 
senescence. It is also possible that TopBPl is essential for replication in undamaged 
cells where difficult DNA structures have to be overcome. The failure to do this over 
several cell divisions could ultimately result in the accumulation of damage leading to 
a catastrophic event resulting in cell death or senescence. This could be tested in 
several ways. 1) Total protein extracts could be prepared from cells siTopBPl treated 
at different time points throughout the 14 day period, these extracts could be run on 
SDS-PAGE gel and the expression of the caspases discussed Chapter 1.5. (Review 
Rupinder et al. 2006) determined by western blotting, TopBPl expression could also 
be tested to ensure that the cells are still knocked down. This would determine if and 
at what point the cells start to undergo apoptosis. 2) Single cell-gel electrophoresis 
'Com ef assays could be used to determine if the cells that have TopBPl knocked 
down do accumulate damage from endogenous sources over time. As the DNA 
fragmented “tails” observed in comet assays are directly proportional to the amount 
of damage, the accumulation o f damage over time could be easily measured in this 
way (Review Collins et al. 2004). The knock down of TopBPl in undamaged cells 
results in the formation o f double strand breaks, characterised by the phosphorylation 
o f H2AX (Kim et a l  2005), suggesting that in the absence of TopBPl cells do start to 
accumulate DNA damage. Senescent cells express a (3-galactosidase enzyme; 
senescence-associated (SA)-p-Gal), therefore this could be used as a marker (Going 
et a l  2002) in TopBPl knocked down cells to determine if they are undergoing 
apoptosis or senescence.
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TopBPl may be involved in replication; interacting with DNA polymerase e 
(Makinemi et al. 2001), studies of D p b ll suggest that TopBPl may be involved in 
the direct recruitment and loading of Cdc45 to replication origins (Araki et al. 1995, 
Wang et a l 2002), and TopBPl increases the ability of the HPV16 replication factor 
E2 to activate replication (Boner et a l 2002). The results shown in Figure 51 
demonstrated that cells do replicate in the absence of TopBPl. The experiments 
described in Chapter 3 provide a system for studying the role o f TopBPl in 
replication, as it has identified cell lines which can and those which cannot survive 
without TopBPl albeit for a limited amount of time.
4.3.2 Genes and Pathways Analysis
This section will focus on the theoretical importance of target pathways of TopBPl in 
light of TopBPl roles in transcription, the DNA damage response, chromatin 
modification and breast cancer. Although this method of analysis provides possible 
insights into additional roles o f TopBPl, further validation o f the microarray results 
are still required as the fold changes are relatively low (less than 1.5) although 
statistically significant. The pathway analysis could also be further supported by 
testing other micro array pathway analysis databases such as GenMAPP 2.0 
(www.GenMAPP.org).
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4.3.2.1 Genes and Pathways Regulated by TopBPl
The data presented in Chapter 3 identified two lists of genes which are regulated by 
TopBPl; genes which were up-regulated and genes which were downregulated 
following the knockdown of TopBPl using siRNA (Table 9 and 10). Importantly 
TopBPl itself was the gene most effected by the siRNA showing a downregulation o f 
-4.8 (p= 2.33 xlO'^), serving as a control for the experiment. These lists of genes will 
be used to further validate the microarray, several significantly up-regulated and 
down-regulated genes could be chosen and the observed effect validated by running 
Real Time-PCR. Pathway analysis was performed on these gene lists using DAVID 
(as described 3.3.4.). This pathway analysis revealed that there were eight pathways 
that were significantly altered following the knockdown of TopBPl (Table 14) 1) 
Sprouty Regulation of Tyrosine kinase signals 2) p38 MAPK signalling pathway, 3) 
Gap Junction, 4) Inositol Phosphate Metabolism, 5) MAPK Signalling Pathway 6) 
Cell Cycle, 7) Estrogen-responsive Protein Efp controls Cell Cycle and Breast 
Tumour Growth and 8) Lysine Degradation.
4.3.2.2. MAPK Signalling Pathway
One of the most significantly effected pathways (following DAVID analysis 3.3.4.) 
by the knockdown of TopBPl is the mitogen activated protein kinase (MAPK) 
signalling pathway. The MAPK signalling pathway on the DAVID database has 246
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members, the knoekdowii o f TopBPl significantly affects 48 genes o f these genes 
(Table 19). Recently, Taricani et a l  (2007) showed that the TopBPl fission yeast 
homologue Rad4^°^^^^ was repressed by srr2 (a stress response gene) and this 
suppression links the stress response and the MAPK signalling response to promote 
eell survival. The MAPK pathway ean be further divided into three separate 
pathways; 1) MAPK/ERK, 2) MAPK/SAPK/JNK and 3) p38 MAPK. p38 MAPK 
signalling pathway which is induced by stress is significantly affected by the 
knockdown of TopBPl. These pathways have several roles within the cell including 
the regulation of cell proliferation, differentiation and death. All three pathways are 
regulated by a hierarehieal cascade. The MAPKK kinases (MAPKKK) phosphorylate 
and activate the MAPK kinases (MAPKK) which activate the MAPK. These MAPK 
then interact with other protein kinases to activate cell proliferation or apoptosis. A 
number of studies have demonstrated the potential role of MAPK signalling in the 
initiation and pathogenesis o f breast cancer. Sivarmas and colleagues compared the 
MAPK activity o f breast cancers to benign tissues and found that the MAPK 
signalling cascade was increased over 6 fold in invasive breast cancers (Migliaccio et 
a l  1998). Breast cancer cell growth can be divided into two groups; oestradiol 
dependent and independent. Oestradiol independent breast cancers often use MAPK 
to mediate cell growth. The breast cancer cell line used for this microarray analysis 
(MCF7) respond to oestradiol, and insulin (Alblas et a l  1998) to stimulate the MAPK 
signalling cascade. Five minutes following the addition of oestradiol, MCF7 eel Is 
show a strong increase in MAPK kinase activity (Migliaccio et a l  1996). The p38 
MAPK pathway induces cell cycle arrest, by targeting stress activated protein 
1 (SAP 1, (Chen et a l  2000) and signal transducer and activator o f transcription
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(STATl, (Ip et al. 1998)). p38 is activated following DNA damage, and activates 
STATl transcription. BRCAl directly interacts with STATl following DNA damage 
providing a link between the DNA damage response and apoptosis. Expression of 
BRCAl in MCF7 cells (by infection o f recombinant adenovirus containing BRCAl 
cDNA) results in G2/M cell cycle arrest via ER K l/2 signalling. BRCAl increased the 
activation o f ERKl/2 by phosphorylation and using a kinase assay; Van and 
colleagues found that BRCAl induced cell cycle arrest via the 14-3-3a and W EEl.
The knockdown of TopBPl in this microarray has shown that 14-3-3a  and W EEl are 
affected by TopBPl. Does TopBPl also regulate ERKl/2 cell cycle control via 14-3- 
3a and W EEl? There are antibodies, commercial kits and MAPK specific inhibitors 
available which would provide a method to investigate if TopBPl does regulate the '
MAPK signalling pathway. It would be necessaiy before proceeding any further to 
investigate if  the knockdown of TopBPl does adversely effect the MAPK pathway.
4.3.23. Estrogen-Responsive RING-finger protein (Efp) controls Cell 
Cycle and Breast Tumour Growth
One of the other pathways significantly affected (p=0.0096) by the knockdown of
TopBPl is the oestrogen responsive protein (Efp) control of the cell cycle during
breast tumour growth (Table 21). Efp has recently been linked to the growth o f breast
cancers; this mechanism of cell growth which is controlled by Efp in breast cancer is
shown in Figure 61. The 14-3-3a  protein under the control o f p53-independent
transcription sequesters CDKs in the cytoplasm. This retention of CDKs blocks entry
into mitosis. Efp facilitates the ubiquitination o f 14-3-3a and therefore its degradation
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by the proteosome (Hermeking et a l  2006). The degradation of 14-3-3a  then releases 
the CDKs which transport to the nucleus and promote uneontrolled eell division 
(Urano et a l 2000), Suzuki et a l  stained 151 breast carcinomas for Efp and found 
that an increase in Efp expression is associated with a decrease in 14-3-3a  expression 
(58/151 cases), supporting the role o f Efp in 14-3-3a  degradation and cell cycle 
progression (Suzuki et a l 2005). Furthermore increased Efp expression is associated 
with a poor survival prognosis (Suzuki et a l 2005) and increased resistance to the 
cancer treatment tamoxifen (McKenna et a l  2000). It is suggested that Efp induces a 
switch in breast cancer growth from estrogen dependent to independent as Efp stable 
transfectant MCF7 cells inoculated into nude mice will produce tumours even in the 
absence of oestrogen (Horie et a l  2003). Because of this the inhibition of Efp is 
being investigated as a possible therapeutic target. It would be necessary to validate if 
this pathway is affected by the knockdown of TopBPl and to do this TopBPl could 
be knocked down using siRNA and 14-3-3a  protein levels could be detected using 
western blotting to see if TopBPl does promote 1 4 -3 -3 g degradation.
Estrogen increases the expression of several estrogen responsive genes in breast 
cancer (Ikeda et a l  2004). These estrogen responsive genes include cytochrome c 
oxidase subunit V ila related polypeptide (COX7RP), estrogen receptor binding 
fragment associated antigen 9 (EBAG9) and estrogen responsive protein (Efp). The 
role of TopBPl in estrogen responsive transcription could be assayed in MCF7 cells 
(as they are estrogen receptor positive) using a luciferase reporter containing estrogen 
responsive elements (EREs) in luciferase transcription assays.
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Figure 61 Cell Cycle control o f Breast cancer Cells by Efp. The order the 
following step is shown on the diagram (Grey circle). (1) p53 dependent transcription 
modulates 14-3-3a activity, which retains CDKs in the cytoplasm. (2) Efp binds 14- 
3-3ct and targets it for degradation by ubiquitination (3). 14-3-3o is degraded by the 
proteosome and CDK are released and travel to the nucleus, (4) and the cell enters 
mitosis.
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4.3.2 4. Cell Cycle
TopBPl is involved replication and cell cycle progression. MCF7 cells in which the 
expression o f TopBPl is knocked down show no cell cycle arrest, compared to 
controls (Figure 51). DAVID analysis indicated that the cell cycle is affected by the 
knockdown of TopBPl (Table 20). Analysis revealed that several proteins involved 
in the initiation of replication are disrupted by the knockdown of TopBPl including 
the ORC subunits 5 and 6, and the MCM proteins 6 and 7. This analysis also revealed 
a change in gene expression within genes involved in cell cycle checkpoints and 
apoptosis; Cell division cycle 2 (G lto S and G2 to M), S phase kinase associated 
protein 2, inhibitors of the cyclin dependent kinases, p57, pi 8 and p l9  (which inhibit 
CDK4), CDK2, CDK6 and W EEl, death associated protein 6, caspase 9, caspase 10, 
p21, arrestin, growth arrest and DNA-damage-inducible-beta. W EEl, like p53, 
inactivates the CDKs, in particular CDK2, which inhibits cell cycle progression, 
interestingly W EEl directly interacts with the Efp targeted protein 14-3-3a (Honda et 
al. 1997) possibly liking the Efp and W EEl cell cycle control. In addition, as 
discussed BRCAl regulates ERK l/2 G2/M cell cycle arrest via W EEl and 14-3-3a 
(Yan et al. 2005).
The gene expression data for the cell cycle pathway shows no bias to either up-
regulated or downregulated genes; 40% of the genes are down-regulated and 60% of
the genes are up-regulated. There is no increase in CDK inhibitors/decrease in CDKs,
or visa versa which might suggest a mechanism of regulation. Further FACS analysis
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would need to be performed incorporating cell cycle inhibitors in cells where TopBPl 
is knocked down to investigate the role o f TopBPl and the cell cycle further. It is 
clear however that although cells can survive without TopBPl for a limited amount 
o f  time (4 days) eventually they stop replicating and undergo apoptosis or senescence 
(3.3.2.).
4 3.2.5. Other significantly Affected Pathways
Other pathways which are significantly affected by TopBPl knockdown are; Sprouty 
Regulation of Tyrosine Signals pathway, gap junctions, inositol phosphate 
metabolism, and the degradation of lysine. The receptor tyrosine kinases control a 
wide variety of cell processes including proliferation, differentiation and cell cycle 
control. The sprouty proteins are ligand induced inhibitors of the receptor tyrosine 
kinase pathways (Manson et al. 2005) and a downregulation in their expression has 
been observed in both prostate and breast cancers (McKie et a l  2004, Lo et al. 2004). 
Inositol phosphate metabolism is involved in a wide variety o f cellular processes 
including calcium release, trafficking, chemotaxis, regulation o f gene expression, 
DNA repair (York et al. 2006) and telomere maintenance (Saiardi et al. 2005, York et 
al. 2005). Gap junctions are also affected by the knockdown of TopBPl; scaffolding 
proteins including casein 1 5, e and tubulin as well as second messengers. Currently 
no connection appears between these pathways and the roles of TopBPl in 
transcription and DNA repair. This might be because there is an overlap between the 
groups o f genes affected by the TopBPl knockdown; for example within the gap 
junction pathway, CDC2, CDC20, MAPKK 1, MAPKK2, and MAPKK5 are
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significantly altered but these genes are also significantly altered during the MAPK 
signalling pathway and cell cycle.
4.3.2.2. Genes and Pathways Regulated by DNA Damage
Five pathways are regulated by DNA damage in the presence of TopBPl (Table 23), 
these include; Oxidative Stress Induced Gene Expression, FAS Signalling Pathway, 
apoptosis, the Proteosome and inositol phosphate metabolism. Although this is 
merely a preliminary result it is reassuring that these pathways are associated with 
cell death (Oxidative stress, FAS signalling, apoptosis). A comparison o f this damage 
gene dataset with the genes regulated following DNA damage in the absence o f 
TopBPl was performed, resulting in a list o f five genes: 1) Olfactory receptor 1, 2) 
Calcium binding protein 3) 5, Calmodulin 2, 4) Tigger transposable element 3 and 5) 
Tubulin P2A. These genes were significantly upregulated following DNA damage in 
the presence of TopBPl however in the absence of TopBPl these genes were 
significantly downregulated following DNA damage (Figure 56b). This indicates that 
their increase in gene expression following DNA damage is specifically regulated by 
TopBPl. The increase in the calmodulin-calcium signalling pathway mediates an 
increase in cell cycle progression and has been associated with several human cancers 
including breast cancer (Lu et a l  1993). Calmodulin forms a complex with calcium, 
and activates several pathways involved in cell growth (Review Strobl et a l 1995), 
including the estrogen receptor dependent transcription activation pathway also 
involved in breast cancer.
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The TopBPl up-regulated and down-regulated genes were compared against breast 
cancer prognosis datasets. This method of analysis derives a prognostic value of the 
gene lists identified in the TopBPl knockout samples using the survival procedure in 
the R-package (Performed by Dr. Keith Vass, Computing Service 
CR-UK Beatson Laboratories, Beatson Institute, Switchback Rd 
Glasgow) to determine if the knockdown of TopBPl and the resultant gene 
expression profile is diagnostic o f poor survival. Following analysis no significant 
correlation found with either survival or relapse; however in one study - a distinct, 
but not significant correlation (p = 0.127) between the TopBPl down-regulated genes 
(Table 9) and relapse in patients with the same phenotype was found. Although this is 
not significant it is suggestive of a possible poorer prognosis associated with a 
downregulation of TopBPl, providing another possible role for TopBPl in breast 
cancer recurrence. This result has a very real consequence for the cancer sufferers it 
might possibly affect as it would change the screening and follow -up monitoring of 
these patients with a high likelihood of cancer recurrence.
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4.3.3. Conclusions and Future Work
This thesis has identified three transcriptional regulatory domains; one activator 
characteristic o f other acidic activation domains similar to BRCAl, which is 
repressed by two adjacent repressor domains. These domains have the potential to 
modify chromatin and in support of this the BRCT5 repressor domain interacts with 
the chromatin remodelling ATPase enzyme B rgl. Both proteins are required for 
transcriptional repression and they physically interact; future experiments would 
focus on identifying the regions where these proteins bind in order to confirm if 
transcriptional repression is mediated by a direct protein-protein interaction using a 
purified system. Indeed transcriptional repression is alleviated following the addition 
o f PIKK inhibitors in undamaged cells, suggesting repression is dependent on the 
phosphorylation of TopBPl, Brgl or an as yet unidentified protein by these kinases. 
More targeted inhibitors will determine which PIKK is involved in this regulation. 
Future work could focus on the identification o f the exact location of these domains, 
identify protein binding partners by proteonomics, and investigate the regulation 
these domains (As discussed 4.1 for example sumoylation, phosphorylation, 
ubiquitination) both in untreated cells and following DNA damage. The identification 
of these transcriptional regulatory domains further reinforces TopBPl as a 
transcription factor.
As TopBPl is a transcription factor, and has been implicated in breast carcinogenesis
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(1.6.4.), possible TopBPl transcriptional targets were investigated by running a gene 
expression array in MCF7 cells in which TopBPl expression was knocked down 
using siRNA. The array studies demonstrate, in combination with previous studies 
that TopBPl is involved in breast carcinogenesis as the pathways regulated by 
TopBPl been previously implicated in breast cancer for example MAPK signalling, 
and estrogen signalling. ChIP on Chip experiments would provide a mechanism for 
identifying TopBPl regulated promoter regions. Understanding the role that TopBPl 
might have in the development of breast cancer would lead to a better understanding 
of disease and ultimately a more targeted cancer therapy strategy. A comparison 
between TopBPl regulated genes identified and breast cancer arrays with survival 
data showed that the genes downregulated in the TopBPl knockout samples are 
associated with recurrence. As TopBPl is aberrantly expressed in breast cancer, and 
perhaps associated with recurrence TopBPl would provide a useful tool as a marker 
for breast cancer. Future studies should focus on the characterisation o f the role of 
TopBPl in breast carcinogenesis. Large population studies investigating the effects of 
cancer drug treatments, against TopBPl staining and survival could be carried out. 
This would determine if TopBPl is associated with poor prognosis, and if TopBPl 
could be used as marker for therapy strategies; for example drug X is associated with 
poor prognosis when TopBPl is aberrantly expressed but drug Y is associated with a 
more positive outcome. The identification o f TopBPl as a marker for poor/good 
cancer prognosis would be of the utmost importance to the women it would 
ultimately affect, providing a more targeted therapy and follow-up strategy.
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